Kv11.1
2538 literature references associated to Kv11.1
1
Hirano-Iwata A
et al.
Reconstitution of Human Ion Channels into Solvent-free Lipid Bilayers Enhanced by Centrifugal Forces.
Biophys. J.,
2016
May
24
, 110 (2207-15).
2
Hayashi S
et al.
Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Eur J Med Chem,
2016
May
23
, 114 (345-64).
3
Zeng H
et al.
Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.
J Pharmacol Toxicol Methods,
2016
May
21
, ().
4
Baczkó I
et al.
Rabbit models as tools for preclinical cardiac electrophysiological safety testing: Importance of repolarization reserve.
Prog. Biophys. Mol. Biol.,
2016
May
18
, ().
5
Su Z
et al.
Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels.
Proc. Natl. Acad. Sci. U.S.A.,
2016
May
17
, 113 (5748-53).
6
Perez-Neut M
et al.
Activation of hERG3 channel stimulates autophagy and promotes cellular senescence in melanoma.
Oncotarget,
2016
Mar
1
, ().
7
Osborne JD
et al.
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
J. Med. Chem.,
2016
Jun
9
, 59 (5221-37).
8
Zhang X
et al.
Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
J Pharmacol Toxicol Methods,
2016
Jun
7
, ().
9
Colatsky T
et al.
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
J Pharmacol Toxicol Methods,
2016
Jun
6
, ().
10
Carbonell-Pascual B
et al.
Comparison between Hodgkin-Huxley and Markov formulations of cardiac ion channels.
J. Theor. Biol.,
2016
Jun
21
, 399 (92-102).
11
Spence S
et al.
Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms.
Toxicol. Sci.,
2016
Jun
2
, ().
12
Șterbuleac D
et al.
An antiarrhythmic agent as a promising lead compound for targeting the hEAG1 ion channel in cancer therapy: insights from molecular dynamics simulations.
Chem Biol Drug Des,
2016
Jun
2
, ().
13
Yamaguchi Y
et al.
Latent pathogenicity of the G38S polymorphism of KCNE1 K(+) channel modulator.
Heart Vessels,
2016
Jun
2
, ().
14
Ng CA
et al.
Tyrosine residues from the S4-S5 linker of Kv11.1 channels are critical for slow deactivation.
J. Biol. Chem.,
2016
Jun
17
, ().
15
Major P
et al.
A novel transgenic rabbit model with reduced repolarization reserve: long QT syndrome caused by a dominant-negative mutation of the KCNE1 gene.
Br. J. Pharmacol.,
2016
Jun
, 173 (2046-61).
16
Wu W
et al.
Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.
Card Electrophysiol Clin,
2016
Jun
, 8 (275-84).
17
Van Driest SL
et al.
Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records.
JAMA,
2016
Jan
5
, 315 (47-57).
18
Cheng J
et al.
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
J. Med. Chem.,
2016
Jan
28
, 59 (578-91).
19
Lee S
et al.
Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Toxicol. Appl. Pharmacol.,
2016
Jan
25
, ().
20
Yu HB
et al.
Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.
Acta Pharmacol. Sin.,
2016
Jan
, 37 (111-23).
21
Heide J
et al.
Differential Response to Risperidone in Schizophrenia Patients by KCNH2 Genotype and Drug Metabolizer Status.
Am J Psychiatry,
2016
Jan
, 173 (53-9).
22
Bodi I
et al.
Mechanisms of acquired long-QT syndrome in patients with propionic acidemia.
Heart Rhythm,
2016
Feb
5
, ().
23
Neubauer J
et al.
Post-mortem whole-exome sequencing (WES) with a focus on cardiac disease-associated genes in five young sudden unexplained death (SUD) cases.
Int. J. Legal Med.,
2016
Feb
4
, ().
24
Gintant G
et al.
Evolution of strategies to improve preclinical cardiac safety testing.
Nat Rev Drug Discov,
2016
Feb
19
, ().
25
Furtado MB
et al.
A novel conditional mouse model for Nkx2-5 reveals transcriptional regulation of cardiac ion channels.
Differentiation,
2016
Feb
17
, ().
26
Nozaki Y
et al.
CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -Assessment of inter-facility and cells lot-to-lot-variability.
Regul. Toxicol. Pharmacol.,
2016
Feb
13
, ().
27
Crottes D
et al.
SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness.
Cancer Res.,
2016
Feb
1
, 76 (607-18).
28
Fang P
et al.
[Progress in research on defective protein trafficking and functional restoration in HERG-associated long QT syndrome].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi,
2016
Feb
, 33 (101-4).
29
Crumb WJ
et al.
An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
J Pharmacol Toxicol Methods,
2016
Apr
6
, ().
30
Marostica E
et al.
PK/PD Modelling of the QT Interval: a Step Towards Defining the Translational Relationship Between In Vitro, Awake Beagle Dogs, and Humans.
AAPS J,
2016
Apr
26
, ().
31
Liu F
et al.
Cotranslational association of mRNA encoding subunits of heteromeric ion channels.
Proc. Natl. Acad. Sci. U.S.A.,
2016
Apr
26
, 113 (4859-64).
32
Atia J
et al.
Reconstruction of Cell Surface Densities of Ion Pumps, Exchangers, and Channels from mRNA Expression, Conductance Kinetics, Whole-Cell Calcium, and Current-Clamp Voltage Recordings, with an Application to Human Uterine Smooth Muscle Cells.
PLoS Comput. Biol.,
2016
Apr
, 12 (e1004828).
33
Ye F
et al.
The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
Toxins (Basel),
2016
, 8 ().
34
Cubeddu LX
Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.
Curr Cardiol Rev,
2016
, 12 (141-54).
35
Eng G
et al.
Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes.
Nat Commun,
2016
, 7 (10312).
36
Ichikawa M
et al.
Multigenerational Inheritance of Long QT Syndrome Type 2 in a Japanese Family.
Intern. Med.,
2016
, 55 (259-62).
37
Zhao Y
et al.
Regulation of SCN3B/scn3b by Interleukin 2 (IL-2): IL-2 modulates SCN3B/scn3b transcript expression and increases sodium current in myocardial cells.
BMC Cardiovasc Disord,
2016
, 16 (1).
38
Hassinen M
et al.
Molecular basis and drug sensitivity of the delayed rectifier (IKr) in the fish heart.
Comp. Biochem. Physiol. C Toxicol. Pharmacol.,
2015 Oct-Nov
, 176-177 (44-51).
39
Arcangeli A
et al.
Novel perspectives in cancer therapy: Targeting ion channels.
Drug Resist. Updat.,
2015 Jul-Aug
, 21-22 (11-9).
40
Meedech P
et al.
Transmural dispersion of repolarization and cardiac remodeling in ventricles of rabbit with right ventricular hypertrophy.
J Pharmacol Toxicol Methods,
2015 Jan-Feb
, 71 (129-36).
41
Hertz CL
et al.
Genetic investigations of sudden unexpected deaths in infancy using next-generation sequencing of 100 genes associated with cardiac diseases.
Eur. J. Hum. Genet.,
2015
Sep
9
, ().
42
González Cabrera D
et al.
Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines.
J. Med. Chem.,
2015
Sep
24
, 58 (7572-9).
43
Salmas RE
et al.
Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.
Biophys. J.,
2015
Sep
15
, 109 (1163-8).
44
Singh SB
et al.
Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6).
Bioorg. Med. Chem. Lett.,
2015
Sep
1
, 25 (3636-43).
45
Singh SB
et al.
Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).
Bioorg. Med. Chem. Lett.,
2015
Sep
1
, 25 (3630-5).
46
Gupta N
et al.
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Cancer Chemother. Pharmacol.,
2015
Sep
, 76 (507-16).
47
Qu Y
et al.
Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Toxicol. Sci.,
2015
Sep
, 147 (286-95).
48
Farrugia A
et al.
Targeted next generation sequencing application in cardiac channelopathies: Analysis of a cohort of autopsy-negative sudden unexplained deaths.
Forensic Sci. Int.,
2015
Sep
, 254 (5-11).
49
Sheng R
et al.
Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.
ACS Chem Neurosci,
2015
Oct
19
, ().
50
Lees-Miller JP
et al.
In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating".
J. Mol. Cell. Cardiol.,
2015
Oct
, 87 (192-3).
51
Melgari D
et al.
hERG potassium channel inhibition by ivabradine requires channel gating.
J. Mol. Cell. Cardiol.,
2015
Oct
, 87 (126-8).
52
Frea S
et al.
New echocardiographic insights in short QT syndrome: More than a channelopathy?
Heart Rhythm,
2015
Oct
, 12 (2096-105).
53
Lee HJ
et al.
Mechanism of inhibition by olanzapine of cloned hERG potassium channels.
Neurosci. Lett.,
2015
Nov
16
, 609 (97-102).
54
Kang Y
et al.
Regulation of the human ether-a-go-go-related gene (hERG) potassium channel by Nedd4 family interacting proteins (Ndfips).
Biochem. J.,
2015
Nov
15
, 472 (71-82).
55
Le Manach C
et al.
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
J. Med. Chem.,
2015
Nov
12
, 58 (8713-22).
56
Zhao H
et al.
Discovery of novel N-aryl piperazine CXCR4 antagonists.
Bioorg. Med. Chem. Lett.,
2015
Nov
1
, 25 (4950-5).
57
Delaunois A
et al.
Cardiac safety of lacosamide: the non-clinical perspective.
Acta Neurol. Scand.,
2015
Nov
, 132 (337-45).
58
Xie S
et al.
Hypaconitine-induced QT prolongation mediated through inhibition of KCNH2 (hERG) potassium channels in conscious dogs.
J Ethnopharmacol,
2015
May
26
, 166 (375-9).
59
Hu N
et al.
High-performance beating pattern function of human induced pluripotent stem cell-derived cardiomyocyte-based biosensors for hERG inhibition recognition.
Biosens Bioelectron,
2015
May
15
, 67 (146-53).
60
Jin SS
et al.
Antiarrhythmic ionic mechanism of Guanfu base A--Selective inhibition of late sodium current in isolated ventricular myocytes from guinea pigs.
Chin J Nat Med,
2015
May
, 13 (361-7).
61
Matus M
et al.
Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.
Mol. Cell. Biochem.,
2015
May
, 403 (199-208).
62
Leren IS
et al.
Cardiac Mechanical Alterations and Genotype Specific Differences in Subjects With Long QT Syndrome.
JACC Cardiovasc Imaging,
2015
May
, 8 (501-10).
63
Pires NM
et al.
Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.
Eur. J. Pharmacol.,
2015
Mar
5
, 750 (98-107).
64
Kolder IC
et al.
Analysis for Genetic Modifiers of Disease Severity in Patients with Long QT Syndrome Type 2.
Circ Cardiovasc Genet,
2015
Mar
3
, ().
65
Liu Z
et al.
Fluorogenic probe for the human Ether-a-Go-Go-Related Gene potassium channel imaging.
Anal. Chem.,
2015
Mar
3
, 87 (2550-4).
66
Perry MD
et al.
Getting to the heart of hERG K(+) channel gating.
J. Physiol. (Lond.),
2015
Mar
27
, ().
67
Muñoz-Esparza C
et al.
Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing.
Rev Esp Cardiol (Engl Ed),
2015
Mar
25
, ().
68
Goodchild SJ
et al.
Sequence of gating charge movement and pore gating in HERG activation and deactivation pathways.
Biophys. J.,
2015
Mar
24
, 108 (1435-47).
69
Perissinotti LL
et al.
Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel.
Biophys. J.,
2015
Mar
24
, 108 (1414-24).
70
Guo J
et al.
NS1643 interacts around L529 of hERG to alter voltage sensor movement on the path to activation.
Biophys. J.,
2015
Mar
24
, 108 (1400-13).
71
Biliczki P
et al.
The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation.
Naunyn Schmiedebergs Arch. Pharmacol.,
2015
Mar
20
, ().
72
Lastraioli E
et al.
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.
Br. J. Cancer,
2015
Mar
17
, 112 (1076-87).
73
Villoutreix BO
et al.
Computational investigations of hERG channel blockers: New insights and current predictive models.
Adv. Drug Deliv. Rev.,
2015
Mar
12
, ().
74
Ivanov SM
et al.
Identification of drug targets related to the induction of ventricular tachyarrhythmia through a systems chemical biology approach.
Toxicol. Sci.,
2015
Mar
12
, ().
75
Yang L
et al.
Intravenous anesthetic propofol inhibits multiple human cardiac potassium channels.
Anesthesiology,
2015
Mar
, 122 (571-84).
76
Han SN
et al.
[Effects of midazolam on hERG K+ channel].
Zhongguo Ying Yong Sheng Li Xue Za Zhi,
2015
Mar
, 31 (143-7).
77
Hayashi K
et al.
Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation.
Circ Arrhythm Electrophysiol,
2015
Jun
30
, ().
78
Zhou FJ
et al.
Two New Classes of T-Type Calcium Channel Inhibitors with New Chemical Scaffolds from Ganoderma cochlear.
Org. Lett.,
2015
Jun
19
, 17 (3082-5).
79
Salmas RE
et al.
In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
J Enzyme Inhib Med Chem,
2015
Jun
17
, (1-9).
80
Grienke U
et al.
Human Ether-à-go-go Related Gene (hERG) Channel Blocking Aporphine Alkaloids from Lotus Leaves and Their Quantitative Analysis in Dietary Weight Loss Supplements.
J. Agric. Food Chem.,
2015
Jun
17
, 63 (5634-9).
81
Ai Y
et al.
Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents.
J. Med. Chem.,
2015
Jun
11
, 58 (4506-20).
82
Wu W
et al.
The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Mol. Pharmacol.,
2015
Jun
, 87 (1042-50).
83
Kurokawa J
et al.
Aromatase knockout mice reveal an impact of estrogen on drug-induced alternation of murine electrocardiography parameters.
J Toxicol Sci,
2015
Jun
, 40 (339-48).
84
Zhao X
et al.
Up-regulation of miR-21 and miR-23a Contributes to As2 O3 -induced hERG Channel Deficiency.
Basic Clin. Pharmacol. Toxicol.,
2015
Jun
, 116 (516-23).
85
Schroder EA
et al.
The cardiomyocyte molecular clock regulates the circadian expression of Kcnh2 and contributes to ventricular repolarization.
Heart Rhythm,
2015
Jun
, 12 (1306-14).
86
Yang LZ
et al.
Urocortin2 prolongs action potential duration and modulates potassium currents in guinea pig myocytes and HEK293 cells.
Eur. J. Pharmacol.,
2015
Jul
5
, 758 (97-106).
87
Stattin EL
et al.
Genetic screening in sudden cardiac death in the young can save future lives.
Int. J. Legal Med.,
2015
Jul
31
, ().
88
Zhang W
et al.
Kcnh2 and Kcnj8 Interactively Regulate Skin Wound Healing and Regeneration.
Wound Repair Regen,
2015
Jul
28
, ().
89
Yue Y
et al.
Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome.
Circulation,
2015
Jul
28
, 132 (230-40).
90
De Mieri M
et al.
hERG Channel Inhibitory Daphnane Diterpenoid Orthoesters and Polycephalones A and B with Unprecedented Skeletons from Gnidia polycephala.
J. Nat. Prod.,
2015
Jul
24
, 78 (1697-707).
91
Lee S
et al.
Cellular mechanisms for trazodone-induced cardiotoxicity.
Hum Exp Toxicol,
2015
Jul
17
, ().
92
Fermini B
et al.
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
J Biomol Screen,
2015
Jul
13
, ().
93
Harrell DT
et al.
Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome.
Int. J. Cardiol.,
2015
Jul
1
, 190 (393-402).
94
Gardner A
et al.
C-Linker Accounts for Differential Sensitivity of ERG1 and ERG2 K+ Channels to RPR260243-Induced Slow Deactivation.
Mol. Pharmacol.,
2015
Jul
, 88 (19-28).
95
Issa NP
et al.
QT interval prolongation in a patient with LQT2 on levetiracetam.
Seizure,
2015
Jul
, 29 (134-6).
96
Li L
et al.
Genetic variants of potassium voltage-gated channel genes (KCNQ1, KCNH2, and KCNE1) affected the risk of atrial fibrillation in elderly patients.
Genet Test Mol Biomarkers,
2015
Jul
, 19 (359-65).
97
Wang Y
et al.
Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells.
Mol Med Rep,
2015
Jul
, 12 (1233-8).
98
Wu ZJ
et al.
Characterization of a Chinese KCNQ1 mutation (R259H) that shortens repolarization and causes short QT syndrome 2.
J Geriatr Cardiol,
2015
Jul
, 12 (394-401).
99
Barsanti PA
et al.
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.
ACS Med Chem Lett,
2015
Jan
8
, 6 (42-6).
100
Wiśniowska B
et al.
Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents.
J Appl Toxicol,
2015
Jan
5
, ().
101
Perez-Neut M
et al.
Stimulation of hERG1 channel activity promotes a calcium-dependent degradation of cyclin E2, but not cyclin E1, in breast cancer cells.
Oncotarget,
2015
Jan
30
, 6 (1631-9).
102
Vedani A
et al.
OpenVirtualToxLab--a platform for generating and exchanging in silico toxicity data.
Toxicol. Lett.,
2015
Jan
22
, 232 (519-32).
103
Saber S
et al.
Complex genetic background in a large family with Brugada syndrome.
Physiol Rep,
2015
Jan
1
, 3 ().
104
Lynch SM
et al.
N-Aryl azacycles as novel sodium channel blockers.
Bioorg. Med. Chem. Lett.,
2015
Jan
1
, 25 (48-52).
105
Riuró H
et al.
Genetic analysis, in silico prediction, and family segregation in long QT syndrome.
Eur. J. Hum. Genet.,
2015
Jan
, 23 (79-85).
106
Xiang F
et al.
Plectasin, first animal toxin-like fungal defensin blocking potassium channels through recognizing channel pore region.
Toxins (Basel),
2015
Jan
, 7 (34-42).
107
Orvos P
et al.
Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential - a safety approach.
Fitoterapia,
2015
Jan
, 100 (156-65).
108
Martin NJ
et al.
Indole alkaloids from the Marquesan plant Rauvolfia nukuhivensis and their effects on ion channels.
Phytochemistry,
2015
Jan
, 109 (84-95).
109
Kubo T
et al.
Phosphatidylinositol4-phosphate 5-kinase prevents the decrease in the HERG potassium current induced by Gq protein-coupled receptor stimulation.
J. Pharmacol. Sci.,
2015
Jan
, 127 (127-34).
110
Chae YJ
et al.
Effects of donepezil on hERG potassium channels.
Brain Res.,
2015
Feb
9
, 1597 (77-85).
111
Wright PD
et al.
A High-Throughput Electrophysiology Assay Identifies Inhibitors of the Inwardly Rectifying Potassium Channel Kir7.1.
J Biomol Screen,
2015
Feb
5
, ().
112
Ellis JM
et al.
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
J. Med. Chem.,
2015
Feb
26
, 58 (1929-39).
113
Männikkö R
et al.
Pharmacological and electrophysiological characterisation of hERG activator AZSMO-23.
Br. J. Pharmacol.,
2015
Feb
12
, ().
114
Cheng Y
et al.
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities.
ACS Med Chem Lett,
2015
Feb
12
, 6 (210-5).
115
Gao Z
et al.
Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy.
Bioorg. Med. Chem.,
2015
Feb
1
, 23 (429-38).
116
Vijayvergiya V
et al.
Single channel and ensemble hERG conductance measured in droplet bilayers.
Biomed Microdevices,
2015
Feb
, 17 (12).
117
Zhang H
et al.
Reporting sodium channel activity using calcium flux: pharmacological promiscuity of cardiac Nav1.5.
Mol. Pharmacol.,
2015
Feb
, 87 (207-17).
118
de Llano CT
et al.
Further evidence of the association between LQT syndrome and epilepsy in a family with KCNQ1 pathogenic variant.
Seizure,
2015
Feb
, 25 (65-7).
119
Pulici M
et al.
Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
ChemMedChem,
2015
Feb
, 10 (276-95).
120
Gasparoli L
et al.
New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity.
Mol. Pharmacol.,
2015
Feb
, 87 (183-96).
121
Oliván-Viguera A
et al.
A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Mol. Pharmacol.,
2015
Feb
, 87 (338-48).
122
Wu CS
et al.
Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.
J Am Heart Assoc,
2015
Feb
, 4 ().
123
Yu Z
et al.
Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.
Br. J. Pharmacol.,
2015
Feb
, 172 (940-55).
124
Zhu W
et al.
Molecular motions that shape the cardiac action potential: Insights from voltage clamp fluorometry.
Prog. Biophys. Mol. Biol.,
2015
Dec
25
, ().
125
Obergrussberger A
et al.
Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module.
J Lab Autom,
2015
Dec
23
, ().
126
Li X
et al.
Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.
Arch. Toxicol.,
2015
Dec
16
, ().
127
Sviripa VM
et al.
Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.
Org. Biomol. Chem.,
2015
Dec
15
, 14 (74-84).
128
Sundby E
et al.
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Eur J Pharm Sci,
2015
Dec
1
, 80 (56-65).
129
Robyns T
et al.
Targeted capture sequencing in a large LQTS family reveals a new pathogenic mutation c.2038delG in KCNH2 initially missed due to allelic dropout.
Acta Cardiol,
2015
Dec
, 70 (747-9).
130
Kanters JK
et al.
Combined gating and trafficking defect in Kv11.1 manifests as a malignant long QT syndrome phenotype in a large Danish p.F29L founder family.
Scand. J. Clin. Lab. Invest.,
2015
Dec
, 75 (699-709).
131
Liang D
et al.
[Expression of human ether-a-go-go-related gene in laryngeal carcinoma].
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,
2015
Dec
, 29 (2160-3).
132
Zhi D
et al.
The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides.
Eur J Pharm Sci,
2015
Aug
30
, 76 (149-55).
133
134
Chen J
et al.
Rab11-dependent Recycling of the Human Ether-a-go-go-related Gene (hERG) Channel.
J. Biol. Chem.,
2015
Aug
21
, 290 (21101-13).
135
Oost T
et al.
Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.
Bioorg. Med. Chem. Lett.,
2015
Aug
15
, 25 (3275-80).
136
Roth GJ
et al.
Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.
Bioorg. Med. Chem. Lett.,
2015
Aug
15
, 25 (3270-4).
137
Yu Z
et al.
Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers.
J. Med. Chem.,
2015
Aug
13
, 58 (5916-29).
138
Anneken L
et al.
Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking.
Eur. Heart J.,
2015
Aug
12
, ().
139
Johannesen L
et al.
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Clin. Pharmacol. Ther.,
2015
Aug
11
, ().
140
Marostica E
et al.
Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
J Pharmacokinet Pharmacodyn,
2015
Aug
11
, ().
141
Deng Q
et al.
Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
Bioorg. Med. Chem. Lett.,
2015
Aug
1
, 25 (2958-62).
142
Osterbur ML
et al.
An Interdomain KCNH2 Mutation Produces an Intermediate Long QT Syndrome.
Hum. Mutat.,
2015
Aug
, 36 (764-73).
143
Lees-Miller JP
et al.
Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4.
J. Mol. Cell. Cardiol.,
2015
Aug
, 85 (71-8).
144
Yasuda C
et al.
The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
J. Physiol. Pharmacol.,
2015
Aug
, 66 (599-607).
145
Zhang C
et al.
Identification of Low-Risk Adult Congenital LQTS Patients.
J. Cardiovasc. Electrophysiol.,
2015
Aug
, 26 (853-8).
146
Koponen M
et al.
Follow-up of 316 molecularly defined pediatric long-QT syndrome patients: clinical course, treatments, and side effects.
Circ Arrhythm Electrophysiol,
2015
Aug
, 8 (815-23).
147
de la Peña P
et al.
Interactions between the N-terminal tail and the gating machinery of hERG K⁺ channels both in closed and open/inactive states.
Pflugers Arch.,
2015
Aug
, 467 (1747-56).
148
Zhang J
et al.
[Effects of allitridum on rapidly delayed rectifier potassium current in HEK293 cell line].
Nan Fang Yi Ke Da Xue Xue Bao,
2015
Aug
, 35 (1128-32, 1142).
149
Brodney MA
et al.
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.
J. Med. Chem.,
2015
Apr
9
, 58 (3223-52).
150
Chae YJ
et al.
Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels.
Eur. J. Pharmacol.,
2015
Apr
5
, 752 (1-7).
151
Williams VS
et al.
Multiplex ligation-dependent probe amplification copy number variant analysis in patients with acquired long QT syndrome.
Europace,
2015
Apr
, 17 (635-41).
152
Erdem M
et al.
herg1b expression as a potential specific marker in pediatric acute myeloid leukemia patients with HERG 897K/K genotype.
Pediatr Hematol Oncol,
2015
Apr
, 32 (182-92).
153
Ferreiro SF
et al.
Acute cardiotoxicity evaluation of the marine biotoxins OA, DTX-1 and YTX.
Toxins (Basel),
2015
Apr
, 7 (1030-47).
154
Melgari D
et al.
hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
J Am Heart Assoc,
2015
Apr
, 4 ().
155
Wang J
et al.
MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel.
J. Mol. Neurosci.,
2015
Apr
, 55 (985-94).
156
Teng G
et al.
Role of mutation and pharmacologic block of human KCNH2 in vasculogenesis and fetal mortality: partial rescue by transforming growth factor-β.
Circ Arrhythm Electrophysiol,
2015
Apr
, 8 (420-8).
157
Han SN
et al.
The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.
Acta Pharmacol. Sin.,
2015
Apr
, 36 (454-62).
158
Obejero-Paz CA
et al.
Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk.
Sci Rep,
2015
, 5 (17623).
159
Badyra B
et al.
How in vitro influences in silico utilized for the prediction of in vivo - pilot study of the drug-induced pro-arrhythmic potency prediction.
Folia Med Cracov,
2015
, 55 (5-19).
160
161
Chang YS
et al.
Mutation Analysis of KCNQ1, KCNH2 and SCN5A Genes in Taiwanese Long QT Syndrome Patients.
Int Heart J,
2015
, 56 (450-3).
162
Leong IU
et al.
Assessment of the predictive accuracy of five in silico prediction tools, alone or in combination, and two metaservers to classify long QT syndrome gene mutations.
BMC Med. Genet.,
2015
, 16 (34).
163
Stephens RF
et al.
Selectivity filters and cysteine-rich extracellular loops in voltage-gated sodium, calcium, and NALCN channels.
Front Physiol,
2015
, 6 (153).
164
Steffensen AB
et al.
High incidence of functional ion-channel abnormalities in a consecutive Long QT cohort with novel missense genetic variants of unknown significance.
Sci Rep,
2015
, 5 (10009).
165
Stimers JR
et al.
Overexpression of the Large-Conductance, Ca2+-Activated K+ (BK) Channel Shortens Action Potential Duration in HL-1 Cardiomyocytes.
PLoS ONE,
2015
, 10 (e0130588).
166
Pugsley MK
et al.
Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Handb Exp Pharmacol,
2015
, 229 (149-203).
167
Hisajima N
et al.
The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Biol. Pharm. Bull.,
2015
, 38 (781-4).
168
Martelli A
et al.
Inhibitors of the renal outer medullary potassium channel: a patent review.
Expert Opin Ther Pat,
2015
, 25 (1035-51).
169
Shi YQ
et al.
Mechanisms underlying probucol-induced hERG-channel deficiency.
Drug Des Devel Ther,
2015
, 9 (3695-704).
170
Molbaek K
et al.
High yield purification of full-length functional hERG K+ channels produced in Saccharomyces cerevisiae.
Microb. Cell Fact.,
2015
, 14 (15).
171
Okada M
et al.
Increase in the titer of lentiviral vectors expressing potassium channels by current blockade during viral vector production.
BMC Neurosci,
2015
, 16 (30).
172
Allegue C
et al.
Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome.
PLoS ONE,
2015
, 10 (e0133037).
173
Shi YQ
et al.
High Glucose Represses hERG K+ Channel Expression through Trafficking Inhibition.
Cell. Physiol. Biochem.,
2015
, 37 (284-96).
174
Lastraioli E
et al.
hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers.
Biomed Res Int,
2015
, 2015 (896432).
175
Giacomini E
et al.
A ligand-based virtual screening approach to identify small molecules as HERG channel activators.
Comb. Chem. High Throughput Screen.,
2015
, 18 (269-80).
176
Pedersen PJ
et al.
Molecular Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium.
PLoS ONE,
2015
, 10 (e0138320).
177
Ji N
et al.
Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro.
Biomed Res Int,
2015
, 2015 (308475).
178
Dey D
et al.
Acute and chronic toxicity, cytochrome p450 enzyme inhibition, and HERG channel blockade studies with a polyherbal, ayurvedic formulation for inflammation.
Biomed Res Int,
2015
, 2015 (971982).
179
Jing Y
et al.
In silico prediction of hERG inhibition.
Future Med Chem,
2015
, 7 (571-86).
180
Liu QN
et al.
Eag Domains Regulate LQT Mutant hERG Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
PLoS ONE,
2015
, 10 (e0123951).
181
Du F
et al.
Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
PLoS ONE,
2015
, 10 (e0118324).
182
Vonderlin N
et al.
Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action.
Drug Des Devel Ther,
2015
, 9 (867-77).
183
Wu W
et al.
Concatenated hERG1 tetramers reveal stoichiometry of altered channel gating by RPR-260243.
Mol. Pharmacol.,
2015
, 87 (401-9).
184
Vicente J
et al.
Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil.
J Am Heart Assoc,
2015
, 4 ().
185
Rast G
et al.
Solubility assessment and on-line exposure confirmation in a patch-clamp assay for hERG (human ether-a-go-go-related gene) potassium channel inhibition.
J Pharmacol Toxicol Methods,
2014 Sep-Oct
, 70 (182-7).
186
Gibson JK
et al.
Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
J Pharmacol Toxicol Methods,
2014 Nov-Dec
, 70 (255-67).
187
Mirams GR
et al.
Prediction of Thorough QT study results using action potential simulations based on ion channel screens.
J Pharmacol Toxicol Methods,
2014 Nov-Dec
, 70 (246-54).
188
Rodríguez-Menchaca AA
et al.
Impact of the whole-cell patch-clamp configuration on the pharmacological assessment of the hERG channel: trazodone as a case example.
J Pharmacol Toxicol Methods,
2014 May-Jun
, 69 (237-44).
189
Kim TW
et al.
Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
J Pharmacol Toxicol Methods,
2014 Jan-Feb
, 69 (49-60).
190
Cai Y
et al.
Down-regulation of ether-a-go-go-related gene potassium channel protein through sustained stimulation of AT1 receptor by angiotensin II.
Biochem. Biophys. Res. Commun.,
2014
Sep
26
, 452 (852-7).
191
Washburn WN
et al.
Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
J. Med. Chem.,
2014
Sep
25
, 57 (7509-22).
192
Brudeli B
et al.
Discovery and pharmacological profile of new hydrophilic 5-HT(4) receptor antagonists.
Bioorg. Med. Chem. Lett.,
2014
Sep
15
, 24 (4598-602).
193
Ng CA
et al.
Multiple interactions between cytoplasmic domains regulate slow deactivation of Kv11.1 channels.
J. Biol. Chem.,
2014
Sep
12
, 289 (25822-32).
194
Shopp GM
et al.
Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation.
Anticancer Res.,
2014
Sep
, 34 (4733-40).
195
Han SN
et al.
Identification and functional characterization of the human ether-a-go-go-related gene Q738X mutant associated with hereditary long QT syndrome type 2.
Int. J. Mol. Med.,
2014
Sep
, 34 (810-5).
196
Choi SH
et al.
Ginseng gintonin activates the human cardiac delayed rectifier K+ channel: involvement of Ca2+/calmodulin binding sites.
Mol. Cells,
2014
Sep
, 37 (656-63).
197
Bartok A
et al.
Margatoxin is a non-selective inhibitor of human Kv1.3 K(+) channels.
Toxicon,
2014
Sep
, 87 (6-16).
198
Kim Y
et al.
Novel thienopyrimidinones as mGluR1 antagonists.
Eur J Med Chem,
2014
Oct
6
, 85 (629-37).
199
Kauthale RR
et al.
Assessment of temperature-induced hERG channel blockade variation by drugs.
J Appl Toxicol,
2014
Oct
28
, ().
200
Kratz JM
et al.
Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools.
J Chem Inf Model,
2014
Oct
27
, 54 (2887-901).
201
Comer E
et al.
Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents.
J. Med. Chem.,
2014
Oct
23
, 57 (8496-502).
202
Perlmutter JI
et al.
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
J. Med. Chem.,
2014
Oct
23
, 57 (8540-62).
203
Patanè S
HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs.
Int. J. Cardiol.,
2014
Oct
20
, 176 (1082-5).
204
Nogawa H
et al.
hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Eur. J. Pharmacol.,
2014
Oct
15
, 741 (336-9).
205
Olde Nordkamp LR
et al.
Syncope in genotype-negative long QT syndrome family members.
Am. J. Cardiol.,
2014
Oct
15
, 114 (1223-8).
206
Wu W
et al.
Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
J. Physiol. (Lond.),
2014
Oct
15
, 592 (4465-80).
207
Reck F
et al.
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.
Bioorg. Med. Chem.,
2014
Oct
1
, 22 (5392-409).
208
Hull CM
et al.
Regional flexibility in the S4-S5 linker regulates hERG channel closed-state stabilization.
Pflugers Arch.,
2014
Oct
, 466 (1911-9).
209
Terentyev D
et al.
Hyperphosphorylation of RyRs underlies triggered activity in transgenic rabbit model of LQT2 syndrome.
Circ. Res.,
2014
Nov
7
, 115 (919-28).
210
Anwar-Mohamed A
et al.
A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.
Toxicol. Lett.,
2014
Nov
4
, 230 (382-92).
211
Linder T
et al.
Structural insights into trapping and dissociation of small molecules in K⁺ channels.
J Chem Inf Model,
2014
Nov
24
, 54 (3218-28).
212
Colenso CK
et al.
Voltage sensor gating charge transfer in a hERG potassium channel model.
Biophys. J.,
2014
Nov
18
, 107 (L25-8).
213
Balasuriya D
et al.
A direct interaction between the sigma-1 receptor and the hERG voltage-gated K+ channel revealed by atomic force microscopy and homogeneous time-resolved fluorescence (HTRF®).
J. Biol. Chem.,
2014
Nov
14
, 289 (32353-63).
214
Scott JS
et al.
Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
J. Med. Chem.,
2014
Nov
13
, 57 (8984-98).
215
Le Manach C
et al.
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a softfocus kinase library: part 2.
J. Med. Chem.,
2014
Nov
13
, 57 (8839-48).
216
Jensen JE
et al.
Understanding the molecular basis of toxin promiscuity: the analgesic sea anemone peptide APETx2 interacts with acid-sensing ion channel 3 and hERG channels via overlapping pharmacophores.
J. Med. Chem.,
2014
Nov
13
, 57 (9195-203).
217
Nikolov NG
et al.
hERG blocking potential of acids and zwitterions characterized by three thresholds for acidity, size and reactivity.
Bioorg. Med. Chem.,
2014
Nov
1
, 22 (6004-13).
218
Luo F
et al.
Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
Mol Biosyst,
2014
Nov
, 10 (2863-9).
219
Gong Q
et al.
Upregulation of functional Kv11.1 isoform expression by inhibition of intronic polyadenylation with antisense morpholino oligonucleotides.
J. Mol. Cell. Cardiol.,
2014
Nov
, 76 (26-32).
220
Loewe A
et al.
In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.
Europace,
2014
Nov
, 16 Suppl 4 (iv30-iv38).
221
Zhao X
et al.
The rescuable function and mechanism of resveratrol on As₂O₃-induced hERG K⁺ channel deficiency.
Naunyn Schmiedebergs Arch. Pharmacol.,
2014
Nov
, 387 (1079-89).
222
Johannesen L
et al.
Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil.
Clin. Pharmacol. Ther.,
2014
Nov
, 96 (549-58).
223
Frolov RV
et al.
Celecoxib and ion channels: a story of unexpected discoveries.
Eur. J. Pharmacol.,
2014
May
5
, 730 (61-71).
224
Shi S
et al.
Chronic N-Methyl-d-Aspartate Receptor Activation Induces Cardiac Electrical Remodeling and Increases Susceptibility to Ventricular Arrhythmias.
Pacing Clin Electrophysiol,
2014
May
30
, ().
225
Ke Y
et al.
Role of the cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) domain in trafficking and stabilization of Kv11.1 channels.
J. Biol. Chem.,
2014
May
16
, 289 (13782-91).
226
Pier DM
et al.
Long-term Channel Block is Required to Inhibit Cellular Transformation by Human Ether-a-go-go-related Gene (Herg1) Potassium Channels.
Mol. Pharmacol.,
2014
May
15
, ().
227
Wang S
et al.
β1-adrenergic regulation of rapid component of delayed rectifier K+ currents in guinea-pig cardiac myocytes.
Mol Med Rep,
2014
May
, 9 (1923-8).
228
Wang Q
et al.
Gain-of-function KCNH2 mutations in patients with Brugada syndrome.
J. Cardiovasc. Electrophysiol.,
2014
May
, 25 (522-30).
229
Hill AP
et al.
Kinetics of drug interaction with the Kv11.1 potassium channel.
Mol. Pharmacol.,
2014
May
, 85 (769-76).
230
231
Crociani O
et al.
hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications.
Clin. Cancer Res.,
2014
Mar
15
, 20 (1502-12).
232
Schumacher-Bass SM
et al.
Role for myosin-V motor proteins in the selective delivery of Kv channel isoforms to the membrane surface of cardiac myocytes.
Circ. Res.,
2014
Mar
14
, 114 (982-92).
233
Bhuiyan ZA
et al.
Not all pathogenic mutations are pathogenic: KCNH2 mutations in two sisters with tetralogy of Fallot.
Int. J. Cardiol.,
2014
Mar
1
, 172 (276-7).
234
Koenig X
et al.
Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.
Addict Biol,
2014
Mar
, 19 (237-9).
235
Rodríguez-Ravelo R
et al.
A K⁺ channel blocking peptide from the Cuban scorpion Rhopalurus garridoi.
Peptides,
2014
Mar
, 53 (42-7).
236
Yu H
et al.
Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome.
Int. J. Mol. Med.,
2014
Mar
, 33 (729-35).
237
Yang Y
et al.
[Construction of pcDNA3-HERG-G572R expression vector and establishment of a cell line stably expressing HKE-HERG-G572R].
Nan Fang Yi Ke Da Xue Xue Bao,
2014
Mar
, 34 (308-11).
238
Young JC
The role of the cytosolic HSP70 chaperone system in diseases caused by misfolding and aberrant trafficking of ion channels.
Dis Model Mech,
2014
Mar
, 7 (319-29).
239
Pond AL
et al.
The mERG1a channel modulates skeletal muscle MuRF1, but not MAFbx, expression.
Muscle Nerve,
2014
Mar
, 49 (378-88).
240
Loewe A
et al.
Arrhythmic potency of human ether-a-go-go-related gene mutations L532P and N588K in a computational model of human atrial myocytes.
Europace,
2014
Mar
, 16 (435-43).
241
Baumgartner S
et al.
Electrophysiological and Morphological Maturation of Murine Fetal Cardiomyocytes During Electrical Stimulation In Vitro.
J. Cardiovasc. Pharmacol. Ther.,
2014
Jun
9
, ().
242
Priest JR
et al.
Molecular Diagnosis of Long-QT syndrome at 10 Days of Life by Rapid Whole Genome Sequencing.
Heart Rhythm,
2014
Jun
25
, ().
243
Coleman N
et al.
New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol.,
2014
Jun
23
, ().
244
Sviripa VM
et al.
2',6'-Dihalostyrylanilines, Pyridines and Pyrimidines for the Inhibition of the Catalytic Subunit of Methionine S-Adenosyltransferase-2 (MAT2A).
J. Med. Chem.,
2014
Jun
20
, ().
245
Hameed P S
et al.
Novel N-Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against Mycobacterium tuberculosis.
J. Med. Chem.,
2014
Jun
12
, 57 (4889-905).
246
Li Q
et al.
Insight into the molecular interaction between the cyclic nucleotide-binding homology domain and the eag domain of the hERG channel.
FEBS Lett.,
2014
Jun
12
, ().
247
Mehta A
et al.
Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
Cardiovasc. Res.,
2014
Jun
1
, 102 (497-506).
248
Wang T
et al.
Muscarinic receptor activation increases hERG channel expression through phosphorylation of ubiquitin ligase Nedd4-2.
Mol. Pharmacol.,
2014
Jun
, 85 (877-86).
249
Moorthy NS
et al.
Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
J Enzyme Inhib Med Chem,
2014
Jun
, 29 (317-24).
250
Pillozzi S
et al.
Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups.
Leukemia,
2014
Jun
, 28 (1352-5).
251
Feng J
et al.
HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96.
Oncotarget,
2014
Jul
30
, 5 (5832-44).
252
Sherhod R
et al.
Emerging pattern mining to aid toxicological knowledge discovery.
J Chem Inf Model,
2014
Jul
28
, 54 (1864-79).
253
Romero L
et al.
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
J. Mol. Cell. Cardiol.,
2014
Jul
, 72 (126-37).
254
Bando S
et al.
Congenital long QT syndrome with compound mutations in the KCNH2 gene.
Heart Vessels,
2014
Jul
, 29 (554-9).
255
Glengarry JM
et al.
Long QT molecular autopsy in sudden infant death syndrome.
Arch. Dis. Child.,
2014
Jul
, 99 (635-40).
256
Luna-Ramírez K
et al.
Structure, molecular modeling, and function of the novel potassium channel blocker urotoxin isolated from the venom of the Australian scorpion Urodacus yaschenkoi.
Mol. Pharmacol.,
2014
Jul
, 86 (28-41).
257
González Cabrera D
et al.
2,4-Diaminothienopyrimidines as Orally Active Antimalarial Agents.
J. Med. Chem.,
2014
Jan
28
, ().
258
Radresa O
et al.
Roles of PKC Isoforms in PMA-Induced Modulation of the hERG Channel (Kv11.1).
J Biomol Screen,
2014
Jan
24
, ().
259
Gohlke BO
et al.
SuperPain--a resource on pain-relieving compounds targeting ion channels.
Nucleic Acids Res.,
2014
Jan
1
, 42 (D1107-12).
260
Yu Z
et al.
Allosteric modulators of the hERG K(+) channel: Radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Toxicol. Appl. Pharmacol.,
2014
Jan
1
, 274 (78-86).
261
Du D
et al.
In-silico modeling of glycosylation modulation dynamics in HERG ion channels and cardiac electrical signals.
IEEE J Biomed Health Inform,
2014
Jan
, 18 (205-14).
262
Chen A
et al.
Integrated platform for functional monitoring of biomimetic heart sheets derived from human pluripotent stem cells.
Biomaterials,
2014
Jan
, 35 (675-83).
263
Hata Y
et al.
Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death.
Int. J. Legal Med.,
2014
Jan
, 128 (105-15).
264
Schulze V
et al.
The opioid methadone induces a local anaesthetic-like inhibition of the cardiac Na⁺ channel, Na(v)1.5.
Br. J. Pharmacol.,
2014
Jan
, 171 (427-37).
265
Mints Y
et al.
Single nucleotide polymorphisms in proximity to K-channel genes are associated with decreased longitudinal QTc variance.
Ann Noninvasive Electrocardiol,
2014
Jan
, 19 (63-9).
266
Dempsey CE
et al.
Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.
J Chem Inf Model,
2014
Feb
24
, 54 (601-12).
267
Nair AG
et al.
IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: improved PK, hERG and metabolic profiles.
Bioorg. Med. Chem. Lett.,
2014
Feb
15
, 24 (1085-8).
268
Choi YJ
et al.
Successful reduction of off-target hERG toxicity by structural modification of a T-type calcium channel blocker.
Bioorg. Med. Chem. Lett.,
2014
Feb
1
, 24 (880-3).
269
Shin DS
et al.
A novel assessment of nefazodone-induced hERG inhibition by electrophysiological and stereochemical method.
Toxicol. Appl. Pharmacol.,
2014
Feb
1
, 274 (361-71).
270
Thurner P
et al.
Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.
J. Pharmacol. Exp. Ther.,
2014
Feb
, 348 (346-58).
271
Ma Q
et al.
Screening for cardiac HERG potassium channel interacting proteins using the yeast two-hybrid technique.
Cell Biol. Int.,
2014
Feb
, 38 (239-45).
272
Ferreiro SF
et al.
In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats.
Arch. Toxicol.,
2014
Feb
, 88 (425-34).
273
Zhang Y
et al.
The SCN5A mutation A1180V is associated with electrocardiographic features of LQT3.
Pediatr Cardiol,
2014
Feb
, 35 (295-300).
274
Roder K
et al.
RING finger protein RNF207, a novel regulator of cardiac excitation.
J. Biol. Chem.,
2014
Dec
5
, 289 (33730-40).
275
Jones DK
et al.
hERG 1b is critical for human cardiac repolarization.
Proc. Natl. Acad. Sci. U.S.A.,
2014
Dec
16
, 111 (18073-7).
276
Ogiyama T
et al.
Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels.
Bioorg. Med. Chem.,
2014
Dec
15
, 22 (6899-907).
277
Lim CJ
et al.
Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.
Bioorg. Med. Chem. Lett.,
2014
Dec
15
, 24 (5832-5).
278
Harcken C
et al.
Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.
ACS Med Chem Lett,
2014
Dec
11
, 5 (1318-23).
279
Epstein O
et al.
Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
J. Med. Chem.,
2014
Dec
11
, 57 (9796-810).
280
Dineen TA
et al.
Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).
J. Med. Chem.,
2014
Dec
11
, 57 (9811-31).
281
Strauss KA
et al.
A population-based study of KCNH7 p.Arg394His and bipolar spectrum disorder.
Hum. Mol. Genet.,
2014
Dec
1
, 23 (6395-406).
282
Bond R
et al.
Congenital long QT syndrome: a case report of LQT2 and LQT13 in a neonate.
Europace,
2014
Dec
, 16 (1807).
283
Ferreiro SF
et al.
In vitro chronic effects on hERG channel caused by the marine biotoxin azaspiracid-2.
Toxicon,
2014
Dec
, 91 (69-75).
284
Lin EC
et al.
Mouse ERG K(+) channel clones reveal differences in protein trafficking and function.
J Am Heart Assoc,
2014
Dec
, 3 (e001491).
285
Zhang KP
et al.
Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.
Acta Pharmacol. Sin.,
2014
Dec
, 35 (1473-84).
286
Li Q
et al.
Structural insight into the transmembrane segments 3 and 4 of the hERG potassium channel.
J. Pept. Sci.,
2014
Dec
, 20 (935-44).
287
Li P
et al.
The human ether-a-go-go-related gene activator NS1643 enhances epilepsy-associated KCNQ channels.
J. Pharmacol. Exp. Ther.,
2014
Dec
, 351 (596-604).
288
Wang Y
et al.
Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing.
J. Am. Coll. Cardiol.,
2014
Aug
5
, 64 (451-9).
289
Schmidtke P
et al.
Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
J Chem Inf Model,
2014
Aug
25
, 54 (2320-33).
290
Thomson SJ
et al.
Concerted all-or-none subunit interactions mediate slow deactivation of human ether-à-go-go-related gene K+ channels.
J. Biol. Chem.,
2014
Aug
22
, 289 (23428-36).
291
Long Y
et al.
Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide.
Eur. J. Pharmacol.,
2014
Aug
15
, 737 (202-9).
292
Cid JM
et al.
Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor.
J. Med. Chem.,
2014
Aug
14
, 57 (6495-512).
293
Spencer CI
et al.
Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia.
Stem Cell Reports,
2014
Aug
12
, 3 (269-81).
294
Hajj A
et al.
KCNH2 polymorphism and methadone dosage interact to enhance QT duration.
Drug Alcohol Depend,
2014
Aug
1
, 141 (34-8).
295
Yun J
et al.
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
Bioorg. Med. Chem. Lett.,
2014
Aug
1
, 24 (3234-7).
296
Imai M
et al.
Novel KCNQ1 splicing mutation in patients with forme fruste LQT1 aggravated by hypokalemia.
J Cardiol,
2014
Aug
, 64 (121-6).
297
Liu LL
et al.
Novel Bayesian classification models for predicting compounds blocking hERG potassium channels.
Acta Pharmacol. Sin.,
2014
Aug
, 35 (1093-102).
298
Alexandrou AJ
et al.
The human ether-a'-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: limited dependence on S6 aromatic residues.
J. Physiol. Pharmacol.,
2014
Aug
, 65 (511-23).
299
Gong Q
et al.
Identification of Kv11.1 isoform switch as a novel pathogenic mechanism of long-QT syndrome.
Circ Cardiovasc Genet,
2014
Aug
, 7 (482-90).
300
Gong Q
et al.
Position of premature termination codons determines susceptibility of hERG mutations to nonsense-mediated mRNA decay in long QT syndrome.
Gene,
2014
Apr
15
, 539 (190-7).
301
Weeke P
et al.
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome.
J. Am. Coll. Cardiol.,
2014
Apr
15
, 63 (1430-7).
302
Martinson AS
et al.
Functional evolution of Erg potassium channel gating reveals an ancient origin for IKr.
Proc. Natl. Acad. Sci. U.S.A.,
2014
Apr
15
, 111 (5712-7).
303
Chanséaume A
et al.
[KCNH2 gene new mutation in a patient with prior diagnosis of epilepsy].
Rev. Neurol. (Paris),
2014
Apr
, 170 (304-5).
305
Noriega-Navarro R
et al.
Novel TASK channels inhibitors derived from dihydropyrrolo[2,1-a]isoquinoline.
Neuropharmacology,
2014
Apr
, 79 (28-36).
306
Silvestre JS
et al.
Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
J. Psychopharmacol. (Oxford),
2014
Apr
, 28 (329-40).
307
Sanguinetti MC
HERG1 channel agonists and cardiac arrhythmia.
Curr Opin Pharmacol,
2014
Apr
, 15 (22-7).
308
Wu W
et al.
Stoichiometry of altered hERG1 channel gating by small molecule activators.
J. Gen. Physiol.,
2014
Apr
, 143 (499-512).
309
Wang D
et al.
Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths.
Forensic Sci. Int.,
2014
Apr
, 237 (90-9).
310
Tester DJ
et al.
GENETICS OF LONG QT SYNDROME.
Methodist Debakey Cardiovasc J,
2014
1
, 10 (29-33).
311
Zhang P
et al.
New Aspects of HERG K(+) Channel Function Depending upon Cardiac Spatial Heterogeneity.
PLoS ONE,
2014
, 9 (e72181).
312
Iyer V
et al.
Modeling Tissue- and Mutation- Specific Electrophysiological Effects in the Long QT Syndrome: Role of the Purkinje Fiber.
PLoS ONE,
2014
, 9 (e97720).
313
Sivagangabalan G
et al.
Regional ion channel gene expression heterogeneity and ventricular fibrillation dynamics in human hearts.
PLoS ONE,
2014
, 9 (e82179).
314
Shao XD
et al.
The mechanism of COX-2 regulating HERG channel in gastric cancer cells.
Bratisl Lek Listy,
2014
, 115 (487-91).
315
Zheng X
et al.
Natural antisense transcripts regulate the neuronal stress response and excitability.
Elife,
2014
, 3 (e01849).
316
Christiansen M
et al.
Mutations in Danish patients with long QT syndrome and the identification of a large founder family with p.F29L in KCNH2.
BMC Med. Genet.,
2014
, 15 (31).
317
Durdagi S
et al.
Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.
BMC Pharmacol Toxicol,
2014
, 15 (14).
318
Schlichter LC
et al.
Regulation of hERG and hEAG channels by Src and by SHP-1 tyrosine phosphatase via an ITIM region in the cyclic nucleotide binding domain.
PLoS ONE,
2014
, 9 (e90024).
319
Munoz C
et al.
Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3.
Cell. Physiol. Biochem.,
2014
, 33 (491-500).
320
Rizzo A
et al.
Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities.
J. Exp. Clin. Cancer Res.,
2014
, 33 (81).
321
Shimizu W
Clinical and genetic diagnosis for inherited cardiac arrhythmias.
J Nippon Med Sch,
2014
, 81 (203-10).
322
Aslanidis A
et al.
RETINA-specific expression of Kcnv2 is controlled by cone-rod homeobox (Crx) and neural retina leucine zipper (Nrl).
Adv. Exp. Med. Biol.,
2014
, 801 (31-41).
323
Jimmy JJ
et al.
Clinical characteristics of patients with congenital long QT syndrome and bigenic mutations.
Chin. Med. J.,
2014
, 127 (1482-6).
324
Polonchuk L
Industrializing electrophysiology: HT automated patch clamp on SyncroPatch® 96 using instant frozen cells.
Methods Mol. Biol.,
2014
, 1183 (81-92).
325
Danker T
et al.
Early identification of hERG liability in drug discovery programs by automated patch clamp.
Front Pharmacol,
2014
, 5 (203).
326
Braga RC
et al.
Tuning HERG out: antitarget QSAR models for drug development.
Curr Top Med Chem,
2014
, 14 (1399-415).
327
Staudacher I
et al.
HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells.
PLoS ONE,
2014
, 9 (e88164).
328
Li G
et al.
Allitridin reduces I Kr current by disrupting the trafficking of human ether-à-go-go-related gene channels.
Cardiology,
2014
, 128 (1-8).
329
Pakladok T
et al.
Up-regulation of hERG K⁺ channels by B-RAF.
PLoS ONE,
2014
, 9 (e87457).
330
Yamaguchi Y
et al.
Glycine/Serine polymorphism at position 38 influences KCNE1 subunit's modulatory actions on rapid and slow delayed rectifier K+ currents.
Circ. J.,
2014
, 78 (610-8).
331
Hu YT
et al.
Open conformation of hERG channel turrets revealed by a specific scorpion toxin BmKKx2.
Cell Biosci,
2014
, 4 (18).
332
Nielsen JB
et al.
Gain-of-function mutations in potassium channel subunit KCNE2 associated with early-onset lone atrial fibrillation.
Biomark Med,
2014
, 8 (557-70).
333
Goodchild SJ
et al.
Gating charge movement precedes ionic current activation in hERG channels.
Channels (Austin),
2014
, 8 (84-9).
334
Liu J
et al.
Patch-clamp technique in ESC-derived cardiomyocytes.
Methods Mol. Biol.,
2014
, 1181 (203-14).
335
Guo X
et al.
Discovery of aroyl piperazine derivatives as IKr & IKs dual inhibitors for cardiac arrhythmia treatment.
Med Chem,
2014
, 10 (497-505).
336
Sanders NG
et al.
Antimalarial efficacy of hydroxyethylapoquinine (SN-119) and its derivatives.
Antimicrob. Agents Chemother.,
2014
, 58 (820-7).
337
Yu CC
et al.
Apamin does not inhibit human cardiac Na+ current, L-type Ca2+ current or other major K+ currents.
PLoS ONE,
2014
, 9 (e96691).
338
Tanaka H
et al.
Effect of terfenadine and pentamidine on the HERG channel and its intracellular trafficking: combined analysis with automated voltage clamp and confocal microscopy.
Biol. Pharm. Bull.,
2014
, 37 (1826-30).
339
Lin TF
et al.
The Eag domain regulates the voltage-dependent inactivation of rat Eag1 K+ channels.
PLoS ONE,
2014
, 9 (e110423).
340
Anderson CL
et al.
Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome.
Nat Commun,
2014
, 5 (5535).
341
Tong WC
et al.
Computational modeling reveals key contributions of KCNQ and hERG currents to the malleability of uterine action potentials underpinning labor.
PLoS ONE,
2014
, 9 (e114034).
342
Hancox JC
et al.
Modification of KCNH2-encoded cardiac potassium channels by KCNE1 polymorphism.
Circ. J.,
2014
, 78 (2330).
343
Schweigmann U
et al.
Elevated heart rate triggers action potential alternans and sudden death. translational study of a homozygous KCNH2 mutation.
PLoS ONE,
2014
, 9 (e103150).
344
Zhang K
et al.
Berberine induces hERG channel deficiency through trafficking inhibition.
Cell. Physiol. Biochem.,
2014
, 34 (691-702).
345
Lee SH
et al.
Blockade of HERG human K+ channels by the antidepressant drug paroxetine.
Biol. Pharm. Bull.,
2014
, 37 (1495-504).
346
Tabata T
et al.
Modification of KCNH2-encoded cardiac potassium channels by KCNE1 polymorphism.
Circ. J.,
2014
, 78 (2331).
347
Lu J
et al.
Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.
PLoS ONE,
2014
, 9 (e115648).
348
Guo J
et al.
Structure driven design of novel human ether-a-go-go-related-gene channel (hERG1) activators.
PLoS ONE,
2014
, 9 (e105553).
349
Zeng H
et al.
Halide Ion Effects on Human Ether-à-go-go Related Gene Potassium Channel Properties.
Assay Drug Dev Technol,
2013 Nov-Dec
, 11 (544-50).
350
Beattie KA
et al.
Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (88-96).
351
Morissette P
et al.
The anesthetized guinea pig: An effective early cardiovascular derisking and lead optimization model.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (137-49).
352
Elkins RC
et al.
Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (112-22).
353
Himmel HM
Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (97-111).
354
Rampe D
et al.
A history of the role of the hERG channel in cardiac risk assessment.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (13-22).
355
Qu Y
et al.
Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (74-81).
356
Chun YS
et al.
Cholesterol regulates HERG K+ channel activation by increasing phospholipase C β1 expression.
Channels (Austin),
2013 Jul-Aug
, 7 (275-87).
357
Gillie DJ
et al.
Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
J Pharmacol Toxicol Methods,
2013 Jan-Feb
, 67 (33-44).
358
Haugaa KH
et al.
Abnormal electroencephalograms in patients with long QT syndrome.
Heart Rhythm,
2013
Sep
27
, ().
360
Park MH
et al.
Effect of azelastine on cardiac repolarization of guinea-pig cardiomyocytes, hERG K⁺ channel, and human L-type and T-type Ca²⁺ channel.
J. Pharmacol. Sci.,
2013
Sep
20
, 123 (67-77).
361
Wang N
et al.
Procaine, a state-dependent blocker, inhibits HERG channels by helix residue Y652 and F656 in the S6 transmembrane domain.
J. Pharmacol. Sci.,
2013
Sep
20
, 123 (25-35).
362
Haitin Y
et al.
The structural mechanism of KCNH-channel regulation by the eag domain.
Nature,
2013
Sep
19
, 501 (444-8).
363
Diamant UB
et al.
Electrophysiological Phenotype in the LQTS Mutations Y111C and R518X in the KCNQ1 Gene.
J. Appl. Physiol.,
2013
Sep
19
, ().
364
Baczkó I
et al.
Characterization of a novel multi-functional resveratrol derivative for the treatment of atrial fibrillation.
Br. J. Pharmacol.,
2013
Sep
18
, ().
365
Di Veroli GY
et al.
hERG Inhibitors With Similar Potency But Different Binding Kinetics Do Not Pose the Same Proarrhythmic Risk: Implications for Drug Safety Assessment.
J. Cardiovasc. Electrophysiol.,
2013
Sep
12
, ().
366
Cordeiro JM
et al.
Developmental changes in expression and biophysics of ion channels in the canine ventricle.
J. Mol. Cell. Cardiol.,
2013
Sep
10
, 64C (79-89).
367
Hedley PL
et al.
The Role of CAV3 in Long QT Syndrome: Clinical and Functional Assessment of a Caveolin-3/Kv11.1 Double Heterozygote Versus Caveolin-3 Single Heterozygote.
Circ Cardiovasc Genet,
2013
Sep
10
, ().
368
Liu C
et al.
Postmortem molecular analysis of KCNQ1, KCNH2, KCNE1 and KCNE2 genes in sudden unexplained nocturnal death syndrome in the Chinese Han population.
Forensic Sci. Int.,
2013
Sep
10
, 231 (82-7).
369
Washburn DG
et al.
The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore.
Bioorg. Med. Chem. Lett.,
2013
Sep
1
, 23 (4979-84).
370
Park JK
et al.
Single Nucleotide Deletion Mutation of KCNH2 Gene is Responsible for LQT Syndrome in a 3-Generation Korean Family.
J. Korean Med. Sci.,
2013
Sep
, 28 (1388-93).
371
Cheng YM
et al.
Functional interactions of voltage sensor charges with an S2 hydrophobic plug in hERG channels.
J. Gen. Physiol.,
2013
Sep
, 142 (289-303).
372
Perry MD
et al.
Hydrophobic interactions between the voltage sensor and pore mediate inactivation in Kv11.1 channels.
J. Gen. Physiol.,
2013
Sep
, 142 (275-88).
373
Nawathe PA
et al.
An LQTS6 MiRP1 mutation suppresses pacemaker current and is associated with sinus bradycardia.
J. Cardiovasc. Electrophysiol.,
2013
Sep
, 24 (1021-7).
374
Zhang P
et al.
Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
J. Pharm. Pharmacol.,
2013
Sep
, 65 (1321-8).
375
Fischer F
et al.
Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.
Naunyn Schmiedebergs Arch. Pharmacol.,
2013
Sep
, 386 (795-804).
376
Olesen MS
et al.
Very early onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation.
Heart Rhythm,
2013
Oct
18
, ().
377
Niculescu D
et al.
Erg potassium currents of neonatal mouse Purkinje cells exhibit fast gating kinetics and are inhibited by mGluR1 activation.
J. Neurosci.,
2013
Oct
16
, 33 (16729-40).
378
Meng J
et al.
Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization.
Eur. J. Pharmacol.,
2013
Oct
15
, 718 (87-97).
379
Hasegawa K
et al.
A Novel KCNQ1 Missense Mutation Identified in a Patient with Juvenile-Onset Atrial Fibrillation Causes Constitutively Open IKs Channels.
Heart Rhythm,
2013
Oct
1
, ().
380
Cuneo BF
et al.
Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratification of perinatal long-QT syndrome.
Circ Arrhythm Electrophysiol,
2013
Oct
, 6 (946-51).
381
Orts DJ
et al.
BcsTx3 is a founder of a novel sea anemone toxin family of potassium channel blocker.
FEBS J.,
2013
Oct
, 280 (4839-52).
382
Andreasen L
et al.
Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation.
Can J Cardiol,
2013
Oct
, 29 (1234-40).
383
Yoshinaga M
et al.
Electrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals.
Circ Arrhythm Electrophysiol,
2013
Oct
, 6 (932-8).
384
Gianulis EC
et al.
Direct interaction of eag domains and cyclic nucleotide-binding homology domains regulate deactivation gating in hERG channels.
J. Gen. Physiol.,
2013
Oct
, 142 (351-66).
385
Fiore A
et al.
Characterization of hERG1 channel role in mouse colorectal carcinogenesis.
Cancer Med,
2013
Oct
, 2 (583-94).
386
Salyer SA
et al.
Vacuolar ATPase driven potassium transport in highly metastatic breast cancer cells.
Biochim. Biophys. Acta,
2013
Oct
, 1832 (1734-43).
387
Lee YS
et al.
Long QT syndrome: a Korean single center study.
J. Korean Med. Sci.,
2013
Oct
, 28 (1454-60).
388
Bodi I
et al.
Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
J. Cardiovasc. Electrophysiol.,
2013
Oct
, 24 (1163-71).
389
Kamei S
et al.
Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor?
J. Hum. Genet.,
2013
Nov
28
, ().
390
Nogawa H
et al.
Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs.
Eur. J. Pharmacol.,
2013
Nov
15
, 720 (29-37).
391
Friddin MS
et al.
Single-channel electrophysiology of cell-free expressed ion channels by direct incorporation in lipid bilayers.
Analyst,
2013
Nov
12
, 138 (7294-8).
392
Stump MR
et al.
LQT2 nonsense mutations generate trafficking defective NH2-terminally truncated channels by the reinitiation of translation.
Am. J. Physiol. Heart Circ. Physiol.,
2013
Nov
1
, 305 (H1397-404).
393
Ayon RJ
et al.
Mutant hERG channel traffic jam. Focus on "Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum".
Am. J. Physiol., Cell Physiol.,
2013
Nov
1
, 305 (C916-8).
394
Smith JL
et al.
Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
Am. J. Physiol., Cell Physiol.,
2013
Nov
1
, 305 (C919-30).
395
Tang H
et al.
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.
Bioorg. Med. Chem. Lett.,
2013
Nov
1
, 23 (5829-32).
396
Coi A
et al.
Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
J. Mol. Graph. Model.,
2013
Nov
, 46 (93-104).
397
Almilaji A
et al.
AMP-activated protein kinase regulates hERG potassium channel.
Pflugers Arch.,
2013
Nov
, 465 (1573-82).
398
Oshima A
et al.
Reconstitution of human ether-a-go-go-related gene channels in microfabricated silicon chips.
Anal. Chem.,
2013
May
7
, 85 (4363-9).
399
Lamothe SM
et al.
The serum- and glucocorticoid-inducible kinases SGK1 and SGK3 regulate hERG channel expression via ubiquitin ligase Nedd4-2 and GTPase Rab11.
J. Biol. Chem.,
2013
May
24
, 288 (15075-84).
400
Koenig X
et al.
Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile.
Toxicol. Appl. Pharmacol.,
2013
May
22
, ().
401
Doherty KR
et al.
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Toxicol. Appl. Pharmacol.,
2013
May
21
, ().
402
Leanza L
et al.
Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines.
Curr. Pharm. Des.,
2013
May
16
, ().
403
Mitton-Fry MJ
et al.
Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Bioorg. Med. Chem. Lett.,
2013
May
15
, 23 (2955-61).
404
Leifert A
et al.
Differential hERG ion channel activity of ultrasmall gold nanoparticles.
Proc. Natl. Acad. Sci. U.S.A.,
2013
May
14
, 110 (8004-9).
405
de la Peña P
et al.
Mapping of interactions between the N- and C-termini and the channel core in HERG K+ channels.
Biochem. J.,
2013
May
1
, 451 (463-74).
406
Andaloussi M
et al.
A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787.
Bioorg. Med. Chem. Lett.,
2013
May
1
, 23 (2663-70).
407
Carr DB
et al.
Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.
Clin Ther,
2013
May
, 35 (646-58).
408
An HS
et al.
Sudden cardiac arrest during anesthesia in a 30-month-old boy with syndactyly: a case of genetically proven Timothy syndrome.
J. Korean Med. Sci.,
2013
May
, 28 (788-91).
409
McBride CM
et al.
Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.
J. Membr. Biol.,
2013
May
, 246 (355-64).
410
Wei X
et al.
ZC88, a novel 4-amino piperidine analog, inhibits the growth of neuroblastoma cells through blocking hERG potassium channel.
Cancer Biol. Ther.,
2013
May
, 14 (450-7).
411
Aziz PF
et al.
Do LQTS gene single nucleotide polymorphisms alter QTc intervals at rest and during exercise stress testing?
Ann Noninvasive Electrocardiol,
2013
May
, 18 (288-93).
412
Matsa E
et al.
Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes.
Eur. Heart J.,
2013
Mar
6
, ().
413
Guo B
et al.
Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.
J. Med. Chem.,
2013
Mar
28
, 56 (2642-50).
414
Park JE
et al.
Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers.
Bioorg. Med. Chem. Lett.,
2013
Mar
15
, 23 (1887-90).
415
Long Y
et al.
Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.
Toxicol. Appl. Pharmacol.,
2013
Mar
1
, 267 (155-66).
416
Babcock JJ
et al.
hERG channel function: beyond long QT.
Acta Pharmacol. Sin.,
2013
Mar
, 34 (329-35).
417
Hashimoto R
et al.
The KCNH2 gene is associated with neurocognition and the risk of schizophrenia.
World J. Biol. Psychiatry,
2013
Mar
, 14 (114-20).
418
Moorthy NS
et al.
QSAR and pharmacophore analysis of a series of piperidinyl urea derivatives as HERG blockers and H3 antagonists.
Curr Drug Discov Technol,
2013
Mar
, 10 (47-58).
419
Orts DJ
et al.
Biochemical and electrophysiological characterization of two sea anemone type 1 potassium toxins from a geographically distant population of Bunodosoma caissarum.
Mar Drugs,
2013
Mar
, 11 (655-79).
420
Jehle J
et al.
Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
Br. J. Pharmacol.,
2013
Mar
, 168 (1215-29).
421
Munoz C
et al.
Klotho sensitivity of the hERG channel.
FEBS Lett.,
2013
Jun
5
, 587 (1663-8).
422
Steinke K
et al.
Coxsackievirus B3 modulates cardiac ion channels.
FASEB J.,
2013
Jun
27
, ().
423
Colenso CK
et al.
Interactions between voltage sensor and pore domains in a hERG K+ channel model from molecular simulations and the effects of a voltage sensor mutation.
J Chem Inf Model,
2013
Jun
24
, 53 (1358-70).
424
Chen Y
et al.
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
J. Med. Chem.,
2013
Jun
13
, 56 (4671-90).
425
Ginman T
et al.
Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity.
J. Med. Chem.,
2013
Jun
13
, 56 (4181-205).
426
Byeon SR
et al.
Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment.
Bioorg. Med. Chem. Lett.,
2013
Jun
1
, 23 (3467-9).
427
Wang S
et al.
Recent developments in computational prediction of HERG blockage.
Curr Top Med Chem,
2013
Jun
1
, 13 (1317-26).
428
Santos Y
et al.
Arrhythmogenic effect of a crude extract from sea anemone Condylactis gigantea: possible involvement of rErg1 channels.
Toxicon,
2013
Jun
1
, 67 (47-54).
429
Townsend C
et al.
Predicting Drug-Induced QT Prolongation and Torsades de Pointes: A Review of Preclinical Endpoint Measures.
Curr Protoc Pharmacol,
2013
Jun
, Chapter 10 (Unit10.16).
430
Gravel AE
et al.
An NMR investigation of the structure, function and role of the hERG channel selectivity filter in the long QT syndrome.
Biochim. Biophys. Acta,
2013
Jun
, 1828 (1494-502).
431
Brudeli B
et al.
Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist.
Eur J Med Chem,
2013
Jun
, 64 (629-37).
432
Lin K
et al.
Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells.
Acta Pharmacol. Sin.,
2013
Jun
, 34 (847-58).
433
Stowasser M
Primary aldosteronism and potassium channel mutations.
Curr Opin Endocrinol Diabetes Obes,
2013
Jun
, 20 (170-9).
434
Lahtinen AM
et al.
Prevalence of arrhythmia-associated gene mutations and risk of sudden cardiac death in the Finnish population.
Ann. Med.,
2013
Jun
, 45 (328-35).
435
Kazmierczak M
et al.
External pH modulates EAG superfamily K+ channels through EAG-specific acidic residues in the voltage sensor.
J. Gen. Physiol.,
2013
Jun
, 141 (721-35).
436
Arcangeli A
et al.
High hERG1 expression in advanced melanoma.
Melanoma Res.,
2013
Jun
, 23 (185-90).
437
Brelidze TI
et al.
Structure of the C-terminal region of an ERG channel and functional implications.
Proc. Natl. Acad. Sci. U.S.A.,
2013
Jul
9
, 110 (11648-53).
438
Nilsson MF
et al.
Comparative effects of sodium channel blockers in short term rat whole embryo culture.
Toxicol. Appl. Pharmacol.,
2013
Jul
8
, ().
439
Cui Z
et al.
Regulation of the human ether-a-go-go-related gene (hERG) channel by Rab4 protein through neural precursor cell-expressed developmentally down-regulated protein 4-2 (Nedd4-2).
J. Biol. Chem.,
2013
Jul
26
, 288 (21876-86).
440
Kiss T
et al.
Identification of diterpene alkaloids from Aconitum napellus subsp. firmum and GIRK channel activities of some Aconitum alkaloids.
Fitoterapia,
2013
Jul
19
, ().
441
Duchatelet S
et al.
Identification of a KCNQ1 Polymorphism Acting as a Protective Modifier against Arrhythmic Risk in Long QT Syndrome.
Circ Cardiovasc Genet,
2013
Jul
15
, ().
442
Seki M
et al.
Synthesis and biological evaluation of pyrrolidine derivatives as novel and potent sodium channel blockers for the treatment of ischemic stroke.
Bioorg. Med. Chem. Lett.,
2013
Jul
15
, 23 (4230-4).
443
Ryu S
et al.
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Bioorg. Med. Chem. Lett.,
2013
Jul
1
, 23 (3848-51).
444
Takanari H
et al.
Efficient and specific cardiac IK1 inhibition by a new pentamidine analogue.
Cardiovasc. Res.,
2013
Jul
1
, 99 (203-14).
445
Varkevisser R
et al.
Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
Br. J. Pharmacol.,
2013
Jul
, 169 (1322-34).
446
Son MK
et al.
Genetic mutation in korean patients of sudden cardiac arrest as a surrogating marker of idiopathic ventricular arrhythmia.
J. Korean Med. Sci.,
2013
Jul
, 28 (1021-6).
447
Lieve KV
et al.
Results of genetic testing in 855 consecutive unrelated patients referred for long QT syndrome in a clinical laboratory.
Genet Test Mol Biomarkers,
2013
Jul
, 17 (553-61).
448
Rayan A
et al.
Indexing molecules for their hERG liability.
Eur J Med Chem,
2013
Jul
, 65 (304-14).
449
Jou CJ
et al.
An In Vivo Cardiac Assay to Determine the Functional Consequences of Putative Long QT Syndrome Mutations.
Circ. Res.,
2013
Jan
9
, ().
450
Ford J
et al.
Human Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial Selective Kv1.5/IKur Inhibitor.
J. Cardiovasc. Pharmacol.,
2013
Jan
29
, ().
451
Di Martino GP
et al.
An automated docking protocol for hERG channel blockers.
J Chem Inf Model,
2013
Jan
28
, 53 (159-75).
452
Li H
et al.
The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.
Bioorg. Med. Chem. Lett.,
2013
Jan
15
, 23 (466-71).
453
Di Veroli GY
et al.
High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Am. J. Physiol. Heart Circ. Physiol.,
2013
Jan
1
, 304 (H104-17).
454
Zhang Y
et al.
Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.
Biochem. Pharmacol.,
2013
Jan
1
, 85 (59-68).
455
Narayana Moorthy NS
et al.
Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Curr Drug Targets,
2013
Jan
1
, 14 (102-13).
456
Liu L
et al.
A novel mutation in the transmembrane nonpore region of the KCNH2 gene causes severe clinical manifestations of long QT syndrome.
Heart Rhythm,
2013
Jan
, 10 (61-7).
457
Zarzoso M
et al.
Mission possible: RNA interference rescues the hERG current.
Heart Rhythm,
2013
Jan
, 10 (137-8).
458
Beattie DT
et al.
An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954.
Vascul. Pharmacol.,
2013
Jan
, 58 (150-6).
459
Lu X
et al.
RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties.
Heart Rhythm,
2013
Jan
, 10 (128-36).
460
Braam SR
et al.
Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes.
Stem Cell Res,
2013
Jan
, 10 (48-56).
461
Ng CA
et al.
Insights into hERG K+ channel structure and function from NMR studies.
Eur. Biophys. J.,
2013
Jan
, 42 (71-9).
462
Wei T
et al.
[Effect of berberine, liensinine and neferine on HERG channel expression].
Zhongguo Zhong Yao Za Zhi,
2013
Jan
, 38 (239-44).
463
Zhang A
et al.
L539 fs/47, a truncated mutation of human ether-a-go-go-related gene (hERG), decreases hERG ion channel currents in HEK 293 cells.
Clin. Exp. Pharmacol. Physiol.,
2013
Jan
, 40 (28-36).
464
Sirenko O
et al.
Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells.
J Biomol Screen,
2013
Jan
, 18 (39-53).
465
Terrenoire C
et al.
Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
J. Gen. Physiol.,
2013
Jan
, 141 (61-72).
466
Su X
et al.
Effect of microculture on cell metabolism and biochemistry: do cells get stressed in microchannels?
Anal. Chem.,
2013
Feb
5
, 85 (1562-70).
467
Hong HK
et al.
Block of hERG K+ channel and prolongation of action potential duration by fluphenazine at submicromolar concentration.
Eur. J. Pharmacol.,
2013
Feb
28
, 702 (165-73).
468
Andreasen C
et al.
Mutations in Genes Encoding Cardiac Ion Channels Previously Associated With Sudden Infant Death Syndrome (SIDS) Are Present With High Frequency in New Exome Data.
Can J Cardiol,
2013
Feb
25
, ().
469
Hausammann GJ
et al.
Generation of an antibody toolbox to characterize hERG.
Biochem. Biophys. Res. Commun.,
2013
Feb
1
, 431 (70-5).
470
Harris RA
et al.
Human metastable epiallele candidates link to common disorders.
Epigenetics,
2013
Feb
, 8 (157-63).
471
Yang LJ
et al.
New targets for the antitumor activity of gambogic acid in hematologic malignancies.
Acta Pharmacol. Sin.,
2013
Feb
, 34 (191-8).
472
Gustina AS
et al.
The eag domain regulates hERG channel inactivation gating via a direct interaction.
J. Gen. Physiol.,
2013
Feb
, 141 (229-41).
473
Dong H
et al.
Functional expression of ERG1 potassium channels in rat alveolar macrophages.
J. Mol. Histol.,
2013
Feb
, 44 (117-24).
474
Norring SA
et al.
Channel sialic acids limit hERG channel activity during the ventricular action potential.
FASEB J.,
2013
Feb
, 27 (622-31).
475
Silva D
et al.
Novel mutation in the KCNH2 gene associated with long QT syndrome.
Rev Port Cardiol,
2013
Feb
, 32 (163-4).
476
Zemzemi N
et al.
Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials.
Br. J. Pharmacol.,
2013
Feb
, 168 (718-33).
477
Hausammann GJ
et al.
Chimeric hERG channels containing a tetramerization domain are functional and stable.
Biochemistry,
2013
Dec
23
, 52 (9237-45).
478
Shi YP
et al.
External protons destabilize the activated voltage sensor in hERG channels.
Eur. Biophys. J.,
2013
Dec
21
, ().
479
Louvel J
et al.
Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
J. Med. Chem.,
2013
Dec
12
, 56 (9427-40).
480
Bellin M
et al.
Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
EMBO J.,
2013
Dec
11
, 32 (3161-75).
481
Iwai C
et al.
Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins.
Cardiovasc. Res.,
2013
Dec
1
, 100 (520-8).
482
He YL
et al.
High-quality triplicate electrocardiogram monitoring in a first-in-man study: potential for early detection of drug-induced QT prolongation.
Int J Clin Pharmacol Ther,
2013
Dec
, 51 (948-57).
483
Apaja PM
et al.
Ubiquitination-dependent quality control of hERG K+ channel with acquired and inherited conformational defect at the plasma membrane.
Mol. Biol. Cell,
2013
Dec
, 24 (3787-804).
484
Hintsa T
et al.
Work stress and the long QT syndrome: high job strain and effort-reward imbalance at work associated with arrhythmic risk in the long QT syndrome.
J. Occup. Environ. Med.,
2013
Dec
, 55 (1387-93).
485
Goineau S
et al.
In vitro safety cardiovascular pharmacology studies: impact of formulation preparation and analysis.
Regul. Toxicol. Pharmacol.,
2013
Dec
, 67 (499-505).
486
Lin J
et al.
[Protein tyrosine phosphatase non-receptor type 12 negatively regulates cardiac HERG channel currents].
Nan Fang Yi Ke Da Xue Xue Bao,
2013
Dec
, 33 (1718-22).
487
Fortunato A
et al.
An analytical method for the quantification of hERG1 channel gene expression in human colorectal cancer.
Diagn. Mol. Pathol.,
2013
Dec
, 22 (215-21).
488
Dowling JE
et al.
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.
ACS Med Chem Lett,
2013
Aug
8
, 4 (800-5).
489
Kato K
et al.
Cardiac Channelopathies Associated with Infantile Fatal Ventricular Arrhythmias: From the Cradle to the Bench.
J. Cardiovasc. Electrophysiol.,
2013
Aug
26
, ().
490
Hayashi M
et al.
Molecular basis of potassium channels in pancreatic duct epithelial cells.
Channels (Austin),
2013
Aug
20
, 7 ().
491
Dou Y
et al.
The neutral, hydrophobic isoleucine at position I521 in the extracellular S4 domain of hERG contributes to channel gating equilibrium.
Am. J. Physiol., Cell Physiol.,
2013
Aug
15
, 305 (C468-78).
492
K E Y
et al.
Trafficking defects in PAS domain mutant Kv11.1 channels: roles of reduced domain stability and altered domain-domain interactions.
Biochem. J.,
2013
Aug
15
, 454 (69-77).
493
Sun H
et al.
Are hERG channel blockers also phospholipidosis inducers?
Bioorg. Med. Chem. Lett.,
2013
Aug
15
, 23 (4587-90).
494
Cicek MS
et al.
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
Hum. Mol. Genet.,
2013
Aug
1
, 22 (3038-47).
495
Kruse M
et al.
The phosphoinositide sensitivity of the KV channel family.
Channels (Austin),
2013
Aug
1
, 7 ().
496
Partemi S
et al.
Loss-of-function KCNH2 mutation in a family with long QT syndrome, epilepsy, and sudden death.
Epilepsia,
2013
Aug
, 54 (e112-6).
497
Sroubek J
et al.
Sequence and structure-specific elements of HERG mRNA determine channel synthesis and trafficking efficiency.
FASEB J.,
2013
Aug
, 27 (3039-53).
498
Gao Y
et al.
A novel deletion-frameshift mutation in the S1 region of HERG gene in a Chinese family with long QT syndrome.
Chin. Med. J.,
2013
Aug
, 126 (3093-6).
499
Choi SW
et al.
Class 3 inhibition of hERG K+ channel by caffeic acid phenethyl ester (CAPE) and curcumin.
Pflugers Arch.,
2013
Aug
, 465 (1121-34).
500
Harris K
et al.
Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
Toxicol. Sci.,
2013
Aug
, 134 (412-26).
501
Arslan Yildiz A
et al.
Biomimetic membrane platform containing hERG potassium channel and its application to drug screening.
Analyst,
2013
Apr
7
, 138 (2007-12).
502
Perry MD
et al.
Pore helices play a dynamic role as integrators of domain motion during Kv11.1 channel inactivation gating.
J. Biol. Chem.,
2013
Apr
19
, 288 (11482-91).
503
Carvalho JF
et al.
Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
J. Med. Chem.,
2013
Apr
11
, 56 (2828-40).
504
Crotti L
et al.
Long QT syndrome-associated mutations in intrauterine fetal death.
JAMA,
2013
Apr
10
, 309 (1473-82).
505
Wang Z
et al.
Components of gating charge movement and S4 voltage-sensor exposure during activation of hERG channels.
J. Gen. Physiol.,
2013
Apr
, 141 (431-43).
506
Shinwari ZM
et al.
Identification of a novel KCNQ1 mutation in a large Saudi family with long QT syndrome: clinical consequences and preventive implications.
Clin. Genet.,
2013
Apr
, 83 (370-4).
508
Yoshikane Y
et al.
A case of long QT syndrome with triple gene abnormalities: digenic mutations in KCNH2 and SCN5A and gene variant in KCNE1.
Heart Rhythm,
2013
Apr
, 10 (600-3).
509
He FZ
et al.
Current pharmacogenomic studies on hERG potassium channels.
Trends Mol Med,
2013
Apr
, 19 (227-38).
510
Adaixo R
et al.
Structural properties of PAS domains from the KCNH potassium channels.
PLoS ONE,
2013
, 8 (e59265).
511
Abdelhady S
et al.
Erg channel is critical in controlling cell volume during cell cycle in embryonic stem cells.
PLoS ONE,
2013
, 8 (e72409).
512
Moric-Janiszewska E
et al.
Quantitative PCR as an Alternative in the Diagnosis of Long-QT Syndrome.
Biomed Res Int,
2013
, 2013 (418604).
513
Ouadid-Ahidouch H
et al.
K(+) channels and cell cycle progression in tumor cells.
Front Physiol,
2013
, 4 (220).
514
Shimizu W
Update of diagnosis and management of inherited cardiac arrhythmias.
Circ. J.,
2013
, 77 (2867-72).
515
Ng CA
et al.
C-Terminal β9-Strand of the Cyclic Nucleotide-Binding Homology Domain Stabilizes Activated States of Kv11.1 Channels.
PLoS ONE,
2013
, 8 (e77032).
516
Springer C
et al.
A fingerprint pair analysis of hERG inhibition data.
Chem Cent J,
2013
, 7 (167).
517
He F
et al.
The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.
PLoS ONE,
2013
, 8 (e61317).
518
Asayama M
et al.
Effects of an hERG activator, ICA-105574, on electrophysiological properties of canine hearts.
J. Pharmacol. Sci.,
2013
, 121 (1-8).
519
Kramer J
et al.
MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes.
Sci Rep,
2013
, 3 (2100).
520
Kireeva N
et al.
Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models.
SAR QSAR Environ Res,
2013
, 24 (103-17).
521
Sampson HM
et al.
Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.
Orphanet J Rare Dis,
2013
, 8 (11).
522
Zhao X
et al.
Ginkgo biloba extract and ginkgolide antiarrhythmic potential by targeting hERG and ICa-L channel.
J. Pharmacol. Sci.,
2013
, 123 (318-27).
523
Bethge N
et al.
Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma.
PLoS ONE,
2013
, 8 (e79602).
524
Mehnert JM
et al.
Electrophysiological characterization of spontaneously contracting cell aggregates obtained from rainbow trout larvae with multielectrode arrays.
Cell. Physiol. Biochem.,
2013
, 32 (1374-85).
525
Shu L
et al.
Modulation of HERG K+ channels by chronic exposure to activators and inhibitors of PKA and PKC: actions independent of PKA and PKC phosphorylation.
Cell. Physiol. Biochem.,
2013
, 32 (1830-44).
526
Karnik R
et al.
Endocytosis of HERG is clathrin-independent and involves arf6.
PLoS ONE,
2013
, 8 (e85630).
527
Pérez Riera AR
et al.
Congenital short QT syndrome: landmarks of the newest arrhythmogenic cardiac channelopathy.
Cardiol J,
2013
, 20 (464-71).
528
Okata S
et al.
The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom.
J. Med. Dent. Sci.,
2013
, 60 (17-22).
529
Ranjan AP
et al.
Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.
J Nanobiotechnology,
2013
, 11 (40).
530
531
Thai KM
et al.
Pharmacophore modeling for antitargets.
Curr Top Med Chem,
2013
, 13 (1002-14).
532
Trolle C
et al.
Long QT interval in Turner syndrome--a high prevalence of LQTS gene mutations.
PLoS ONE,
2013
, 8 (e69614).
533
Babcock JJ
et al.
Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors.
PLoS ONE,
2013
, 8 (e69513).
534
Pakladok T
et al.
PIKfyve sensitivity of hERG channels.
Cell. Physiol. Biochem.,
2013
, 31 (785-94).
535
Lansu K
et al.
Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program.
Cell Death Dis,
2013
, 4 (e652).
536
Crociani O
et al.
hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer.
Sci Rep,
2013
, 3 (3308).
537
Mi Y
et al.
The role of potassium channel activation in celecoxib-induced analgesic action.
PLoS ONE,
2013
, 8 (e54797).
538
Andrsova I
et al.
Clinical characteristics of 30 Czech families with long QT syndrome and KCNQ1 and KCNH2 gene mutations: importance of exercise testing.
J Electrocardiol,
2012 Nov-Dec
, 45 (746-51).
539
Ildarova R
et al.
Sodium-channel blockers might contribute to the prevention of ventricular tachycardia in patients with long QT syndrome type 2: a description of 4 cases.
J Electrocardiol,
2012 May-Jun
, 45 (237-43).
540
[Three-dimensional structure of human Kv10.2 ion channel studied by single particle electron microscopy and molecular modeling].
Bioorg. Khim.,
2012 Mar-Apr
, 38 (177-84).
541
Zhao Y
et al.
Transfection by eukaryotic expression vector pcDNA3-HERG inhibits the cultured neonatal rabbit ventricular myocyte hypertrophy induced by phenylephrine.
Cardiovasc. Pathol.,
2012 Jul-Aug
, 21 (339-45).
542
Liu Q
et al.
Effect of daurisoline on HERG channel electrophysiological function and protein expression.
J. Nat. Prod.,
2012
Sep
28
, 75 (1539-45).
543
Guo J
et al.
Cell surface expression of human ether-a-go-go-related gene (hERG) channels is regulated by caveolin-3 protein via the ubiquitin ligase Nedd4-2.
J. Biol. Chem.,
2012
Sep
28
, 287 (33132-41).
544
Jindal HK
et al.
Proteomic analyses of transgenic LQT1 and LQT2 rabbit hearts elucidate an increase in expression and activity of energy producing enzymes.
J Proteomics,
2012
Sep
18
, 75 (5254-65).
545
Mattmann ME
et al.
Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.
Bioorg. Med. Chem. Lett.,
2012
Sep
15
, 22 (5936-41).
546
Dossetter AG
et al.
Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.
Bioorg. Med. Chem. Lett.,
2012
Sep
1
, 22 (5563-8).
547
Tan PS
et al.
Voltage-sensing domain mode shift is coupled to the activation gate by the N-terminal tail of hERG channels.
J. Gen. Physiol.,
2012
Sep
, 140 (293-306).
548
Zumhagen S
et al.
Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy.
Herzschrittmacherther Elektrophysiol,
2012
Sep
, 23 (211-9).
549
Garg V
et al.
Tuning of EAG K(+) channel inactivation: molecular determinants of amplification by mutations and a small molecule.
J. Gen. Physiol.,
2012
Sep
, 140 (307-24).
550
Annedi SC
et al.
Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.
Eur J Med Chem,
2012
Sep
, 55 (94-107).
551
Kapoor A
et al.
Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.
Antimicrob. Agents Chemother.,
2012
Sep
, 56 (4891-9).
552
Jonsson MK
et al.
Deciphering hERG channels: molecular basis of the rapid component of the delayed rectifier potassium current.
J. Mol. Cell. Cardiol.,
2012
Sep
, 53 (369-74).
553
Bhattarai D
et al.
Synthesis and in vitro antibacterial activity of novel 3-azabicyclo[3.3.0]octanyl oxazolidinones.
Chem Biol Drug Des,
2012
Sep
, 80 (388-97).
554
Lee SH
et al.
Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.
Arch. Pharm. Res.,
2012
Sep
, 35 (1655-64).
555
Quail T
et al.
Chaotic dynamics in cardiac aggregates induced by potassium channel block.
Chaos,
2012
Sep
, 22 (033140).
556
Cid JM
et al.
Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor.
J. Med. Chem.,
2012
Oct
25
, 55 (8770-89).
557
Durdagi S
et al.
Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding.
J Chem Inf Model,
2012
Oct
22
, 52 (2760-74).
558
Abderemane-Ali F
et al.
Dual effect of phosphatidyl (4,5)-bisphosphate PIP2 on Shaker K+ channels.
J. Biol. Chem.,
2012
Oct
19
, 287 (36158-67).
559
Procopiou PA
et al.
Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.
Bioorg. Med. Chem.,
2012
Oct
15
, 20 (6097-108).
560
Giudicessi JR
et al.
Phylogenetic and physicochemical analyses enhance the classification of rare nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome.
Circ Cardiovasc Genet,
2012
Oct
1
, 5 (519-28).
561
Chu W
et al.
Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.
Cardiovasc. Res.,
2012
Oct
1
, 96 (90-8).
562
Högberg T
et al.
Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?
Bioorg. Med. Chem. Lett.,
2012
Oct
1
, 22 (6039-47).
563
Khalaf AI
et al.
Design, synthesis and antibacterial activity of minor groove binders: the role of non-cationic tail groups.
Eur J Med Chem,
2012
Oct
, 56 (39-47).
564
Asghar MY
et al.
Sphingosine 1-phosphate and human ether-a'-go-go-related gene potassium channels modulate migration in human anaplastic thyroid cancer cells.
Endocr. Relat. Cancer,
2012
Oct
, 19 (667-80).
565
Lee HA
et al.
Wide spectrum of inhibitory effects of sertraline on cardiac ion channels.
Korean J. Physiol. Pharmacol.,
2012
Oct
, 16 (327-32).
566
Winkel BG
et al.
The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases.
J. Cardiovasc. Electrophysiol.,
2012
Oct
, 23 (1092-8).
567
Wiśniowska B
et al.
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
J Appl Toxicol,
2012
Oct
, 32 (858-66).
568
Wen D
et al.
Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates.
J Appl Toxicol,
2012
Oct
, 32 (834-42).
569
Zhao QH
et al.
[KCNQ1, KCNH2, KCNE1 and KCNE2 potassium channels gene variants in sudden manhood death syndrome].
Fa Yi Xue Za Zhi,
2012
Oct
, 28 (337-41, 346).
570
Nirogi R
et al.
Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.
J. Med. Chem.,
2012
Nov
8
, 55 (9255-69).
571
Swahn BM
et al.
Design and synthesis of β-Site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
J. Med. Chem.,
2012
Nov
8
, 55 (9346-61).
572
Dong Q
et al.
Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate.
Biol. Pharm. Bull.,
2012
Nov
30
, ().
573
Sherhod R
et al.
Automating knowledge discovery for toxicity prediction using jumping emerging pattern mining.
J Chem Inf Model,
2012
Nov
26
, 52 (3074-87).
574
Portonovo SA
et al.
hERG drug response measured in droplet bilayers.
Biomed Microdevices,
2012
Nov
18
, ().
575
Potet F
et al.
Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
J. Biol. Chem.,
2012
Nov
16
, 287 (39613-25).
576
Bahl A
et al.
The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bioorg. Med. Chem. Lett.,
2012
Nov
1
, 22 (6688-93).
577
Edelmann J
et al.
Long QT syndrome mutation detection by SNaPshot technique.
Int. J. Legal Med.,
2012
Nov
, 126 (969-73).
578
Kinoshita K
et al.
A novel missense mutation causing a G487R substitution in the S2-S3 loop of human ether-à-go-go-related gene channel.
J. Cardiovasc. Electrophysiol.,
2012
Nov
, 23 (1246-53).
579
Stump MR
et al.
Early LQT2 nonsense mutation generates N-terminally truncated hERG channels with altered gating properties by the reinitiation of translation.
J. Mol. Cell. Cardiol.,
2012
Nov
, 53 (725-33).
580
Kam YL
et al.
HYP-1, a novel diamide compound, relieves inflammatory and neuropathic pain in rats.
Pharmacol. Biochem. Behav.,
2012
Nov
, 103 (33-42).
581
Zhang Y
et al.
hERG ion channel pharmacology: cell membrane liposomes in porous-supported lipid bilayers compared with whole-cell patch-clamping.
Eur. Biophys. J.,
2012
Nov
, 41 (949-58).
582
Xie S
et al.
Identification of a new specific Kv1.3 channel blocker, Ctri9577, from the scorpion Chaerilus tricostatus.
,
2012
May
8
, ().
583
Donovan AJ
et al.
LQT2 Mutation on the Kv11.1 Ion Channel Inhibits Current Activity by Ablating a PKCα Consensus Site.
,
2012
May
31
, ().
584
Du YM
et al.
18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.
,
2012
May
21
, ().
585
Skidmore J
et al.
Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.
Bioorg. Med. Chem. Lett.,
2012
May
15
, 22 (3560-3).
586
Kasai S
et al.
Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.
J. Med. Chem.,
2012
May
10
, 55 (4336-51).
587
Tang H
et al.
Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.
ACS Med Chem Lett,
2012
May
10
, 3 (367-72).
588
Chen J
et al.
Binding interface of cardiac potassium channel proteins identified by hydrogen deuterium exchange of synthetic peptides.
Anal Bioanal Chem,
2012
May
, 403 (1303-9).
589
Jiménez-Vargas JM
et al.
Interacting sites of scorpion toxin ErgTx1 with hERG1 K+ channels.
Toxicon,
2012
May
, 59 (633-41).
590
Boström J
et al.
Oxadiazoles in medicinal chemistry.
J. Med. Chem.,
2012
Mar
8
, 55 (1817-30).
591
Skerlj R
et al.
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
ACS Med Chem Lett,
2012
Mar
8
, 3 (216-21).
592
Wacker SJ
et al.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.
,
2012
Mar
30
, ().
593
Menéndez ST
et al.
Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas.
,
2012
Mar
30
, ().
594
Ramnauth J
et al.
1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors: lead optimization studies resulting in the identification of N-(1-(2-(methylamino)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a p
J. Med. Chem.,
2012
Mar
22
, 55 (2882-93).
595
Hanrahan P
et al.
Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.
Bioorg. Med. Chem. Lett.,
2012
Mar
15
, 22 (2271-8).
596
Liu GX
et al.
Differential conditions for early after-depolarizations and triggered activity in cardiomyocytes derived from transgenic LQT1 and LQT2 rabbits.
J. Physiol. (Lond.),
2012
Mar
1
, 590 (1171-80).
597
Bregman H
et al.
The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.
Bioorg. Med. Chem. Lett.,
2012
Mar
1
, 22 (2033-42).
598
Chakka N
et al.
Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists.
Bioorg. Med. Chem. Lett.,
2012
Mar
1
, 22 (2052-62).
599
Lacombe P
et al.
3,4-Diarylpiperidines as potent renin inhibitors.
Bioorg. Med. Chem. Lett.,
2012
Mar
1
, 22 (1953-7).
600
Moorthy NS
et al.
Structural analysis of 2-piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities.
Curr Drug Discov Technol,
2012
Mar
, 9 (25-38).
601
Zhao XY
et al.
Frequency- and state-dependent blockade of human ether-a-go-go-related gene K+ channel by arecoline hydrobromide.
Chin. Med. J.,
2012
Mar
, 125 (1068-75).
602
Kaddar N
et al.
Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.
J. Cardiovasc. Pharmacol. Ther.,
2012
Mar
, 17 (102-9).
603
Tan Y
et al.
Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.
J Mol Model,
2012
Mar
, 18 (1023-36).
604
Peterson LB
et al.
The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.
Mol. Pharm.,
2012
Jun
4
, 9 (1841-6).
605
Gunnström M
et al.
Antipsychotic drugs cause bradycardia in GD 13 rat embryos in vitro.
,
2012
Jun
28
, ().
606
Su BH
et al.
Predictive toxicology modeling: protocols for exploring hERG classification and Tetrahymena pyriformis end point predictions.
J Chem Inf Model,
2012
Jun
25
, 52 (1660-73).
607
Pérez-Victoria I
et al.
Isolation and structural elucidation of cyclic tetrapeptides from Onychocola sclerotica.
J. Nat. Prod.,
2012
Jun
22
, 75 (1210-4).
608
Carosati E
et al.
1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story so Far And Perspectives (Part 2): Action in Other Targets and Antitargets.
,
2012
Jun
18
, ().
609
Cumming JG
et al.
The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
Bioorg. Med. Chem. Lett.,
2012
Jun
15
, 22 (3895-9).
610
Pajouhesh H
et al.
Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.
Bioorg. Med. Chem. Lett.,
2012
Jun
15
, 22 (4153-8).
611
Mihalic JT
et al.
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
Bioorg. Med. Chem. Lett.,
2012
Jun
1
, 22 (3781-5).
612
Zhao J
et al.
Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
J Ethnopharmacol,
2012
Jun
1
, 141 (685-91).
613
Guo J
et al.
A422T mutation in HERG potassium channel retained in ER is rescurable by pharmacologic or molecular chaperones.
Biochem. Biophys. Res. Commun.,
2012
Jun
1
, 422 (305-10).
614
Van Slyke AC
et al.
Proton block of the pore underlies the inhibition of hERG cardiac K+ channels during acidosis.
Am. J. Physiol., Cell Physiol.,
2012
Jun
, 302 (C1797-806).
615
Goineau S
et al.
Whole-cell configuration of the patch-clamp technique in the hERG channel assay to predict the ability of a compound to prolong QT interval.
Curr Protoc Pharmacol,
2012
Jun
, Chapter 10 (Unit 10.15.).
616
Lu HR
et al.
Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Br. J. Pharmacol.,
2012
Jun
, 166 (1490-502).
617
Li P
et al.
Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels.
Acta Pharmacol. Sin.,
2012
Jun
, 33 (728-36).
618
Donner BC
et al.
A presumably benign human ether-a-go-go-related gene mutation (R176W) with a malignant primary manifestation of long QT syndrome.
Cardiol Young,
2012
Jun
, 22 (360-3).
619
Tester DJ
et al.
Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing.
Mayo Clin. Proc.,
2012
Jun
, 87 (524-39).
620
Gönczi M
et al.
Age-dependent changes in ion channel mRNA expression in canine cardiac tissues.
Gen. Physiol. Biophys.,
2012
Jun
, 31 (153-62).
621
Parikh A
et al.
Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.
Heart Rhythm,
2012
Jun
, 9 (953-60).
622
De Conti L
et al.
Complexities of 5'splice site definition: implications in clinical analyses.
RNA Biol,
2012
Jun
, 9 (911-23).
623
Kulzer M
et al.
Inhibition of cardiac Kir2.1-2.3 channels by beta3 adrenoreceptor antagonist SR 59230A.
Biochem. Biophys. Res. Commun.,
2012
Jul
27
, 424 (315-20).
624
Zhang H
et al.
Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel.
Proc. Natl. Acad. Sci. U.S.A.,
2012
Jul
17
, 109 (11866-71).
625
Hayashi M
et al.
An intermediate-conductance Ca2+-activated K+ channel is important for secretion in pancreatic duct cells.
Am. J. Physiol., Cell Physiol.,
2012
Jul
15
, 303 (C151-9).
626
Park MH
et al.
Acute alteration of cardiac ECG, action potential, I(Kr) and the human ether-a-go-go-related gene (hERG) K+ channel by PCB 126 and PCB 77.
Toxicol. Appl. Pharmacol.,
2012
Jul
1
, 262 (60-9).
627
Ivachtchenko AV
et al.
Antagonists of 5-HT₆ receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines-Synthesis and 'structure-activity' relationship.
Bioorg. Med. Chem. Lett.,
2012
Jul
1
, 22 (4273-80).
628
Apud JA
et al.
Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia.
Am J Psychiatry,
2012
Jul
1
, 169 (725-34).
629
Jasper A
et al.
Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.
Eur J Med Chem,
2012
Jul
, 53 (327-36).
630
Vandenberg JI
et al.
hERG K(+) channels: structure, function, and clinical significance.
Physiol. Rev.,
2012
Jul
, 92 (1393-478).
631
Vigneault P
et al.
Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration.
Pharmacol. Res.,
2012
Jul
, 66 (60-5).
632
Fujii M
et al.
Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
J Biomol Screen,
2012
Jul
, 17 (773-84).
633
Moorthy NS
et al.
Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
SAR QSAR Environ Res,
2012
Jul
, 23 (521-36).
634
Crotti L
et al.
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant.
Heart Rhythm,
2012
Jul
, 9 (1104-12).
635
Sroubek J
et al.
The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel.
J. Immunol. Methods,
2012
Jan
31
, 375 (215-22).
636
Eichenbaum G
et al.
Role of Mixed Ion Channel Effects in the Cardiovascular Safety Assessment of the Novel Anti-MRSA Fluoroquinolone JNJ-Q2.
,
2012
Jan
31
, ().
637
Hu CW
et al.
Curcumin inhibits hERG potassium channels in vitro.
Toxicol. Lett.,
2012
Jan
25
, 208 (192-6).
638
Vilums M
et al.
Understanding of molecular substructures that contribute to hERG K+ channel blockade: synthesis and biological evaluation of E-4031 analogues.
ChemMedChem,
2012
Jan
2
, 7 (107-13).
639
McCauley JP
et al.
Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.
Bioorg. Med. Chem. Lett.,
2012
Jan
15
, 22 (1169-73).
640
Nguyen HN
et al.
Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
Bioorg. Med. Chem. Lett.,
2012
Jan
15
, 22 (1055-60).
641
Becknell NC
et al.
Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
Bioorg. Med. Chem. Lett.,
2012
Jan
1
, 22 (186-9).
642
Sundar BG
et al.
Novel brain penetrant benzofuropiperidine 5-HT₆ receptor antagonists.
Bioorg. Med. Chem. Lett.,
2012
Jan
1
, 22 (120-3).
643
Puppala D
et al.
Comparative gene expression profiling in human-induced pluripotent stem cell--derived cardiocytes and human and cynomolgus heart tissue.
Toxicol. Sci.,
2012
Jan
, 131 (292-301).
644
Krishnan Y
et al.
Partially dominant mutant channel defect corresponding with intermediate LQT2 phenotype.
Pacing Clin Electrophysiol,
2012
Jan
, 35 (3-16).
645
Hjaeresen ML
et al.
Time course and duration of changes in Kv7.2 and Kv11.1 mRNA expression in the hippocampus and piriform cortex following electroconvulsive stimulations.
Brain Stimul,
2012
Jan
, 5 (55-60).
646
Huang X
et al.
Comparative effects of Guanfu base A and Guanfu base G on HERG K+ channel.
J. Cardiovasc. Pharmacol.,
2012
Jan
, 59 (77-83).
647
El Harchi A
et al.
Molecular determinants of hERG potassium channel inhibition by disopyramide.
J. Mol. Cell. Cardiol.,
2012
Jan
, 52 (185-95).
648
649
Wu SN
et al.
The inhibition by di(2-ethylhexyl)-phthalate of erg-mediated K(+) current in pituitary tumor (GH (3)) cells.
,
2012
Feb
8
, ().
650
Yamakawa Y
et al.
Pharmacophore modeling for hERG channel facilitation.
Biochem. Biophys. Res. Commun.,
2012
Feb
3
, 418 (161-6).
651
Aidery P
et al.
Identification and functional characterization of the novel human ether-a-go-go-related gene (hERG) R744P mutant associated with hereditary long QT syndrome 2.
Biochem. Biophys. Res. Commun.,
2012
Feb
24
, 418 (830-5).
652
Liang G
et al.
A β-tryptase inhibitor with a tropanylamide scaffold to improve in vitro stability and to lower hERG channel binding affinity.
Bioorg. Med. Chem. Lett.,
2012
Feb
15
, 22 (1606-10).
653
Cumming JG
et al.
Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
Bioorg. Med. Chem. Lett.,
2012
Feb
15
, 22 (1655-9).
654
Jonsson MK
et al.
Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
,
2012
Feb
14
, ().
655
Polak S
et al.
Slow delayed rectifying potassium current (I(Ks) ) - analysis of the in vitro inhibition data and predictive model development.
,
2012
Feb
14
, ().
656
Yang X
et al.
Oestrogen upregulates L-type Ca²⁺ channels via oestrogen-receptor- by a regional genomic mechanism in female rabbit hearts.
J. Physiol. (Lond.),
2012
Feb
1
, 590 (493-508).
657
Zhang R
et al.
Human ether-à-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer.
Oncol. Rep.,
2012
Feb
, 27 (433-40).
658
Dennis AT
et al.
Molecular determinants of pentamidine-induced hERG trafficking inhibition.
Mol. Pharmacol.,
2012
Feb
, 81 (198-209).
659
Zhang M
et al.
KCNE2 protein is more abundant in ventricles than in atria and can accelerate hERG protein degradation in a phosphorylation-dependent manner.
Am. J. Physiol. Heart Circ. Physiol.,
2012
Feb
, 302 (H910-22).
660
Baaklini I
et al.
The DNAJA2 substrate release mechanism is essential for chaperone-mediated folding.
J. Biol. Chem.,
2012
Dec
7
, 287 (41939-54).
661
Wang X
et al.
Positive selection-guided mutational analysis revealing two key functional sites of scorpion ERG K(+) channel toxins.
Biochem. Biophys. Res. Commun.,
2012
Dec
7
, 429 (111-6).
662
Pareja K
et al.
Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
Channels (Austin),
2012
Dec
6
, 7 ().
663
González Cabrera D
et al.
Structure-activity relationship studies of orally active antimalarial 3,5-substituted 2-aminopyridines.
J. Med. Chem.,
2012
Dec
27
, 55 (11022-30).
664
Schweikart K
et al.
The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.
Toxicol In Vitro,
2012
Dec
20
, 27 (745-751).
665
Ishii K
et al.
Endocytic regulation of voltage-dependent potassium channels in the heart.
J. Pharmacol. Sci.,
2012
Dec
18
, 120 (264-9).
666
Organ-Darling LE
et al.
Interactions between hERG and KCNQ1 α-subunits are mediated by their C-termini and modulated by cAMP.
Am. J. Physiol. Heart Circ. Physiol.,
2012
Dec
15
, ().
667
Campbell K
et al.
Spatial gradients in action potential duration created by regional magnetofection of hERG are a substrate for wavebreak and turbulent propagation in cardiomyocyte monolayers.
J. Physiol. (Lond.),
2012
Dec
15
, 590 (6363-79).
668
Tanis VM
et al.
Azabenzthiazole inhibitors of leukotriene A₄ hydrolase.
Bioorg. Med. Chem. Lett.,
2012
Dec
15
, 22 (7504-11).
669
Balijepalli SY
et al.
Mechanism of Loss of Kv11.1 K+ Current in Mutant T421M-Kv11.1-Expressing Rat Ventricular Myocytes: Interaction of Trafficking and Gating.
Circulation,
2012
Dec
11
, 126 (2809-18).
670
Warner B
Genetic variation in KCNH2 and a unique hERG isoform in patients with schizophrenia: efficacy-safety link.
Am J Psychiatry,
2012
Dec
1
, 169 (1318; author reply 1318-9).
671
Gaunt TR
et al.
Integration of Genetics into a Systems Model of Electrocardiographic Traits Using HumanCVD BeadChip.
Circ Cardiovasc Genet,
2012
Dec
1
, 5 (630-8).
672
Peigneur S
et al.
A natural point mutation changes both target selectivity and mechanism of action of sea anemone toxins.
FASEB J.,
2012
Dec
, 26 (5141-51).
673
Ng HQ
et al.
Purification and structural characterization of the voltage-sensor domain of the hERG potassium channel.
Protein Expr. Purif.,
2012
Dec
, 86 (98-104).
674
Peters MF
et al.
Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
Assay Drug Dev Technol,
2012
Dec
, 10 (525-32).
675
Reck F
et al.
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.
J. Med. Chem.,
2012
Aug
9
, 55 (6916-33).
676
Butini S
et al.
Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
J. Med. Chem.,
2012
Aug
9
, 55 (6898-915).
677
Broccatelli F
et al.
QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability.
Mol. Pharm.,
2012
Aug
6
, 9 (2290-301).
678
Liu Y
et al.
Effects of the natural flavone trimethylapigenin on cardiac potassium currents.
Biochem. Pharmacol.,
2012
Aug
15
, 84 (498-506).
679
Twiner MJ
et al.
Marine Algal Toxin Azaspiracid Is an Open-State Blocker of hERG Potassium Channels.
Chem. Res. Toxicol.,
2012
Aug
10
, ().
680
Chen L
et al.
Confirmation of a proarrhythmic risk underlying the clinical use of common Chinese herbal intravenous injections.
J Ethnopharmacol,
2012
Aug
1
, 142 (829-35).
681
Sams AG
et al.
Hit-to-lead investigation of a series of novel combined dopamine D2 and muscarinic M1 receptor ligands with putative antipsychotic and pro-cognitive potential.
Bioorg. Med. Chem. Lett.,
2012
Aug
1
, 22 (5134-40).
682
Zheng F
et al.
Human ether-a-go-go-related gene K+ channels regulate shedding of leukemia cell-derived microvesicles.
Leuk. Lymphoma,
2012
Aug
, 53 (1592-8).
683
Kruse M
et al.
Regulation of voltage-gated potassium channels by PI(4,5)P2.
J. Gen. Physiol.,
2012
Aug
, 140 (189-205).
684
Durdagi S
et al.
Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643.
J. Pharmacol. Exp. Ther.,
2012
Aug
, 342 (441-52).
685
Gustina AS
et al.
HERG potassium channel regulation by the N-terminal eag domain.
Cell. Signal.,
2012
Aug
, 24 (1592-8).
686
Chinushi M
et al.
Exercise-related QT interval shortening with a peaked T wave in a healthy boy with a family history of sudden cardiac death.
Pacing Clin Electrophysiol,
2012
Aug
, 35 (e239-42).
687
Krishnan Y
et al.
Mechanisms underlying the protein-kinase mediated regulation of the HERG potassium channel synthesis.
Biochim. Biophys. Acta,
2012
Aug
, 1823 (1273-84).
688
Jiménez-Vargas JM
et al.
Toxin modulators and blockers of hERG K(+) channels.
,
2012
Apr
5
, ().
689
Vedani A
et al.
VirtualToxLab - A platform for estimating the toxic potential of drugs, chemicals and natural products.
,
2012
Apr
4
, ().
690
Cavalli A
et al.
Computational design and discovery of "minimally structured" hERG blockers.
J. Med. Chem.,
2012
Apr
26
, 55 (4010-4).
691
Liu X
et al.
Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.
Life Sci.,
2012
Apr
20
, 90 (607-11).
692
Wang S
et al.
ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.
Mol. Pharm.,
2012
Apr
2
, 9 (996-1010).
693
Zamorano-León JJ
et al.
KCNH2 Gene Mutation: A Potential Link Between Epilepsy and Long QT-2 Syndrome.
,
2012
Apr
19
, ().
694
Vigneault P
et al.
Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.
Eur. J. Pharmacol.,
2012
Apr
15
, 681 (68-74).
695
Finlay HJ
et al.
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor.
J. Med. Chem.,
2012
Apr
12
, 55 (3036-48).
696
Vachal P
et al.
1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.
J. Med. Chem.,
2012
Apr
12
, 55 (2945-59).
697
Handzlik J
et al.
Antiarrhythmic properties of phenylpiperazine derivatives of phenytoin with α₁-adrenoceptor affinities.
Bioorg. Med. Chem.,
2012
Apr
1
, 20 (2290-303).
698
Son HJ
et al.
A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.
Br. J. Pharmacol.,
2012
Apr
, 165 (2213-27).
699
Ababneh D
et al.
Antidepressants Cause Bradycardia and Heart Block in GD 13 Rat Embryos In Vitro.
Birth Defects Res. B Dev. Reprod. Toxicol.,
2012
Apr
, 95 (184-93).
700
Cheng H
et al.
High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943.
Br. J. Pharmacol.,
2012
Apr
, 165 (2260-73).
701
Alonso M
et al.
Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats.
Br. J. Pharmacol.,
2012
Apr
, 165 (2274-91).
702
Carretero L
et al.
Cell type influences the molecular mechanisms involved in hormonal regulation of ERG K+ channels.
Pflugers Arch.,
2012
Apr
, 463 (685-702).
703
Misner DL
et al.
Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys.
Br. J. Pharmacol.,
2012
Apr
, 165 (2771-86).
704
Hirano-Iwata A
et al.
Stable lipid bilayers based on micro- and nano-fabrication as a platform for recording ion-channel activities.
Anal Sci,
2012
, 28 (1049-57).
705
Ceccarini L
et al.
Ion conduction through the hERG potassium channel.
PLoS ONE,
2012
, 7 (e49017).
706
Hoekstra M
et al.
Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias.
Front Physiol,
2012
, 3 (346).
707
Sung DJ
et al.
Blockade of K+ and Ca2+ channels by azole antifungal agents in neonatal rat ventricular myocytes.
Biol. Pharm. Bull.,
2012
, 35 (1469-75).
708
Moreno C
et al.
Polyunsaturated Fatty acids modify the gating of kv channels.
Front Pharmacol,
2012
, 3 (163).
709
Polak S
et al.
Tox-database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition.
BMC Pharmacol Toxicol,
2012
, 13 (6).
710
Stump MR
et al.
Isoform-specific dominant-negative effects associated with hERG1 G628S mutation in long QT syndrome.
PLoS ONE,
2012
, 7 (e42552).
711
Ng CA
et al.
The S4-S5 linker acts as a signal integrator for HERG K+ channel activation and deactivation gating.
PLoS ONE,
2012
, 7 (e31640).
712
Dong ZX
et al.
Comparative effects of liensinine and neferine on the human ether-a-go-go-related gene potassium channel and pharmacological activity analysis.
Cell. Physiol. Biochem.,
2012
, 29 (431-42).
713
Harley CA
et al.
Changes in channel trafficking and protein stability caused by LQT2 mutations in the PAS domain of the HERG channel.
PLoS ONE,
2012
, 7 (e32654).
714
Wang Y
et al.
Trafficking-deficient G572R-hERG and E637K-hERG activate stress and clearance pathways in endoplasmic reticulum.
PLoS ONE,
2012
, 7 (e29885).
715
Cheng YM
et al.
Voltage-dependent gating of HERG potassium channels.
Front Pharmacol,
2012
, 3 (83).
716
Polonchuk L
Toward a New Gold Standard for Early Safety: Automated Temperature-Controlled hERG Test on the PatchLiner.
Front Pharmacol,
2012
, 3 (3).
717
Yang XF
et al.
The antibody targeting the e314 Peptide of human kv1.3 pore region serves as a novel, potent and specific channel blocker.
PLoS ONE,
2012
, 7 (e36379).
718
Nishimoto O
et al.
Peripartum cardiomyopathy presenting with syncope due to Torsades de pointes: a case of long QT syndrome with a novel KCNH2 mutation.
Intern. Med.,
2012
, 51 (461-4).
719
Ferro F
et al.
Long-chain acylcarnitines regulate the hERG channel.
PLoS ONE,
2012
, 7 (e41686).
720
Köpfer DA
et al.
A molecular switch driving inactivation in the cardiac K+ channel HERG.
PLoS ONE,
2012
, 7 (e41023).
721
Bilet A
et al.
Effects of the small molecule HERG activator NS1643 on Kv11.3 channels.
PLoS ONE,
2012
, 7 (e50886).
722
Lazarczyk MJ
et al.
Selective acquired long QT syndrome (saLQTS) upon risperidone treatment.
BMC Psychiatry,
2012
, 12 (220).
723
Heide J
et al.
The schizophrenia-associated Kv11.1-3.1 isoform results in reduced current accumulation during repetitive brief depolarizations.
PLoS ONE,
2012
, 7 (e45624).
724
Munoz C
et al.
Stimulation of HERG channel activity by β-catenin.
PLoS ONE,
2012
, 7 (e43353).
725
Xu XH
et al.
Allitridi inhibits multiple cardiac potassium channels expressed in HEK 293 cells.
PLoS ONE,
2012
, 7 (e51550).
726
Sato A
et al.
Long QT syndrome with nocturnal cardiac events caused by a KCNH2 missense mutation (G604S).
Intern. Med.,
2012
, 51 (1857-60).
727
Moric-Janiszewska E
et al.
Molecular diagnostics of families with long-QT syndrome.
Cardiol J,
2012
, 19 (159-67).
728
Takahara A
et al.
Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized guinea pigs.
J. Pharmacol. Sci.,
2012
, 120 (165-75).
729
El Harchi A
et al.
Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
PLoS ONE,
2012
, 7 (e52451).
730
Sato A
et al.
Benign premature ventricular complexes from the right ventricular outflow tract triggered polymorphic ventricular tachycardia in a latent type 2 LQTS patient.
Intern. Med.,
2012
, 51 (3261-5).
731
Zhang GH
et al.
Cytocompatible performance of thermosensitive poly(N-isopropylacrylamide) nanoparticles.
J Biomater Sci Polym Ed,
2012
, 23 (1569-78).
732
Qu Y
et al.
hERG potency estimates based upon dose solution analysis: What have we learned?
J Pharmacol Toxicol Methods,
2011 Nov-Dec
, 64 (251-7).
733
Champeroux P
et al.
A step towards characterisation of electrophysiological profile of torsadogenic drugs.
J Pharmacol Toxicol Methods,
2011 May-Jun
, 63 (269-78).
734
Watson KJ
et al.
Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
J Pharmacol Toxicol Methods,
2011 May-Jun
, 63 (304-13).
735
Patoine D
et al.
A novel KCNQ1 variant (L203P) associated with torsades de pointes-related syncope in a Steinert syndrome patient.
Can J Cardiol,
2011 Mar-Apr
, 27 (263.e5-12).
736
Dennis AT
et al.
Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.
J. Biol. Chem.,
2011
Sep
30
, 286 (34413-25).
737
Zhang X
et al.
Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
Bioorg. Med. Chem. Lett.,
2011
Sep
15
, 21 (5577-82).
738
Geng B
et al.
Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors.
Bioorg. Med. Chem. Lett.,
2011
Sep
15
, 21 (5432-5).
739
Abi-Gerges N
et al.
hERG subunit composition determines differential drug sensitivity.
Br. J. Pharmacol.,
2011
Sep
, 164 (419-32).
740
Lee BH
et al.
Effects of the histamine H(1) receptor antagonist hydroxyzine on hERG K(+) channels and cardiac action potential duration.
Acta Pharmacol. Sin.,
2011
Sep
, 32 (1128-37).
741
Guo J
et al.
Interaction between the cardiac rapidly (IKr) and slowly (IKs) activating delayed rectifier potassium channels revealed by low K+-induced hERG endocytic degradation.
J. Biol. Chem.,
2011
Oct
7
, 286 (34664-74).
742
van der Stelt M
et al.
Discovery and Optimization of 1-(4-(Pyridin-2-yl)benzyl)imidazolidine-2,4-dione Derivatives As a Novel Class of Selective Cannabinoid CB2 Receptor Agonists.
J. Med. Chem.,
2011
Oct
27
, 54 (7350-62).
743
Banasavadi-Siddegowda YK
et al.
FKBP38 Peptidylprolyl isomerase promotes the folding of cystic fibrosis transmembrane conductance regulator in the endoplasmic reticulum.
,
2011
Oct
26
, ().
744
Donovan BT
et al.
Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and Na(V)1.5 blockade.
,
2011
Oct
2
, ().
745
Metz M
et al.
Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.
J. Am. Chem. Soc.,
2011
Oct
19
, 133 (16477-85).
746
Saba S
et al.
Cardiac Levels of NOS1AP RNA from Right Ventricular Tissue Recovered During Lead Extraction.
,
2011
Oct
18
, ().
747
Zhou Y
et al.
Ionic mechanisms underlying cardiac toxicity of the organochloride solvent trichloromethane.
,
2011
Oct
17
, ().
748
Schwoerer AP
et al.
Bupivacaine Destabilizes Action Potential Duration in Cellular and Computational Models of Long QT Syndrome 1.
,
2011
Oct
14
, ().
749
Woo HM
et al.
Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers.
Bioorg. Med. Chem. Lett.,
2011
Oct
1
, 21 (5910-5).
750
Müller A
et al.
Synthesis of a series of γ-amino alcohols comprising an N-methyl isoindoline moiety and their evaluation as NMDA receptor antagonists.
Bioorg. Med. Chem. Lett.,
2011
Oct
1
, 21 (5795-9).
751
Nof E
et al.
LQT5 masquerading as LQT2: a dominant negative effect of KCNE1-D85N rare polymorphism on KCNH2 current.
Europace,
2011
Oct
, 13 (1478-83).
752
Jeon SH
et al.
Effects of nortriptyline on QT prolongation: a safety pharmacology study.
Hum Exp Toxicol,
2011
Oct
, 30 (1649-56).
753
Migdalovich D
et al.
Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome.
Heart Rhythm,
2011
Oct
, 8 (1537-43).
754
Barsheshet A
et al.
Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation.
Circ Cardiovasc Genet,
2011
Oct
, 4 (491-9).
755
Narayana Moorthy NS
et al.
In silico-based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG, and other toxic effects.
J Biomol Screen,
2011
Oct
, 16 (1037-46).
756
Garg V
et al.
Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide.
Mol. Pharmacol.,
2011
Oct
, 80 (630-7).
757
Tester DJ
et al.
Unexplained drownings and the cardiac channelopathies: a molecular autopsy series.
Mayo Clin. Proc.,
2011
Oct
, 86 (941-7).
758
Wang RR
et al.
The effects of paeoniflorin monomer of a Chinese herb on cardiac ion channels.
Chin. Med. J.,
2011
Oct
, 124 (3105-11).
759
Kilinc OU
et al.
Successful Elimination of Significant Arrhythmia Burden with Flecainide in an Adolescent with Long QT Syndrome Type 3.
,
2011
Nov
30
, ().
760
Lahti AL
et al.
Human disease model for long QT syndrome type 2 using iPS cells demonstrates arrhythmogenic characteristics in cell culture.
,
2011
Nov
3
, ().
761
Aoki Y
et al.
Role of ion channels in sepsis-induced atrial tachyarrhythmias in guinea pigs.
,
2011
Nov
3
, ().
762
Du-Cuny L
et al.
A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
J Chem Inf Model,
2011
Nov
28
, 51 (2948-60).
763
Reck F
et al.
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.
J. Med. Chem.,
2011
Nov
24
, 54 (7834-47).
764
Wang W
et al.
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Bioorg. Med. Chem. Lett.,
2011
Nov
15
, 21 (6646-51).
765
Honda M
et al.
Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells.
J. Pharmacol. Sci.,
2011
Nov
15
, 117 (149-59).
766
Ferrer T
et al.
Molecular Coupling in the Human ether-a-go-go-related gene-1 (hERG1) K+ Channel Inactivation Pathway.
J. Biol. Chem.,
2011
Nov
11
, 286 (39091-9).
767
Glassmeier G
et al.
Inhibition of HERG1 K(+) channel protein expression decreases cell proliferation of human small cell lung cancer cells.
,
2011
Nov
11
, ().
768
Furutani K
et al.
A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents.
Biochem. Biophys. Res. Commun.,
2011
Nov
11
, 415 (141-6).
769
González Cabrera D
et al.
Novel orally active antimalarial thiazoles.
J. Med. Chem.,
2011
Nov
10
, 54 (7713-9).
770
Fan X
et al.
Novel electropharmacological activity of amiodarone on human HCN channels heterologously expressed in the Xenopus oocytes.
Eur. J. Pharmacol.,
2011
Nov
1
, 669 (15-23).
771
Lange A
et al.
Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro.
Lung Cancer,
2011
Nov
, 74 (178-87).
772
Bai YL
et al.
HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
J. Mol. Cell. Cardiol.,
2011
Nov
, 51 (876-80).
773
Schuster AM
et al.
Strong activation of ether-à-go-go-related gene 1 K+ channel isoforms by NS1643 in human embryonic kidney 293 and Chinese hamster ovary cells.
Mol. Pharmacol.,
2011
Nov
, 80 (930-42).
774
Shang BY
et al.
[Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
Yao Xue Xue Bao,
2011
Nov
, 46 (1321-5).
775
de la Peña P
et al.
Demonstration of physical proximity between the N terminus and the S4-S5 linker of the human ether-a-go-go-related gene (hERG) potassium channel.
J. Biol. Chem.,
2011
May
27
, 286 (19065-75).
776
Wiles JA
et al.
Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
J. Med. Chem.,
2011
May
12
, 54 (3418-25).
777
Golden AP
et al.
IonFlux: A Microfluidic Patch Clamp System Evaluated with Human Ether-à-go-go Related Gene Channel Physiology and Pharmacology.
,
2011
May
11
, ().
778
Xia M
et al.
Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Toxicol. Appl. Pharmacol.,
2011
May
1
, 252 (250-8).
779
Zheng F
et al.
Role of hERG1 K(+) channels in leukemia cells as a positive regulator in SDF-1a-induced proliferation.
Hematology,
2011
May
, 16 (177-84).
780
Ando F
et al.
Synergic effects of β-estradiol and erythromycin on hERG currents.
J. Membr. Biol.,
2011
May
, 241 (31-8).
781
Soma K
et al.
Abundant expression of KCNE1 in the left ventricle of the miniature pig.
Heart Vessels,
2011
May
, 26 (353-6).
782
Schramm A
et al.
HERG channel inhibitors in extracts of Coptidis rhizoma.
Planta Med.,
2011
May
, 77 (692-7).
783
Benson AP
et al.
Quantitative prediction of the arrhythmogenic effects of de novo hERG mutations in computational models of human ventricular tissues.
Eur. Biophys. J.,
2011
May
, 40 (627-39).
784
Guo J
et al.
Involvement of caveolin in probucol-induced reduction in hERG plasma-membrane expression.
Mol. Pharmacol.,
2011
May
, 79 (806-13).
785
Ouillé A
et al.
ION CHANNEL BLOCKING PROFILE OF COMPOUNDS WITH REPORTED TORSADOGENIC EFFECTS: WHAT CAN BE LEARNED?
,
2011
Mar
8
, ().
786
Luker T
et al.
Zwitterionic CRTh2 antagonists.
J. Med. Chem.,
2011
Mar
24
, 54 (1779-88).
787
Matsa E
et al.
Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
,
2011
Mar
2
, ().
788
Novotny T
et al.
Mutation Analysis Ion Channel Genes Ventricular Fibrillation Survivors with Coronary Artery Disease.
,
2011
Mar
16
, ().
789
Huang N
et al.
The EGFP/hERG fusion protein alter the electrophysiological properties of hERG channels in HEK293 cells.
Cell Biol. Int.,
2011
Mar
1
, 35 (193-9).
790
Gustina AS
et al.
hERG potassium channel gating is mediated by N- and C-terminal region interactions.
J. Gen. Physiol.,
2011
Mar
, 137 (315-25).
791
Sun Y
et al.
A novel mutation in the KCNH2 gene associated with short QT syndrome.
J. Mol. Cell. Cardiol.,
2011
Mar
, 50 (433-41).
792
Forgo P
et al.
Diterpene alkaloids from Aconitum anthora and assessment of the hERG-inhibiting ability of Aconitum alkaloids.
Planta Med.,
2011
Mar
, 77 (368-73).
793
Skinner JR
et al.
Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds.
Heart Rhythm,
2011
Mar
, 8 (412-9).
794
Amorós I
et al.
Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome.
Heart Rhythm,
2011
Mar
, 8 (463-70).
795
Kazmierski WM
et al.
Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.
J. Med. Chem.,
2011
Jun
9
, 54 (3756-67).
796
Zhao J
et al.
Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
Eur. J. Pharmacol.,
2011
Jun
25
, 660 (259-67).
797
Ducray R
et al.
Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: Optimization of the aniline.
,
2011
Jun
25
, ().
798
Shimizu W
et al.
Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels.
Circ. Res.,
2011
Jun
24
, 109 (97-109).
799
Gianulis EC
et al.
Rescue of aberrant gating by a genetically encoded PAS (Per-Arnt-Sim) domain in several long QT syndrome mutant human ether-á-go-go-related gene potassium channels.
J. Biol. Chem.,
2011
Jun
24
, 286 (22160-9).
800
Chambers KF
et al.
Stromal upregulation of lateral epithelial adhesions: Gene expression analysis of signalling pathways in prostate epithelium.
,
2011
Jun
22
, 18 (45).
801
Buber J
et al.
Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2.
Circulation,
2011
Jun
21
, 123 (2784-91).
802
Sroubek J
et al.
Protein kinase A activity at the endoplasmic reticulum surface is responsible for augmentation of human ether-a-go-go-related gene product (HERG).
J. Biol. Chem.,
2011
Jun
17
, 286 (21927-36).
803
Shultz MD
et al.
Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors.
,
2011
Jun
17
, ().
804
Crottes D
et al.
Sigma 1 receptor regulates HERG channel expression through a post-translational mechanism in leukemic cells.
,
2011
Jun
16
, ().
805
Liu Y
et al.
The role of the 4''-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series.
Bioorg. Med. Chem. Lett.,
2011
Jun
15
, 21 (3712-4).
806
Brown DG
et al.
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
Bioorg. Med. Chem. Lett.,
2011
Jun
1
, 21 (3399-403).
807
Taboureau O
et al.
In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Comb. Chem. High Throughput Screen.,
2011
Jun
1
, 14 (375-87).
808
Zhou PZ
et al.
Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules.
Acta Pharmacol. Sin.,
2011
Jun
, 32 (781-8).
809
Vigneault P
et al.
Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
J. Cardiovasc. Pharmacol.,
2011
Jun
, 57 (690-5).
810
Choi KH
et al.
hERG channel blockade by externally applied quaternary ammonium derivatives.
Biochim. Biophys. Acta,
2011
Jun
, 1808 (1560-6).
811
Lin YL
et al.
Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes.
J Clin Pharmacol,
2011
Jun
, 51 (819-29).
812
Johansson A
Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists.
Expert Opin Ther Pat,
2011
Jun
, 21 (905-25).
813
Hreiche R
et al.
Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers.
J Pharm Sci,
2011
Jun
, 100 (2469-81).
814
Mo J
et al.
Altered gene expression by low-dose arsenic exposure in humans and cultured cardiomyocytes: assessment by real-time PCR arrays.
Int J Environ Res Public Health,
2011
Jun
, 8 (2090-108).
816
Shao L
et al.
Synthesis and Pharmacological Characterization of Bicyclic Triple Reuptake Inhibitor 3-Aryl Octahydrocyclopenta[c]pyrrole Analogues.
,
2011
Jul
8
, ().
817
Szabó G
et al.
Enhanced Repolarization Capacity: New Potential Antiarrhythmic Strategy Based on hERG Channel Activation.
,
2011
Jul
21
, ().
818
Zhang YH
et al.
The hERG K(+) channel S4 domain L532P mutation: Characterization at 37°C.
,
2011
Jul
14
, ().
819
Bregman H
et al.
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
J. Med. Chem.,
2011
Jul
14
, 54 (4427-45).
820
Boukharta L
et al.
Computer simulations of structure-activity relationships for HERG channel blockers.
Biochemistry,
2011
Jul
12
, 50 (6146-56).
821
Utech T
et al.
Synthesis and pharmacological evaluation of a potent and selective σ1 receptor antagonist with high antiallodynic activity.
Arch. Pharm. (Weinheim),
2011
Jul
, 344 (415-21).
822
Smith JL
et al.
Trafficking-deficient hERG K⁺ channels linked to long QT syndrome are regulated by a microtubule-dependent quality control compartment in the ER.
Am. J. Physiol., Cell Physiol.,
2011
Jul
, 301 (C75-85).
823
Couderc JP
et al.
T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition.
Heart Rhythm,
2011
Jul
, 8 (1036-43).
824
Wallace JL
et al.
The life and death of breast cancer cells: proposing a role for the effects of phytoestrogens on potassium channels.
J. Membr. Biol.,
2011
Jul
, 242 (53-67).
825
Hayakawa EH
et al.
Comparison of protein behavior between wild-type and G601S hERG in living cells by fluorescence correlation spectroscopy.
J Physiol Sci,
2011
Jul
, 61 (313-9).
826
Peal DS
et al.
Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen.
Circulation,
2011
Jan
4
, 123 (23-30).
827
Barc J
et al.
Screening for copy number variation in genes associated with the long QT syndrome: clinical relevance.
J. Am. Coll. Cardiol.,
2011
Jan
4
, 57 (40-7).
828
Pillozzi S
et al.
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Blood,
2011
Jan
20
, 117 (902-14).
829
Obiol-Pardo C
et al.
A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity.
,
2011
Jan
20
, ().
830
Best JM
et al.
The Small GTPase Rab11b Regulates Degradation of Surface Membrane L-Type Cav1.2 Channels.
,
2011
Jan
19
, ().
831
Itzhaki I
et al.
Modelling the long QT syndrome with induced pluripotent stem cells.
,
2011
Jan
16
, ().
832
Millat G
et al.
Development of a high resolution melting method for the detection of genetic variations in Long QT Syndrome.
Clin. Chim. Acta,
2011
Jan
14
, 412 (203-7).
833
Stupple PA
et al.
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
J. Med. Chem.,
2011
Jan
13
, 54 (67-77).
834
Han S
et al.
Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Eur. J. Pharmacol.,
2011
Jan
10
, 650 (138-44).
835
Tye H
et al.
Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.
Bioorg. Med. Chem. Lett.,
2011
Jan
1
, 21 (34-7).
836
Firth AL
et al.
Functional ion channels in human pulmonary artery smooth muscle cells: Voltage-dependent cation channels.
Pulm Circ,
2011
Jan
1
, 1 (48-71).
837
Gong Q
et al.
Inhibition of nonsense-mediated mRNA decay by antisense morpholino oligonucleotides restores functional expression of hERG nonsense and frameshift mutations in long-QT syndrome.
J. Mol. Cell. Cardiol.,
2011
Jan
, 50 (223-9).
838
Grunnet M
et al.
Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.
Mol. Pharmacol.,
2011
Jan
, 79 (1-9).
839
Bartos DC
et al.
R231C mutation in KCNQ1 causes long QT syndrome type 1 and familial atrial fibrillation.
Heart Rhythm,
2011
Jan
, 8 (48-55).
840
Stump MR
et al.
Multiple splicing defects caused by hERG splice site mutation 2592+1G>A associated with long QT syndrome.
Am. J. Physiol. Heart Circ. Physiol.,
2011
Jan
, 300 (H312-8).
841
Parkman HP
et al.
Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.
Dig. Dis. Sci.,
2011
Jan
, 56 (115-24).
842
Mirams GR
et al.
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
,
2011
Feb
7
, ().
843
Ernesto C
et al.
[Investigation of ion channel gene variants in patients with long QT syndrome.]
,
2011
Feb
4
, ().
844
Durdagi S
et al.
Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
J Chem Inf Model,
2011
Feb
28
, 51 (463-74).
845
Muskett FW
et al.
Mechanistic insight into human ether-à-go-go-related gene (hERG) K+ channel deactivation gating from the solution structure of the EAG domain.
J. Biol. Chem.,
2011
Feb
25
, 286 (6184-91).
846
Sun T
et al.
The role of monoubiquitination in endocytic degradation of human ether-a-go-go-related gene (hERG) channels under low K+ conditions.
J. Biol. Chem.,
2011
Feb
25
, 286 (6751-9).
847
Li P
et al.
Reciprocal control of hERG stability by Hsp70 and Hsc70 with implication for restoration of LQT2 mutant stability.
Circ. Res.,
2011
Feb
18
, 108 (458-68).
848
Du CY
et al.
Enhanced inhibitory effect of acidosis on hERG potassium channels that incorporate the hERG1b isoform.
Biochem. Biophys. Res. Commun.,
2011
Feb
11
, 405 (222-7).
849
Gintant G
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
Pharmacol. Ther.,
2011
Feb
, 129 (109-19).
850
Sinha N
et al.
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Eur J Med Chem,
2011
Feb
, 46 (618-30).
851
Hu C
et al.
Down-regulation of the human ether-a-go-go-related gene in rat cardiac hypertrophy.
Am. J. Med. Sci.,
2011
Feb
, 341 (119-25).
852
Staudacher I
et al.
hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.
Naunyn Schmiedebergs Arch. Pharmacol.,
2011
Feb
, 383 (119-39).
853
van Noord C
et al.
Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death.
Heart,
2011
Feb
, 97 (215-20).
854
Zhu S
et al.
Molecular diversity and functional evolution of scorpion potassium channel toxins.
Mol. Cell Proteomics,
2011
Feb
, 10 (M110.002832).
855
Bentzen BH
et al.
Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits.
J. Cardiovasc. Pharmacol.,
2011
Feb
, 57 (223-30).
856
Arcangeli A
et al.
Targeting Ion Channels in Leukemias: A New Challenge for Treatment.
,
2011
Dec
29
, ().
857
Davies MR
et al.
An In silico Canine Cardiac Midmyocardial Action Potential Duration Model as a Tool for Early Drug Safety Assessment.
,
2011
Dec
23
, ().
858
859
860
Brocklehurst KJ
et al.
Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
Bioorg. Med. Chem. Lett.,
2011
Dec
15
, 21 (7310-6).
861
Yamazaki K
et al.
A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval.
,
2011
Dec
14
, ().
862
Zheng F
et al.
Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K(+) channels in chronic myelogenous leukemia.
,
2011
Dec
10
, ().
863
Du F
et al.
hERGCentral: A Large Database to Store, Retrieve, and Analyze Compound-Human Ether-à-go-go Related Gene Channel Interactions to Facilitate Cardiotoxicity Assessment in Drug Development.
Assay Drug Dev Technol,
2011
Dec
, 9 (580-8).
864
Chen J
et al.
A dual mechanism for I(Ks) current reduction by the pathogenic mutation KCNQ1-S277L.
Pacing Clin Electrophysiol,
2011
Dec
, 34 (1652-64).
865
Holme P
et al.
A generic bioanalytical method development strategy and fit-for-purpose qualification to support hERG in vitro sample analysis.
Bioanalysis,
2011
Dec
, 3 (2739-45).
866
Adeniran I
et al.
Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome.
PLoS Comput. Biol.,
2011
Dec
, 7 (e1002313).
867
Trudeau MC
et al.
hERG1a N-terminal eag domain-containing polypeptides regulate homomeric hERG1b and heteromeric hERG1a/hERG1b channels: a possible mechanism for long QT syndrome.
J. Gen. Physiol.,
2011
Dec
, 138 (581-92).
868
Sung RK
et al.
QTc prolongation and family history of sudden death in a patient with desmin cardiomyopathy.
Pacing Clin Electrophysiol,
2011
Dec
, 34 (e105-8).
869
Aziz PF
et al.
Genotype- and mutation site-specific QT adaptation during exercise, recovery, and postural changes in children with long-QT syndrome.
Circ Arrhythm Electrophysiol,
2011
Dec
, 4 (867-73).
870
Shao C
et al.
Electrophysiological study of V535M hERG mutation of LQT2.
J. Huazhong Univ. Sci. Technol. Med. Sci.,
2011
Dec
, 31 (741-8).
872
Es-Salah-Lamoureux Z
et al.
Blockade of permeation by potassium but normal gating of the G628S nonconducting hERG channel mutant.
Biophys. J.,
2011
Aug
3
, 101 (662-70).
873
Giustetto C
et al.
Long-term follow-up of patients with short QT syndrome.
J. Am. Coll. Cardiol.,
2011
Aug
2
, 58 (587-95).
874
Park SJ
et al.
Bioactive sulfoximines: syntheses and properties of Vioxx analogs.
Bioorg. Med. Chem. Lett.,
2011
Aug
15
, 21 (4888-90).
875
Abassi YA
et al.
Dynamic Monitoring of Beating Periodicity of Stem Cell Derived Cardiomyocytes as a Predictive Tool for Preclinical Safety Assessment.
,
2011
Aug
12
, ().
876
Choi SH
et al.
Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction.
Eur. J. Pharmacol.,
2011
Aug
1
, 663 (59-67).
877
Gayen S
et al.
An NMR study of the N-terminal domain of wild-type hERG and a T65P trafficking deficient hERG mutant.
Proteins,
2011
Aug
, 79 (2557-65).
878
Sintra Grilo L
et al.
Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Eur J Med Chem,
2011
Aug
, 46 (3486-98).
879
Witchel HJ
Drug-induced hERG block and long QT syndrome.
Cardiovasc Ther,
2011
Aug
, 29 (251-9).
880
Du D
et al.
Multi-scale modeling of glycosylation modulation dynamics in cardiac electrical signaling.
Conf Proc IEEE Eng Med Biol Soc,
2011
Aug
, 2011 (104-7).
881
Fougere RR
et al.
Functional characterization of the LQT2-causing mutation R582C and the associated voltage-dependent fluorescence signal.
Heart Rhythm,
2011
Aug
, 8 (1273-80).
882
Zarraga IG
et al.
Nonsense-mediated mRNA decay caused by a frameshift mutation in a large kindred of type 2 long QT syndrome.
Heart Rhythm,
2011
Aug
, 8 (1200-6).
883
Peigneur S
et al.
A bifunctional sea anemone peptide with Kunitz type protease and potassium channel inhibiting properties.
,
2011
Apr
5
, ().
884
Wu ZY
et al.
progesterone impairs herg trafficking by disruption of intracellular cholesterol homeostasis.
,
2011
Apr
27
, ().
885
Shen MY
et al.
A Comprehensive SVM Binary hERG Classification Model Based on Extensive but Biased Endpoint hERG Data Sets.
,
2011
Apr
19
, ().
886
Fox BM
et al.
Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition.
Bioorg. Med. Chem. Lett.,
2011
Apr
15
, 21 (2460-7).
887
Du CY
et al.
Pharmacological Inhibition of the hERG Potassium Channel Is Modulated by Extracellular But Not Intracellular Acidosis.
,
2011
Apr
13
, ().
888
Albesa M
et al.
Nedd4-2 dependent ubiquitylation and regulation of the cardiac potassium channel hERG.
,
2011
Apr
1
, ().
889
El Gebeily G
et al.
Upregulation of ventricular potassium channels by chronic tamoxifen treatment.
Cardiovasc. Res.,
2011
Apr
1
, 90 (68-76).
890
Windisch A
et al.
Trapping and dissociation of propafenone derivatives in HERG channels.
Br. J. Pharmacol.,
2011
Apr
, 162 (1542-52).
891
Hekkala AM
et al.
Epinephrine bolus test in detecting long QT syndrome mutation carriers with indeterminable electrocardiographic phenotype.
Ann Noninvasive Electrocardiol,
2011
Apr
, 16 (172-9).
892
Grilo LS
et al.
Patient with syncope and LQTS carrying a mutation in the PAS domain of the hERG1 channel.
Ann Noninvasive Electrocardiol,
2011
Apr
, 16 (213-8).
893
Qu Y
et al.
BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
J. Pharmacol. Exp. Ther.,
2011
Apr
, 337 (2-8).
894
Kim SH
et al.
Identification of cyclicsulfonamide derivatives with an acetamide group as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
Chem. Pharm. Bull.,
2011
, 59 (46-52).
895
Lahtinen AM
et al.
KCNE1 D85N polymorphism - a sex-specific modifier in type 1 long QT syndrome?
BMC Med. Genet.,
2011
, 12 (11).
896
Moric Janiszewska E
et al.
Expression of genes KCNQ1 and HERG encoding potassium ion channels Ik(r), Ik(s) in long QT syndrome.
Kardiol Pol,
2011
, 69 (423-9).
897
Chen XL
et al.
Manual whole-cell patch-clamping of the HERG cardiac K+ channel.
Methods Mol. Biol.,
2011
, 691 (151-63).
898
Kaczorowski GJ
et al.
The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling.
Front Pharmacol,
2011
, 2 (78).
899
Mihic A
et al.
Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation.
PLoS ONE,
2011
, 6 (e18273).
900
Sugiyama H
et al.
Circulating KCNH2 current-activating factor in patients with heart failure and ventricular tachyarrhythmia.
PLoS ONE,
2011
, 6 (e19897).
901
Ng CA
et al.
The N-terminal tail of hERG contains an amphipathic α-helix that regulates channel deactivation.
PLoS ONE,
2011
, 6 (e16191).
902
Jehle J
et al.
Novel roles for hERG K(+) channels in cell proliferation and apoptosis.
Cell Death Dis,
2011
, 2 (e193).
903
Hishigaki H
et al.
hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds.
Database (Oxford),
2011
, 2011 (bar017).
904
Möller C
et al.
Automated electrophysiology makes the pace for cardiac ion channel safety screening.
Front Pharmacol,
2011
, 2 (73).
905
Frolov RV
et al.
Inhibition of HERG potassium channels by celecoxib and its mechanism.
PLoS ONE,
2011
, 6 (e26344).
906
Knape K
et al.
In silico Analysis of Conformational Changes Induced by Mutation of Aromatic Binding Residues: Consequences for Drug Binding in the hERG K+ Channel.
PLoS ONE,
2011
, 6 (e28778).
907
Banderali U
et al.
Curcumin Blocks Kv11.1 (erg) Potassium Current and Slows Proliferation in the Infant Acute Monocytic Leukemia Cell line THP-1.
Cell. Physiol. Biochem.,
2011
, 28 (1169-80).
908
Eldstrom J
et al.
The voltage-gated channel accessory protein KCNE2: multiple ion channel partners, multiple ways to long QT syndrome.
Expert Rev Mol Med,
2011
, 13 (e38).
909
Zhang Y
et al.
Potential therapeutic value of antioxidants for abnormal prolongation of QT interval and the associated arrhythmias in a rabbit model of diabetes.
Cell. Physiol. Biochem.,
2011
, 28 (97-102).
910
Fernández-Trillo J
et al.
Molecular determinants of interactions between the N-terminal domain and the transmembrane core that modulate hERG K+ channel gating.
PLoS ONE,
2011
, 6 (e24674).
911
Yun J
et al.
Hirsutenone directly blocks human ether-a-go-go related gene K+ channels.
Biol. Pharm. Bull.,
2011
, 34 (1815-22).
912
Li P
et al.
Novel effects of extracts from poisonous mushrooms on expression and function of the human ether-a-go-go-related gene channel.
Biol. Pharm. Bull.,
2011
, 34 (1474-80).
913
Briasoulis A
et al.
QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Cardiology,
2011
, 120 (103-10).
914
Kawai Y
et al.
A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.
Chem. Pharm. Bull.,
2011
, 59 (1110-6).
915
Cordeiro S
et al.
Expression pattern of Kv11 (Ether à-go-go-related gene; erg) K+ channels in the mouse retina.
PLoS ONE,
2011
, 6 (e29490).
916
Zhang YH
et al.
Characterization of recombinant hERG K(+) channel inhibition by the active metabolite of amiodarone desethyl-amiodarone.
J Electrocardiol,
2010 Sep-Oct
, 43 (440-8).
917
Ahrendt E
et al.
Channel triage: Emerging insights into the processing and quality control of hERG potassium channels by DnaJA proteins 1, 2 and 4.
Channels (Austin),
2010 Sep-Oct
, 4 (335-6).
918
Milnes JT
et al.
Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
J Pharmacol Toxicol Methods,
2010 Mar-Apr
, 61 (178-91).
919
Himmel HM
et al.
QTc shortening with a new investigational cancer drug: a brief case study.
J Pharmacol Toxicol Methods,
2010 Jul-Aug
, 62 (72-81).
920
Wilders R
et al.
Role of the R1135H KCNH2 mutation in Brugada syndrome.
Int. J. Cardiol.,
2010
Sep
24
, 144 (149-51).
921
Yasuda S
et al.
A family of hereditary long QT syndrome caused by Q738X HERG mutation.
Int. J. Cardiol.,
2010
Sep
24
, 144 (69-72).
922
Haugaa KH
et al.
Transmural Differences in Myocardial Contraction in Long-QT Syndrome. Mechanical Consequences of Ion Channel Dysfunction.
,
2010
Sep
20
, ().
923
Ren XQ
et al.
Pore Mutants of HERG and KvLQT1 Downregulate the Reciprocal Currents in Stable Cell Lines.
,
2010
Sep
10
, ().
924
Perry M
et al.
Revealing the structural basis of action of hERG potassium channel activators and blockers.
J. Physiol. (Lond.),
2010
Sep
1
, 588 (3157-67).
925
Bokil NJ
et al.
Molecular genetics of long QT syndrome.
Mol. Genet. Metab.,
2010
Sep
, 101 (1-8).
926
Mathie A
Ion channels as novel therapeutic targets in the treatment of pain.
J. Pharm. Pharmacol.,
2010
Sep
, 62 (1089-95).
927
Zünkler BJ
et al.
Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
Cardiovasc. Toxicol.,
2010
Sep
, 10 (161-5).
928
Lazzerini PE
et al.
Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypotheses.
Scand. J. Immunol.,
2010
Sep
, 72 (213-22).
929
Shao L
et al.
Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.
,
2010
Oct
28
, ().
930
Shim WS
et al.
An aqueous extract of Poncirus fructus activates the prokinetic activity of 5-HT receptor subtype 4 without hERG interaction.
J Ethnopharmacol,
2010
Oct
28
, 132 (328-33).
931
Papadatos G
et al.
Lead optimization using matched molecular pairs: inclusion of contextual information for enhanced prediction of HERG inhibition, solubility, and lipophilicity.
J Chem Inf Model,
2010
Oct
25
, 50 (1872-86).
932
Zhou J
et al.
Effect of Lead Ion on the Function of the Human Ether-À-Go-Go-Related Gene K(+) Channel.
,
2010
Oct
2
, ().
933
Gong Q
et al.
Alternative splicing and polyadenylation contribute to the generation of hERG1 C-terminal isoforms.
J. Biol. Chem.,
2010
Oct
15
, 285 (32233-41).
934
Tester DJ
et al.
Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing.
Am. J. Cardiol.,
2010
Oct
15
, 106 (1124-8).
935
Liu Y
et al.
9-Dihydroerythromycins as non-antibiotic motilin receptor agonists.
Bioorg. Med. Chem. Lett.,
2010
Oct
1
, 20 (5658-61).
936
Li Q
et al.
1H, 13C and 15N chemical shift assignments for the N-terminal domain of the voltage-gated potassium channel-hERG.
Biomol NMR Assign,
2010
Oct
, 4 (211-3).
937
Wu HJ
et al.
Effect of matrine on human ether à go-go related gene (HERG) channels expressed in Chinese hamster ovary cells.
Chin J Integr Med,
2010
Oct
, 16 (430-4).
938
Larsen AP
Role of ERG1 isoforms in modulation of ERG1 channel trafficking and function.
Pflugers Arch.,
2010
Oct
, 460 (803-12).
939
Larsen AP
et al.
Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels.
Br. J. Pharmacol.,
2010
Oct
, 161 (614-28).
940
Jeong I
et al.
Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.
Pflugers Arch.,
2010
Oct
, 460 (851-62).
941
Hondeghem LM
et al.
Oscillations of cardiac wave length and proarrhythmia.
Naunyn Schmiedebergs Arch. Pharmacol.,
2010
Oct
, 382 (367-76).
942
Du CY
et al.
Acidosis impairs the protective role of hERG K(+) channels against premature stimulation.
J. Cardiovasc. Electrophysiol.,
2010
Oct
, 21 (1160-9).
943
Zhang XH
et al.
The calmodulin inhibitor N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide directly blocks human ether à-go-go-related gene potassium channels stably expressed in human embryonic kidney 293 cells.
Br. J. Pharmacol.,
2010
Oct
, 161 (872-84).
944
Abela D
et al.
The effect of drugs with ion channel-blocking activity on the early embryonic rat heart.
Birth Defects Res. B Dev. Reprod. Toxicol.,
2010
Oct
, 89 (429-40).
945
Lian J
et al.
Novel characteristics of a trafficking-defective G572R-hERG channel linked to hereditary long QT syndrome.
Can J Cardiol,
2010
Oct
, 26 (417-22).
946
Kuryshev YA
et al.
Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels.
J. Cardiovasc. Pharmacol.,
2010
Oct
, 56 (420-30).
947
Sordel T
et al.
The development of high quality seals for silicon patch-clamp chips.
Biomaterials,
2010
Oct
, 31 (7398-410).
948
Kim MJ
et al.
High-content screening of drug-induced cardiotoxicity using quantitative single cell imaging cytometry on microfluidic device.
,
2010
Nov
8
, ().
949
Angus D
et al.
The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.
,
2010
Nov
6
, ().
950
Van Slyke AC
et al.
Mutations within the S4-S5 linker alter voltage sensor constraints in hERG K+ channels.
Biophys. J.,
2010
Nov
3
, 99 (2841-52).
951
Oka Y
et al.
Atrioventricular block-induced Torsades de Pointes with clinical and molecular backgrounds similar to congenital long QT syndrome.
Circ. J.,
2010
Nov
25
, 74 (2562-71).
952
953
Pryde DC
et al.
An in situ oxidation strategy towards overcoming hERG affinity.
Bioorg. Med. Chem. Lett.,
2010
Nov
15
, 20 (6400-4).
954
Anderson JT
et al.
Investigation of 4-piperidinols as novel H3 antagonists.
Bioorg. Med. Chem. Lett.,
2010
Nov
1
, 20 (6246-9).
955
Rankovic Z
et al.
Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.
Bioorg. Med. Chem. Lett.,
2010
Nov
1
, 20 (6237-41).
956
Liu Y
et al.
9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety.
Bioorg. Med. Chem.,
2010
Nov
1
, 18 (7651-8).
957
Subbotina J
et al.
Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations.
Proteins,
2010
Nov
1
, 78 (2922-34).
958
Sy RW
et al.
Repolarization dynamics during exercise discriminate between LQT1 and LQT2 genotypes.
J. Cardiovasc. Electrophysiol.,
2010
Nov
, 21 (1242-6).
959
Doddareddy MR
et al.
Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
ChemMedChem,
2010
May
3
, 5 (716-29).
960
Yan L
et al.
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
J. Med. Chem.,
2010
May
27
, 53 (4028-37).
961
Kang J
et al.
In Vitro Electrocardiographic and Cardiac Ion Channel Effects of (-)-Epigallocatechin-3-Gallate, the Main Catechin of Green Tea.
,
2010
May
18
, ().
962
Klon AE
Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development.
,
2010
May
14
, ().
963
Palmer AM
et al.
Tetrahydrochromenoimidazoles as potassium-competitive acid blockers (P-CABs): structure-activity relationship of their antisecretory properties and their affinity toward the hERG channel.
J. Med. Chem.,
2010
May
13
, 53 (3645-74).
964
Chen J
et al.
Post-transcriptional control of HERG potassium channel protein by {alpha}-adrenergic receptor stimulation.
,
2010
May
12
, ().
965
Leong IU
et al.
Identification and expression analysis of kcnh2 genes in the zebrafish.
,
2010
May
10
, ().
966
Lavrador-Erb K
et al.
The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.
Bioorg. Med. Chem. Lett.,
2010
May
1
, 20 (2916-9).
967
Gu SJ
et al.
Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.
Bioorg. Med. Chem. Lett.,
2010
May
1
, 20 (2705-8).
968
Allegue C
et al.
A new approach to long QT syndrome mutation detection by Sequenom MassARRAY system.
Electrophoresis,
2010
May
, 31 (1648-55).
969
Kim KS
et al.
Blockade of hERG K(+) channel by antimalarial drug, primaquine.
Arch. Pharm. Res.,
2010
May
, 33 (769-73).
970
Obers S
et al.
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Naunyn Schmiedebergs Arch. Pharmacol.,
2010
May
, 381 (385-400).
971
Möller C
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
Expert Rev Clin Pharmacol,
2010
May
, 3 (321-9).
972
Beacham DW
et al.
Cell-Based Potassium Ion Channel Screening Using the FluxORTM Assay.
,
2010
Mar
5
, ().
973
Porthan K
et al.
Relationship of Common Candidate Gene Variants to Electrocardiographic T-Wave Peak to T-Wave End Interval and T-Wave Morphology Parameters.
,
2010
Mar
4
, ().
974
975
Xing J
et al.
Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652.
Eur. J. Pharmacol.,
2010
Mar
25
, 630 (1-9).
976
Stary A
et al.
Toward a consensus model of the HERG potassium channel.
ChemMedChem,
2010
Mar
1
, 5 (455-67).
977
Amin AS
et al.
Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome.
Neth Heart J,
2010
Mar
, 18 (165-9).
978
Itoh H
et al.
Long QT Syndrome with Compound Mutations is Associated with a More Severe Phenotype :A Japanese Multicenter Study.
,
2010
Jun
8
, ().
979
Butini S
et al.
Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
J. Med. Chem.,
2010
Jun
24
, 53 (4803-7).
980
Pinard E
et al.
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.
J. Med. Chem.,
2010
Jun
24
, 53 (4603-14).
981
Gaborit N
et al.
Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts.
,
2010
Jun
21
, ().
982
Su BH
et al.
In Silico Binary Classification QSAR Models Based on 4D-Fingerprints and MOE Descriptors for Prediction of hERG Blockage.
,
2010
Jun
21
, ().
983
Amit G
et al.
Selective molecular potassium channel blockade prevents atrial fibrillation.
Circulation,
2010
Jun
1
, 121 (2263-70).
984
Valdivia CR
et al.
Loss-of-function mutation of the SCN3B-encoded sodium channel {beta}3 subunit associated with a case of idiopathic ventricular fibrillation.
Cardiovasc. Res.,
2010
Jun
1
, 86 (392-400).
985
Lin EC
et al.
Properties of WT and mutant hERG K(+) channels expressed in neonatal mouse cardiomyocytes.
Am. J. Physiol. Heart Circ. Physiol.,
2010
Jun
, 298 (H1842-9).
986
Zhou Q
et al.
Regulation of the voltage-insensitive step of HERG activation by extracellular pH.
Am. J. Physiol. Heart Circ. Physiol.,
2010
Jun
, 298 (H1710-8).
987
Gong JH
et al.
HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells.
Oncol. Rep.,
2010
Jun
, 23 (1747-56).
988
Toyoda F
et al.
Characterization of the rapidly activating delayed rectifier potassium current, I (Kr), in HL-1 mouse atrial myocytes.
J. Membr. Biol.,
2010
Jun
, 235 (73-87).
989
990
991
Ivachtchenko AV
et al.
(3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor.
J. Med. Chem.,
2010
Jul
22
, 53 (5186-96).
992
994
Tester DJ
et al.
Epidemiologic, molecular, and functional evidence suggest A572D-SCN5A should not be considered an independent LQT3-susceptibility mutation.
Heart Rhythm,
2010
Jul
, 7 (912-9).
995
van Noord C
et al.
Drug- and non-drug-associated QT interval prolongation.
Br J Clin Pharmacol,
2010
Jul
, 70 (16-23).
997
Ganapathi SB
et al.
Ceramide modulates HERG potassium channel gating by translocation into lipid rafts.
Am. J. Physiol., Cell Physiol.,
2010
Jul
, 299 (C74-86).
998
Hayashi K
et al.
Trafficking-competent KCNQ1 variably influences the function of HERG long QT alleles.
Heart Rhythm,
2010
Jul
, 7 (973-80).
999
Testai L
et al.
Effects of K openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs.
J. Pharm. Pharmacol.,
2010
Jul
, 62 (924-30).
1000
Walker VE
et al.
Hsp40 chaperones promote degradation of the HERG potassium channel.
J. Biol. Chem.,
2010
Jan
29
, 285 (3319-29).
1001
Berlin M
et al.
Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists.
,
2010
Jan
28
, ().
1002
Lin H
et al.
Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.
Bioorg. Med. Chem. Lett.,
2010
Jan
15
, 20 (684-8).
1003
Kallander LS
et al.
Improving the developability profile of pyrrolidine progesterone receptor partial agonists.
Bioorg. Med. Chem. Lett.,
2010
Jan
1
, 20 (371-4).
1004
Martyn DC
et al.
Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines.
Bioorg. Med. Chem. Lett.,
2010
Jan
1
, 20 (228-31).
1005
Bagnes C
et al.
Antineoplastic Chemotherapy Induced QTc Prolongation.
Curr Drug Saf,
2010
Jan
1
, 5 (93-6).
1006
Ponte ML
et al.
Mechanisms of Drug Induced QT Interval Prolongation.
Curr Drug Saf,
2010
Jan
1
, 5 (44-53).
1007
Ramström C
et al.
Regulation of HERG (KCNH2) potassium channel surface expression by diacylglycerol.
Cell. Mol. Life Sci.,
2010
Jan
, 67 (157-69).
1008
Staudacher I
et al.
hERG: protein trafficking and potential for therapy and drug side effects.
Curr Opin Drug Discov Devel,
2010
Jan
, 13 (23-30).
1009
Dolderer JH
et al.
HERG1 gene expression as a specific tumor marker in colorectal tissues.
Eur J Surg Oncol,
2010
Jan
, 36 (72-7).
1010
Gerlach AC
et al.
Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).
Mol. Pharmacol.,
2010
Jan
, 77 (58-68).
1011
Charpentier F
et al.
Delayed rectifier K(+) currents and cardiac repolarization.
J. Mol. Cell. Cardiol.,
2010
Jan
, 48 (37-44).
1012
Guth BD
et al.
Dealing with hERG liabilities early: diverse approaches to an important goal in drug development.
Br. J. Pharmacol.,
2010
Jan
, 159 (22-4).
1013
Pollard CE
et al.
An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk.
Br. J. Pharmacol.,
2010
Jan
, 159 (12-21).
1014
Wallis RM
Integrated risk assessment and predictive value to humans of non-clinical repolarization assays.
Br. J. Pharmacol.,
2010
Jan
, 159 (115-21).
1015
Ducroq J
et al.
Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).
Br. J. Pharmacol.,
2010
Jan
, 159 (93-101).
1016
Männikkö R
et al.
Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel.
Br. J. Pharmacol.,
2010
Jan
, 159 (102-14).
1017
Alvarez PA
et al.
QT alterations in psychopharmacology: proven candidates and suspects.
Curr Drug Saf,
2010
Jan
, 5 (97-104).
1018
Keller GA
et al.
Other drugs acting on nervous system associated with QT-interval prolongation.
Curr Drug Saf,
2010
Jan
, 5 (105-11).
1019
Afrasiabi E
et al.
Expression and significance of HERG (KCNH2) potassium channels in the regulation of MDA-MB-435S melanoma cell proliferation and migration.
Cell. Signal.,
2010
Jan
, 22 (57-64).
1020
Thai KM
et al.
The hERG Potassium Channel and Drug Trapping: Insight from Docking Studies with Propafenone Derivatives.
,
2010
Feb
9
, ().
1021
Redaelli E
et al.
Target promiscuity and heterogeneous effects of tarantula venom peptides affecting Na+ and K+ ion channels.
J. Biol. Chem.,
2010
Feb
5
, 285 (4130-42).
1022
Massaeli H
et al.
Extracellular K+ Is a Prerequisite for the Function and Plasma Membrane Stability of HERG Channels.
,
2010
Feb
4
, ().
1023
Nugiel DA
et al.
De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.
J. Med. Chem.,
2010
Feb
25
, 53 (1876-80).
1024
de Boer T
et al.
The anti-protozoal drug pentamidine blocks K(IR)2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel.
,
2010
Feb
24
, ().
1025
Radhakrishnan K
et al.
Heat Shock Proteins and Ion Channels. Functional Interactions and Therapeutic Consequences.
,
2010
Feb
16
, ().
1026
Grunnet M
Repolarization of the cardiac action potential. Does an increase in repolarization capacity constitute a new anti-arrhythmic principle?
Acta Physiol (Oxf),
2010
Feb
, 198 Suppl 676 (1-48).
1027
Witchel HJ
Emerging trends in ion channel-based assays for predicting the cardiac safety of drugs.
IDrugs,
2010
Feb
, 13 (90-6).
1028
Lian J
et al.
[A novel mutation of the KCNH2 gene in a family with congenital long QT syndrome]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi,
2010
Feb
, 27 (77-80).
1029
Carrisoza R
et al.
Expression and immunolocalization of ERG1 potassium channels in the rat kidney.
Histochem. Cell Biol.,
2010
Feb
, 133 (189-99).
1030
Li Q
et al.
NMR solution structure of the N-terminal domain of hERG and its interaction with the S4-S5 linker.
Biochem. Biophys. Res. Commun.,
2010
Dec
3
, 403 (126-32).
1031
Su X
et al.
Microfluidic Cell Culture and Its Application in High-Throughput Drug Screening: Cardiotoxicity Assay for hERG Channels.
J Biomol Screen,
2010
Dec
3
, ().
1032
Asher V
et al.
Eag and HERG potassium channels as novel therapeutic targets in cancer.
,
2010
Dec
29
, 8 (113).
1033
Caldwell JJ
et al.
Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2.
,
2010
Dec
27
, ().
1034
Wang DT
et al.
Mapping the sequence of conformational changes underlying selectivity filter gating in the K(v)11.1 potassium channel.
,
2010
Dec
19
, ().
1035
Hou L
et al.
A major role for HERG in determining frequency of reentry in neonatal rat ventricular myocyte monolayer.
Circ. Res.,
2010
Dec
10
, 107 (1503-11).
1036
Pinard E
et al.
Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.
Bioorg. Med. Chem. Lett.,
2010
Dec
1
, 20 (6960-5).
1037
Yoshino H
et al.
Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.
Bioorg. Med. Chem.,
2010
Dec
1
, 18 (8150-7).
1038
Surman MD
et al.
5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.
Bioorg. Med. Chem. Lett.,
2010
Dec
1
, 20 (7015-9).
1039
Thewlis KM
et al.
N-substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators.
Bioorg. Med. Chem. Lett.,
2010
Dec
1
, 20 (7116-9).
1040
Harmati G
et al.
Effects of the PKC inhibitors chelerythrine and bisindolylmaleimide I (GF 109203X) on delayed rectifier K(+) currents.
,
2010
Dec
1
, ().
1041
Cao X
et al.
Cardiac ion channel safety profiling on the IonWorks Quattro automated patch clamp system.
Assay Drug Dev Technol,
2010
Dec
, 8 (766-80).
1042
Schmalhofer WA
et al.
A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
Assay Drug Dev Technol,
2010
Dec
, 8 (714-26).
1043
Zou B
et al.
Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-à-go-go related gene potassium channels.
Assay Drug Dev Technol,
2010
Dec
, 8 (743-54).
1044
Oh S
et al.
Remodeling of ion channel expression in patients with chronic atrial fibrillation and mitral valvular heart disease.
Korean J. Intern. Med.,
2010
Dec
, 25 (377-85).
1045
Oshiro C
et al.
KCNH2 pharmacogenomics summary.
Pharmacogenet. Genomics,
2010
Dec
, 20 (775-7).
1046
Zhang XM
et al.
[Chinfloxacin hydrochloride inhibits HERG potassium channel at open state].
Yao Xue Xue Bao,
2010
Dec
, 45 (1491-6).
1047
Cordeiro JM
et al.
Overlapping LQT1 and LQT2 phenotype in a patient with long QT syndrome associated with loss-of-function variations in KCNQ1 and KCNH2.
Can. J. Physiol. Pharmacol.,
2010
Dec
, 88 (1181-90).
1048
Bridal TR
et al.
Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Assay Drug Dev Technol,
2010
Dec
, 8 (755-65).
1049
Kim JA
et al.
Trigger-specific risk factors and response to therapy in long QT syndrome type 2.
Heart Rhythm,
2010
Dec
, 7 (1797-805).
1050
Davenport AJ
et al.
Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program.
Assay Drug Dev Technol,
2010
Dec
, 8 (781-9).
1051
Huang XP
et al.
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
Assay Drug Dev Technol,
2010
Dec
, 8 (727-42).
1052
Rodriguez N
et al.
Phosphatidylinositol-4,5-Bisphosphate (PIP(2)) Stabilizes the Open Pore Conformation of the Kv11.1 (hERG) Channel.
,
2010
Aug
9
, 99 (1110-1118).
1054
Massaeli H
et al.
Involvement of caveolin in low K+-induced endocytic degradation of cell-surface human ether-a-go-go-related gene (hERG) channels.
J. Biol. Chem.,
2010
Aug
27
, 285 (27259-64).
1055
Durdagi S
et al.
Insights into the Molecular Mechanism of hERG1 Channel Activation and Blockade by Drugs.
,
2010
Aug
26
, ().
1056
Tu E
et al.
Post-Mortem Review and Genetic Analysis of Sudden Unexpected Death in Epilepsy (SUDEP) Cases.
,
2010
Aug
24
, ().
1057
Li Y
et al.
Aconitine blocks HERG and Kv1.5 potassium channels.
,
2010
Aug
19
, 131 (187-195).
1058
Vandenberg JI
Oxidative stress fine-tunes the dance of hERG K+ channels.
J. Physiol. (Lond.),
2010
Aug
15
, 588 (2975).
1059
Kolbe K
et al.
Cysteine 723 in the C-linker segment confers oxidative inhibition of hERG1 potassium channels.
J. Physiol. (Lond.),
2010
Aug
15
, 588 (2999-3009).
1060
Muskett FW
et al.
Resonance assignment and secondary structure prediction of the N-terminal domain of hERG (Kv11.1).
,
2010
Aug
14
, ().
1061
Gao B
et al.
A potent potassium channel blocker from Mesobuthus eupeus scorpion venom.
,
2010
Aug
13
, ().
1062
Bromidge SM
et al.
Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).
J. Med. Chem.,
2010
Aug
12
, 53 (5827-43).
1063
Meng W
et al.
Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
J. Med. Chem.,
2010
Aug
12
, 53 (5620-8).
1064
Akar FG
Use-dependent modulation of myocardial conduction by a new class of HERG agonists: deal breaker or cherry on top?
J. Cardiovasc. Electrophysiol.,
2010
Aug
1
, 21 (930-2).
1065
Larsen AP
et al.
Pharmacological activation of IKr impairs conduction in guinea pig hearts.
J. Cardiovasc. Electrophysiol.,
2010
Aug
1
, 21 (923-9).
1066
Chen WH
et al.
State-dependent blockade of human ether-a-go-go-related gene (hERG) K(+) channels by changrolin in stably transfected HEK293 cells.
Acta Pharmacol. Sin.,
2010
Aug
, 31 (915-22).
1067
Stead LF
et al.
KvDB; mining and mapping sequence variants in voltage-gated potassium channels.
Hum. Mutat.,
2010
Aug
, 31 (908-17).
1068
Abbruzzese J
et al.
Modification of hERG1 channel gating by Cd2+.
J. Gen. Physiol.,
2010
Aug
, 136 (203-24).
1069
Guo J
et al.
The action of a novel fluoroquinolone antibiotic agent antofloxacin hydrochloride on human-ether-à-go-go-related gene potassium channel.
Basic Clin. Pharmacol. Toxicol.,
2010
Aug
, 107 (643-9).
1070
Hong HK
et al.
Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine.
Biochem. Biophys. Res. Commun.,
2010
Apr
9
, 394 (536-41).
1071
Gessner G
et al.
The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism.
Eur. J. Pharmacol.,
2010
Apr
25
, 632 (52-9).
1072
Albert CM
et al.
Common Variants in Cardiac Ion Channel Genes Are Associated with Sudden Cardiac Death.
,
2010
Apr
17
, ().
1073
Lee HA
et al.
Electrophysiological Effects of the Anti-Cancer Drug Lapatinib on Cardiac Repolarization.
,
2010
Apr
12
, ().
1074
Pekkanen-Mattila M
et al.
Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype.
Exp. Biol. Med. (Maywood),
2010
Apr
1
, 235 (522-30).
1075
Wong JA
et al.
Utility of treadmill testing in identification and genotype prediction in long-QT syndrome.
Circ Arrhythm Electrophysiol,
2010
Apr
1
, 3 (120-5).
1076
Nilsson MF
et al.
Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs.
Reprod. Toxicol.,
2010
Apr
, 29 (156-63).
1077
Gladding PA
et al.
Posthumous diagnosis of long QT syndrome from neonatal screening cards.
Heart Rhythm,
2010
Apr
, 7 (481-6).
1078
Subbiah RN
et al.
Torsades de pointes during complete atrioventricular block: Genetic factors and electrocardiogram correlates.
Can J Cardiol,
2010
Apr
, 26 (208-12).
1079
Ding XW
et al.
Prognostic significance of hERG1 expression in gastric cancer.
Dig. Dis. Sci.,
2010
Apr
, 55 (1004-10).
1080
Yasuda K
[On-chip Cellomics technology for drug screening system using cardiomyocyte cells from human stem cell]
Yakugaku Zasshi,
2010
Apr
, 130 (545-57).
1081
Qian JY
et al.
Altered cytosolic Ca2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants.
Toxicol In Vitro,
2010
Apr
, 24 (960-72).
1082
Friemel A
et al.
Interactions at human ether-à-go-go-related gene channels.
Toxicol. Sci.,
2010
Apr
, 114 (346-55).
1083
Nof E
et al.
A common single nucleotide polymorphism can exacerbate long-QT type 2 syndrome leading to sudden infant death.
Circ Cardiovasc Genet,
2010
Apr
, 3 (199-206).
1084
Margulis M
et al.
Protein binding-dependent decreases in hERG channel blocker potency assessed by whole-cell voltage clamp in serum.
J. Cardiovasc. Pharmacol.,
2010
Apr
, 55 (368-76).
1085
Kise H
et al.
Cardiac and haemodynamic effects of tacrolimus in the halothane-anaesthetized dog.
Basic Clin. Pharmacol. Toxicol.,
2010
Apr
, 106 (288-95).
1086
Kotta CM
et al.
Cardiac ion channel gene mutations in Greek long QT syndrome patients.
J. Appl. Genet.,
2010
, 51 (515-8).
1087
Atalar F
et al.
Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study.
Behav Brain Funct,
2010
, 6 (27).
1088
Larsen AP
et al.
Differential expression of hERG1 channel isoforms reproduces properties of native I(Kr) and modulates cardiac action potential characteristics.
PLoS ONE,
2010
, 5 (e9021).
1089
Hunter C
et al.
Selective inhibitors of Kv11.1 regulate IL-6 expression by macrophages in response to TLR/IL-1R ligands.
ScientificWorldJournal,
2010
, 10 (1580-96).
1090
Eckey K
et al.
Modulation of human ether a gogo related channels by CASQ2 contributes to etiology of catecholaminergic polymorphic ventricular tachycardia (CPVT).
Cell. Physiol. Biochem.,
2010
, 26 (503-12).
1091
Hidaka S
et al.
Nonlinear classification of hERG channel inhibitory activity by unsupervised classification method.
J Toxicol Sci,
2010
, 35 (393-9).
1092
Xu X
et al.
Long-term fish oil supplementation induces cardiac electrical remodeling by changing channel protein expression in the rabbit model.
PLoS ONE,
2010
, 5 (e10140).
1093
Asher V
et al.
The Eag potassium channel as a new prognostic marker in ovarian cancer.
Diagn Pathol,
2010
, 5 (78).
1094
Grilo LS
et al.
Stereoselective block of hERG channel by bupivacaine scrutinized at molecular level.
Chimia (Aarau),
2010
, 64 (165-9).
1095
Fortunato P
et al.
Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway.
BMC Cancer,
2010
, 10 (504).
1096
Hu MQ
et al.
The novel mechanism of oxymatrine affecting HERG currents at different temperatures.
Cell. Physiol. Biochem.,
2010
, 26 (513-22).
1097
Tabrizchi R
Molecular mechanisms of adverse drug reactions in cardiac tissue.
Handb Exp Pharmacol,
2010
, (77-109).
1098
Grilo LS
et al.
Takotsubo cardiomyopathy and congenital long QT syndrome in a patient with a novel duplication in the Per-Arnt-Sim (PAS) domain of hERG1.
Heart Rhythm,
2010
, 7 (260-5).
1099
Pillozzi S
et al.
Physical and functional interaction between integrins and hERG1 channels in cancer cells.
Adv. Exp. Med. Biol.,
2010
, 674 (55-67).
1100
Masi A
et al.
Optical methods in the study of protein-protein interactions.
Adv. Exp. Med. Biol.,
2010
, 674 (33-42).
1101
Es-Salah-Lamoureux Z
et al.
Fluorescence-tracking of activation gating in human ERG channels reveals rapid S4 movement and slow pore opening.
PLoS ONE,
2010
, 5 (e10876).
1102
Wakamatsu A
et al.
Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study.
J Pharmacol Toxicol Methods,
2009 May-Jun
, 59 (128-34).
1103
Lee HA
et al.
Cellular mechanism of the QT prolongation induced by sulpiride.
Int. J. Toxicol.,
2009 May-Jun
, 28 (207-12).
1104
Markert M
et al.
Validation of the normal, freely moving Göttingen minipig for pharmacological safety testing.
J Pharmacol Toxicol Methods,
2009 Jul-Aug
, 60 (79-87).
1105
Mo ZL
et al.
Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress.
J Pharmacol Toxicol Methods,
2009 Jul-Aug
, 60 (39-44).
1106
Towart R
et al.
Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
J Pharmacol Toxicol Methods,
2009 Jul-Aug
, 60 (1-10).
1107
Brimecombe JC
et al.
Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability.
,
2009 Jan-Feb
, 59 (29-34).
1108
Choveau FS
et al.
Transfer of rolf S3-S4 linker to HERG eliminates activation gating but spares inactivation.
Biophys. J.,
2009
Sep
2
, 97 (1323-34).
1109
Papp F
et al.
Tst26, a novel peptide blocker of Kv1.2 and Kv1.3 channels from the venom of Tityus stigmurus.
Toxicon,
2009
Sep
15
, 54 (379-89).
1110
Suzuki T
et al.
Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
Bioorg. Med. Chem. Lett.,
2009
Sep
15
, 19 (5339-45).
1111
Itoh H
et al.
A novel KCNH2 mutation as a modifier for short QT interval.
Int. J. Cardiol.,
2009
Sep
11
, 137 (83-5).
1112
Moree WJ
et al.
Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.
J. Med. Chem.,
2009
Sep
10
, 52 (5307-10).
1113
Mosley CA
et al.
Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors.
Bioorg. Med. Chem.,
2009
Sep
1
, 17 (6463-80).
1114
McIntyre CJ
et al.
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.
Bioorg. Med. Chem. Lett.,
2009
Sep
1
, 19 (5132-5).
1115
Wu L
et al.
Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.
Am. J. Physiol. Heart Circ. Physiol.,
2009
Sep
, 297 (H1048-57).
1116
Raschi E
et al.
hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
Expert Opin Drug Metab Toxicol,
2009
Sep
, 5 (1005-21).
1117
Kapplinger JD
et al.
Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.
Heart Rhythm,
2009
Sep
, 6 (1297-303).
1118
Guo J
et al.
Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines.
J. Clin. Invest.,
2009
Sep
, 119 (2745-57).
1119
Robertson GA
Endocytic control of ion channel density as a target for cardiovascular disease.
J. Clin. Invest.,
2009
Sep
, 119 (2531-4).
1120
Brelidze TI
et al.
Absence of direct cyclic nucleotide modulation of mEAG1 and hERG1 channels revealed with fluorescence and electrophysiological methods.
J. Biol. Chem.,
2009
Oct
9
, 284 (27989-97).
1121
Lacerda AE
et al.
Vanoxerine: Cellular Mechanism of a New Antiarrhythmic.
J. Cardiovasc. Electrophysiol.,
2009
Oct
8
, ().
1123
Bagnes C
et al.
Antineoplastic Chemotherapy Induced QTc Prolongation.
,
2009
Oct
7
, ().
1124
Hardy AB
et al.
Characterization of Erg K+ channels in alpha- and beta-cells of mouse and human islets.
J. Biol. Chem.,
2009
Oct
30
, 284 (30441-52).
1125
Nanduri J
et al.
Hypoxia inhibits maturation and trafficking of hERG K(+) channel protein: Role of Hsp90 and ROS.
Biochem. Biophys. Res. Commun.,
2009
Oct
16
, 388 (212-6).
1126
Ziv O
et al.
Origin of complex behaviour of spatially discordant alternans in a transgenic rabbit model of type 2 long QT syndrome.
J. Physiol. (Lond.),
2009
Oct
1
, 587 (4661-80).
1127
Komada T
et al.
Pharmacological characterization and determination of pharmacokinetic and pharmacodynamic relationship of PF-00885706, a novel partial agonist selective for the 5-HT(4) receptor.
Pharmacol. Res.,
2009
Oct
, 60 (237-46).
1128
1129
Wang QS
et al.
Genetic polymorphism of KCNH2 confers predisposition of acquired atrial fibrillation in Chinese.
J. Cardiovasc. Electrophysiol.,
2009
Oct
, 20 (1158-62).
1130
Nakamura Y
et al.
Famotidine neither affects action potential parameters nor inhibits human ether-a-go-go-related gene (hERG) K+ current.
J Toxicol Sci,
2009
Oct
, 34 (563-7).
1131
Itoh H
et al.
Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome.
Circ Arrhythm Electrophysiol,
2009
Oct
, 2 (511-23).
1132
Zhao YH
et al.
[Eukaryotic expression vector pcDNA3-HERG transfection inhibits angiotensin II induced neonatal rabbit ventricular myocyte hypertrophy in vitro]
Zhonghua Xin Xue Guan Bing Za Zhi,
2009
Oct
, 37 (931-5).
1133
Cui G
et al.
Effect of Gambogic acid on the regulation of hERG channel in K562 cells in vitro.
J. Huazhong Univ. Sci. Technol. Med. Sci.,
2009
Oct
, 29 (540-5).
1134
Kapa S
et al.
Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants.
Circulation,
2009
Nov
3
, 120 (1752-60).
1135
Perry M
et al.
PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.
Proc. Natl. Acad. Sci. U.S.A.,
2009
Nov
24
, 106 (20075-80).
1136
Shimizu W
et al.
Genotype-phenotype aspects of type 2 long QT syndrome.
J. Am. Coll. Cardiol.,
2009
Nov
24
, 54 (2052-62).
1137
Zamponi GW
et al.
Scaffold-based design and synthesis of potent N-type calcium channel blockers.
Bioorg. Med. Chem. Lett.,
2009
Nov
15
, 19 (6467-72).
1138
Shaw SJ
et al.
Structure-activity relationships of 9-substituted-9-dihydroerythromycin-based motilin agonists: optimizing for potency and safety.
J. Med. Chem.,
2009
Nov
12
, 52 (6851-9).
1139
Titus SA
et al.
A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.
Anal. Biochem.,
2009
Nov
1
, 394 (30-8).
1140
Jo SH
et al.
H(1) antihistamine drug promethazine directly blocks hERG K(+) channel.
Pharmacol. Res.,
2009
Nov
, 60 (429-37).
1141
Hirdes W
et al.
Erg K+ currents modulate excitability in mouse mitral/tufted neurons.
Pflugers Arch.,
2009
Nov
, 459 (55-70).
1142
Ritchie TJ
et al.
The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?
Drug Discov. Today,
2009
Nov
, 14 (1011-20).
1143
Ogawa K
et al.
Isolated non-compaction of the ventricular myocardium associated with long QT syndrome: a report of 2 cases.
Circ. J.,
2009
Nov
, 73 (2169-72).
1144
Lees-Miller JP
et al.
Interactions of H562 in the S5 helix with T618 and S621 in the pore helix are important determinants of hERG1 potassium channel structure and function.
Biophys. J.,
2009
May
6
, 96 (3600-10).
1145
Sato N
et al.
Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
J. Med. Chem.,
2009
May
28
, 52 (3385-96).
1146
Karczewski J
et al.
Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
Biochem. Pharmacol.,
2009
May
15
, 77 (1602-11).
1147
Greenwood IA
et al.
Loss of functional K+ channels encoded by ether-à-go-go-related genes in mouse myometrium prior to labour onset.
J. Physiol. (Lond.),
2009
May
15
, 587 (2313-26).
1148
Mikami T
et al.
In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
Eur. J. Pharmacol.,
2009
May
1
, 609 (5-12).
1149
Wiśniowska B
et al.
hERG in vitro interchange factors--development and verification.
Toxicol. Mech. Methods,
2009
May
, 19 (278-84).
1150
Wiese C
et al.
Pharmacological and metabolic characterisation of the potent sigma1 receptor ligand 1'-benzyl-3-methoxy-3H-spiro[[2]benzofuran-1,4'-piperidine].
J. Pharm. Pharmacol.,
2009
May
, 61 (631-40).
1151
Nishio H
et al.
Identification of an ethnic-specific variant (V207M) of the KCNQ1 cardiac potassium channel gene in sudden unexplained death and implications from a knock-in mouse model.
Int. J. Legal Med.,
2009
May
, 123 (253-7).
1152
Ermondi G
et al.
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
,
2009
May
, 44 (1926-32).
1153
Chen J
et al.
PKA phosphorylation of HERG protein regulates the rate of channel synthesis.
Am. J. Physiol. Heart Circ. Physiol.,
2009
May
, 296 (H1244-54).
1154
Abbott GW
et al.
HERG biosynthesis: the positive influence of negative charge.
Am. J. Physiol. Heart Circ. Physiol.,
2009
May
, 296 (H1211-2).
1155
Huffaker SJ
et al.
A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia.
Nat. Med.,
2009
May
, 15 (509-18).
1157
Imai YN
et al.
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
J. Med. Chem.,
2009
Mar
26
, 52 (1630-8).
1158
Pages G
et al.
Structure of the pore-helix of the hERG K(+) channel.
Eur. Biophys. J.,
2009
Mar
21
, ().
1159
Owen DR
et al.
2,4-Diaminopyridine delta-opioid receptor agonists and their associated hERG pharmacology.
Bioorg. Med. Chem. Lett.,
2009
Mar
15
, 19 (1702-6).
1160
Barber CG
et al.
1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: Part 2.
Bioorg. Med. Chem. Lett.,
2009
Mar
1
, 19 (1499-503).
1161
McPate MJ
et al.
Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
J. Physiol. Pharmacol.,
2009
Mar
, 60 (23-41).
1162
McBride BF
The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation.
,
2009
Mar
, 49 (258-67).
1164
Salama G
et al.
Arrhythmia phenotype in mouse models of human long QT.
,
2009
Mar
, 24 (77-87).
1165
Guo YS
et al.
[Comparative pharmacophore analysis of dual dopamine D2/5-HT(2A) receptor antagonists]
Yao Xue Xue Bao,
2009
Mar
, 44 (314-20).
1166
Zaks-Makhina E
et al.
Specific and slow inhibition of the kir2.1 K+ channel by gambogic acid.
J. Biol. Chem.,
2009
Jun
5
, 284 (15432-8).
1167
Ureche ON
et al.
Differential modulation of cardiac potassium channels by Grb adaptor proteins.
Biochem. Biophys. Res. Commun.,
2009
Jun
19
, 384 (28-31).
1168
Walker DP
et al.
Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.
Bioorg. Med. Chem. Lett.,
2009
Jun
15
, 19 (3253-8).
1169
Patel SD
et al.
Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: alleviating hERG interactions through structure based design.
Bioorg. Med. Chem. Lett.,
2009
Jun
15
, 19 (3339-43).
1170
Stepanovic SZ
et al.
The evolutionarily conserved residue A653 plays a key role in HERG channel closing.
J. Physiol. (Lond.),
2009
Jun
1
, 587 (2555-66).
1171
Kobayashi K
et al.
Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity.
Bioorg. Med. Chem. Lett.,
2009
Jun
1
, 19 (3100-3).
1172
Hardman RM
et al.
Ether-à-go-go-related gene K+ channels contribute to threshold excitability of mouse auditory brainstem neurons.
J. Physiol. (Lond.),
2009
Jun
1
, 587 (2487-97).
1173
McBride BF
et al.
Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG.
Pharmacogenomics J.,
2009
Jun
, 9 (194-201).
1174
Chen MX
et al.
In vitro profiling against ion channels beyond hERG as an early indicator of cardiac risk.
Curr. Opin. Mol. Ther.,
2009
Jun
, 11 (269-81).
1175
Park SJ
et al.
Effects of mixed herbal extracts from parched Puerariae radix, gingered Magnoliae cortex, Glycyrrhizae radix and Euphorbiae radix (KIOM-79) on cardiac ion channels and action potentials.
J. Korean Med. Sci.,
2009
Jun
, 24 (403-12).
1176
Bush WS
et al.
Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias.
Pharmacogenomics,
2009
Jun
, 10 (1043-53).
1177
Hansen K
et al.
Bias-correction of regression models: a case study on hERG inhibition.
,
2009
Jun
, 49 (1486-96).
1178
Al-Owais M
et al.
Role of intracellular domains in the function of the herg potassium channel.
Eur. Biophys. J.,
2009
Jun
, 38 (569-76).
1179
Feigenspan A
et al.
Ether-à-gogo-related gene (erg1) potassium channels shape the dark response of horizontal cells in the mammalian retina.
Pflugers Arch.,
2009
Jun
, 458 (359-77).
1180
Sun Y
et al.
A novel nonsense mutation Y652X in the S6/pore region of human ether-go-go gene found in a long QT syndrome family.
Scand. Cardiovasc. J.,
2009
Jun
, 43 (181-6).
1181
Zachariae U
et al.
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
J. Med. Chem.,
2009
Jul
23
, 52 (4266-76).
1182
Guo L
et al.
Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
,
2009
Jul
17
, ().
1183
Barrows B
et al.
Extracellular potassium dependency of block of HERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation.
Channels (Austin),
2009
Jul
15
, 3 ().
1184
Kobayashi K
et al.
Discovery of novel arylpyrazole series as potent and selective opioid receptor-like 1 (ORL1) antagonists.
Bioorg. Med. Chem. Lett.,
2009
Jul
1
, 19 (3627-31).
1185
Zankov DP
et al.
Adrenergic regulation of the rapid component of delayed rectifier K+ current: implications for arrhythmogenesis in LQT2 patients.
Heart Rhythm,
2009
Jul
, 6 (1038-46).
1186
Zhou Q
et al.
Identification of Ikr kinetics and drug binding in native myocytes.
,
2009
Jul
, 37 (1294-309).
1187
McBride BF
et al.
The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel.
J. Cardiovasc. Pharmacol.,
2009
Jul
, 54 (63-71).
1188
Carlsson L
et al.
Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo.
J. Cardiovasc. Pharmacol.,
2009
Jul
, 54 (82-9).
1189
Hamon J
et al.
In vitro safety pharmacology profiling: what else beyond hERG?
Future Med Chem,
2009
Jul
, 1 (645-65).
1190
Ju P
et al.
The pore domain outer helix contributes to both activation and inactivation of the HERG K+ channel.
J. Biol. Chem.,
2009
Jan
9
, 284 (1000-8).
1191
Zamorano-León JJ
et al.
Novel mutation (H402R) in the S1 domain of KCNH2-encoded gene associated with long QT syndrome in a Spanish family.
Int. J. Cardiol.,
2009
Jan
9
, ().
1192
Yamashita M
et al.
The role of ether-a-go-go-related gene K(+) channels in glucocorticoid inhibition of adrenocorticotropin release by rat pituitary cells.
Regul. Pept.,
2009
Jan
8
, 152 (73-8).
1193
Delisle BP
et al.
Small GTPase determinants for the Golgi processing and plasmalemmal expression of human ether-a-go-go related (hERG) K+ channels.
J. Biol. Chem.,
2009
Jan
30
, 284 (2844-53).
1194
Johnson JN
et al.
Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy.
Neurology,
2009
Jan
20
, 72 (224-31).
1195
Pedroso N
et al.
Modulation of plasma membrane lipid profile and microdomains by H2O2 in Saccharomyces cerevisiae.
Free Radic. Biol. Med.,
2009
Jan
15
, 46 (289-98).
1196
Scherer D
et al.
Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents.
Br. J. Pharmacol.,
2009
Jan
, 156 (226-36).
1197
Lehtinen AB
et al.
Relationship between genetic variants in myocardial sodium and potassium channel genes and QT interval duration in diabetics: the Diabetes Heart Study.
Ann Noninvasive Electrocardiol,
2009
Jan
, 14 (72-9).
1198
Farre C
et al.
Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology.
Comb. Chem. High Throughput Screen.,
2009
Jan
, 12 (24-37).
1199
Kim KS
et al.
Effect of sibutramine HCl on cardiac hERG K+ channel.
Mol. Cell. Biochem.,
2009
Jan
, 320 (125-31).
1200
Kakusaka S
et al.
A receptor-independent effect of estrone sulfate on the HERG channel.
J. Pharmacol. Sci.,
2009
Jan
, 109 (152-6).
1201
Barber CG
et al.
1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
Bioorg. Med. Chem. Lett.,
2009
Feb
15
, 19 (1075-9).
1202
Yang HT
et al.
HERG -F463L Potassium Channels Linked to Long QT Syndrome Reduce I Current by a Trafficking-Deficient Mechanism.
Clin. Exp. Pharmacol. Physiol.,
2009
Feb
10
, ().
1203
Nisius B
et al.
Similarity-based classifier using topomers to provide a knowledge base for hERG channel inhibition.
,
2009
Feb
, 49 (247-56).
1204
Fanoe S
et al.
Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Br J Clin Pharmacol,
2009
Feb
, 67 (172-9).
1205
Potet F
et al.
Genetic screening in C. elegans identifies rho-GTPase activating protein 6 as novel HERG regulator.
J. Mol. Cell. Cardiol.,
2009
Feb
, 46 (257-67).
1206
Huang X
et al.
The effects of a novel anti-arrhythmic drug, acehytisine hydrochloride, on the human ether-a-go-go related gene K channel and its trafficking.
Basic Clin. Pharmacol. Toxicol.,
2009
Feb
, 104 (145-54).
1207
Crotti L
et al.
A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome.
Heart Rhythm,
2009
Feb
, 6 (212-8).
1208
Koehl GE
et al.
Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice.
Oncogene,
2009
Dec
7
, ().
1209
Braam SR
et al.
Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.
,
2009
Dec
3
, ().
1210
Chun YS
et al.
Cholesterol modulates ion channels via down-regulation of phosphatidylinositol 4,5-bisphosphate.
,
2009
Dec
14
, ().
1211
Shamovsky I
et al.
Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites.
J. Med. Chem.,
2009
Dec
10
, 52 (7706-23).
1212
Shi RM
et al.
[Gene mutation analysis of a Chinese family of congenital long Q-T syndrome type three.]
Zhonghua Er Ke Za Zhi,
2009
Dec
, 47 (926-30).
1213
Elliott DJ
et al.
Movement of the S4 segment in the hERG potassium channel during membrane depolarization.
Mol. Membr. Biol.,
2009
Dec
, 26 (435-47).
1214
Fenu LA
et al.
Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay.
J. Comput. Aided Mol. Des.,
2009
Dec
, 23 (883-95).
1215
Wulff H
et al.
Voltage-gated potassium channels as therapeutic targets.
Nat Rev Drug Discov,
2009
Dec
, 8 (982-1001).
1216
Hong HK
et al.
Inhibition of the human ether-a-go-go-related gene (HERG) K+ channels by Lindera erythrocarpa.
J. Korean Med. Sci.,
2009
Dec
, 24 (1089-98).
1217
Biliczki P
et al.
Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs alpha-subunit interaction.
Heart Rhythm,
2009
Dec
, 6 (1792-801).
1218
Iturralde-Torres P
et al.
[Genetic in long QT syndromes]
Arch Cardiol Mex,
2009
Dec
, 79 Suppl 2 (26-30).
1219
Takahara A
et al.
Clobutinol delays ventricular repolarization in the guinea pig heart: comparison with cardiac effects of HERG K+ channel inhibitor E-4031.
J. Cardiovasc. Pharmacol.,
2009
Dec
, 54 (552-9).
1220
Gustina AS
et al.
A recombinant N-terminal domain fully restores deactivation gating in N-truncated and long QT syndrome mutant hERG potassium channels.
Proc. Natl. Acad. Sci. U.S.A.,
2009
Aug
4
, 106 (13082-7).
1221
Nishio Y
et al.
D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome.
J. Am. Coll. Cardiol.,
2009
Aug
25
, 54 (812-9).
1222
Omichi C
et al.
Congenital long QT syndrome presenting with a history of epilepsy: Misdiagnosis or relationship between channelopathies of the heart and brain?
Epilepsia,
2009
Aug
19
, ().
1223
Gleeson P
et al.
ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.
Bioorg. Med. Chem.,
2009
Aug
15
, 17 (5906-19).
1224
Cho K
et al.
Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.
Bioorg. Med. Chem. Lett.,
2009
Aug
15
, 19 (4781-5).
1225
Sugimoto Y
et al.
Synthesis and biological evaluation of imidazole derivatives as novel NOP/ORL1 receptor antagonists: exploration and optimization of alternative pyrazole structure.
Bioorg. Med. Chem. Lett.,
2009
Aug
15
, 19 (4611-6).
1226
Washburn DG
et al.
Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists.
Bioorg. Med. Chem. Lett.,
2009
Aug
15
, 19 (4664-8).
1227
McPate MJ
et al.
hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome.
Biochem. Biophys. Res. Commun.,
2009
Aug
14
, 386 (111-7).
1228
Berglund S
et al.
Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
Bioorg. Med. Chem. Lett.,
2009
Aug
1
, 19 (4274-9).
1229
Berglund S
et al.
Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition.
Bioorg. Med. Chem. Lett.,
2009
Aug
1
, 19 (4268-73).
1230
Kameda M
et al.
Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
Bioorg. Med. Chem. Lett.,
2009
Aug
1
, 19 (4325-9).
1231
Li H
et al.
The role of hERG1 K+ channels and a functional link between hERG1 K+ channels and SDF-1 in acute leukemic cell migration.
Exp. Cell Res.,
2009
Aug
1
, 315 (2256-64).
1232
Coon T
et al.
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
Bioorg. Med. Chem. Lett.,
2009
Aug
1
, 19 (4380-4).
1233
Yokoyama H
et al.
Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs.
J. Pharmacol. Sci.,
2009
Aug
, 110 (476-82).
1234
Gu DF
et al.
Blockade of HERG K+ channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells.
Naunyn Schmiedebergs Arch. Pharmacol.,
2009
Aug
, 380 (143-51).
1235
Hreiche R
et al.
Impact of glucose concentration on cardiac ventricular repolarization under I Kr/I Ks blocking agents.
J. Mol. Cell. Cardiol.,
2009
Aug
, 47 (210-20).
1236
Keller DI
et al.
Characterization of novel KCNH2 mutations in type 2 long QT syndrome manifesting as seizures.
Can J Cardiol,
2009
Aug
, 25 (455-62).
1237
Einarsen K
et al.
Functional properties of human neuronal Kv11 channels.
Pflugers Arch.,
2009
Aug
, 458 (689-700).
1238
Thai KM
et al.
Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
Mol. Divers.,
2009
Aug
, 13 (321-36).
1239
Zhao JT
et al.
Not all hERG pore domain mutations have a severe phenotype: G584S has an inactivation gating defect with mild phenotype compared to G572S, which has a dominant negative trafficking defect and a severe phenotype.
J. Cardiovasc. Electrophysiol.,
2009
Aug
, 20 (923-30).
1240
Cubeddu LX
Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.
Curr Cardiol Rev,
2009
Aug
, 5 (166-76).
1241
Scholz EP
et al.
Biophysical properties of zebrafish ether-à-go-go related gene potassium channels.
Biochem. Biophys. Res. Commun.,
2009
Apr
3
, 381 (159-64).
1242
Wang S
et al.
Rapid component I(Kr) of cardiac delayed rectifier potassium currents in guinea-pig is inhibited by alpha(1)-adrenoreceptor activation via protein kinase A and protein kinase C-dependent pathways.
Eur. J. Pharmacol.,
2009
Apr
17
, 608 (1-6).
1243
Hayashi K
et al.
Long QT syndrome and associated gene mutation carriers in Japanese children: Results from ECG screening examination.
Clin. Sci.,
2009
Apr
16
, ().
1244
Bromidge SM
et al.
8-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors--part II.
Bioorg. Med. Chem. Lett.,
2009
Apr
15
, 19 (2338-42).
1245
Zhang P
et al.
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
Bioorg. Med. Chem. Lett.,
2009
Apr
15
, 19 (2179-85).
1246
Su Z
et al.
Electrophysiologic characterization of a novel hERG channel activator.
Biochem. Pharmacol.,
2009
Apr
15
, 77 (1383-90).
1247
Zhao XL
et al.
Comparative effects of sophocarpine and sophoridine on hERG K+ channel.
Eur. J. Pharmacol.,
2009
Apr
1
, 607 (15-22).
1248
Ganapathi SB
et al.
State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
Am. J. Physiol., Cell Physiol.,
2009
Apr
, 296 (C701-10).
1249
Ohno S
et al.
Novel KCNE3 mutation reduces repolarizing potassium current and associated with long QT syndrome.
Hum. Mutat.,
2009
Apr
, 30 (557-63).
1250
Yao Y
et al.
Aminoglycoside antibiotics restore functional expression of truncated HERG channels produced by nonsense mutations.
,
2009
Apr
, 6 (553-60).
1251
Redpath CJ
et al.
Rapid genetic testing facilitating the diagnosis of short QT syndrome.
,
2009
Apr
, 25 (e133-5).
1252
Wang L
et al.
Intracellular potassium stabilizes human ether-à-go-go-related gene channels for export from endoplasmic reticulum.
Mol. Pharmacol.,
2009
Apr
, 75 (927-37).
1253
Marjamaa A
et al.
Common candidate gene variants are associated with QT interval duration in the general population.
J. Intern. Med.,
2009
Apr
, 265 (448-58).
1254
Alonso-Ron C
et al.
Participation of HERG channel cytoplasmic structures on regulation by the G protein-coupled TRH receptor.
Pflugers Arch.,
2009
Apr
, 457 (1237-52).
1255
Polak S
et al.
Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
,
2009
Apr
, 29 (183-206).
1256
Newton-Cheh C
et al.
Common variants at ten loci influence QT interval duration in the QTGEN Study.
Nat. Genet.,
2009
Apr
, 41 (399-406).
1257
Pfeufer A
et al.
Common variants at ten loci modulate the QT interval duration in the QTSCD Study.
Nat. Genet.,
2009
Apr
, 41 (407-14).
1258
Wadhwa S
et al.
Differential expression of potassium ion channels in human renal cell carcinoma.
,
2009
, 41 (251-7).
1260
Mruk K
et al.
Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes.
PLoS ONE,
2009
, 4 (e4236).
1261
Lin C
et al.
The effects of chiral isolates of methadone on the cardiac potassium channel IKr.
Cardiology,
2009
, 113 (59-65).
1262
Raitakari OT
et al.
Common variation in NOS1AP and KCNH2 genes and QT interval duration in young adults. The Cardiovascular Risk in Young Finns Study.
Ann. Med.,
2009
, 41 (144-51).
1263
Jones KA
et al.
Automated Patch Clamping Using the QPatch.
Methods Mol. Biol.,
2009
, 565 (209-23).
1264
Du L
et al.
The interactions between hERG potassium channel and blockers.
,
2009
, 9 (330-8).
1265
Diochot S
et al.
Sea anemone toxins affecting potassium channels.
Prog. Mol. Subcell. Biol.,
2009
, 46 (99-122).
1266
Marjamaa A
et al.
High prevalence of four long QT syndrome founder mutations in the Finnish population.
Ann. Med.,
2009
, 41 (234-40).
1267
Grunnet M
et al.
hERG1 channel activators: a new anti-arrhythmic principle.
Prog. Biophys. Mol. Biol.,
2008 Oct-Nov
, 98 (347-62).
1268
Perrin MJ
et al.
Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.
Prog. Biophys. Mol. Biol.,
2008 Oct-Nov
, 98 (137-48).
1269
Mittelstadt SW
et al.
Evaluation of zebrafish embryos as a model for assessing inhibition of hERG.
,
2008 Mar-Apr
, 57 (100-5).
1271
Li Q
et al.
hERG classification model based on a combination of support vector machine method and GRIND descriptors.
Mol. Pharm.,
2008 Jan-Feb
, 5 (117-27).
1272
Fink M
et al.
Contributions of HERG K+ current to repolarization of the human ventricular action potential.
Prog. Biophys. Mol. Biol.,
2008 Jan-Apr
, 96 (357-76).
1273
Hsueh CH
et al.
Functional studies on three novel HCNH2 mutations in Taiwan: identification of distinct mechanisms of channel defect and dissociation between glycosylation defect and assembly defect.
Biochem. Biophys. Res. Commun.,
2008
Sep
5
, 373 (572-8).
1274
Sale H
et al.
Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome.
Circ. Res.,
2008
Sep
26
, 103 (e81-95).
1275
Gentile S
et al.
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity.
Proc. Natl. Acad. Sci. U.S.A.,
2008
Sep
23
, 105 (14704-8).
1276
Abdel-Mottaleb Y
et al.
A common "hot spot" confers hERG blockade activity to alpha-scorpion toxins affecting K+ channels.
Biochem. Pharmacol.,
2008
Sep
15
, 76 (805-15).
1277
Jo SH
et al.
Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652.
Eur. J. Pharmacol.,
2008
Sep
11
, 592 (19-25).
1278
Dai DZ
et al.
Induced ion currents and the endothelin pathway as targets for anti-arrhythmic agents.
,
2008
Sep
, 9 (1001-8).
1279
Lin J
et al.
The four and a half LIM domain protein 2 interacts with and regulates the HERG channel.
FEBS J.,
2008
Sep
, 275 (4531-9).
1280
Ridley JM
et al.
Modulation by testosterone of an endogenous hERG potassium channel current.
J. Physiol. Pharmacol.,
2008
Sep
, 59 (395-407).
1281
Wang X
et al.
Kv11.1 channel subunit composition includes MinK and varies developmentally in mouse cardiac muscle.
Dev. Dyn.,
2008
Sep
, 237 (2430-7).
1282
Larsen AP
et al.
Characterization of hERG1a and hERG1b potassium channels-a possible role for hERG1b in the I (Kr) current.
Pflugers Arch.,
2008
Sep
, 456 (1137-48).
1283
Eddy CA
et al.
Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome.
Heart Rhythm,
2008
Sep
, 5 (1275-81).
1284
Yang ZQ
et al.
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
J. Med. Chem.,
2008
Oct
23
, 51 (6471-7).
1285
Guay D
et al.
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
Bioorg. Med. Chem. Lett.,
2008
Oct
15
, 18 (5554-8).
1286
Pessia M
et al.
ERG voltage-gated K+ channels regulate excitability and discharge dynamics of the medial vestibular nucleus neurones.
J. Physiol. (Lond.),
2008
Oct
15
, 586 (4877-90).
1287
Irie O
et al.
Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.
Bioorg. Med. Chem. Lett.,
2008
Oct
1
, 18 (5280-4).
1288
Levoin N
et al.
Refined docking as a valuable tool for lead optimization: application to histamine H3 receptor antagonists.
Arch. Pharm. (Weinheim),
2008
Oct
, 341 (610-23).
1289
Miranda P
et al.
FRET with multiply labeled HERG K(+) channels as a reporter of the in vivo coarse architecture of the cytoplasmic domains.
Biochim. Biophys. Acta,
2008
Oct
, 1783 (1681-99).
1290
Sawa M
Strategies for the design of selective protein kinase inhibitors.
,
2008
Oct
, 8 (1291-7).
1291
Lin J
et al.
The regulation of the cardiac potassium channel (HERG) by caveolin-1.
Biochem. Cell Biol.,
2008
Oct
, 86 (405-15).
1292
White EJ
et al.
Ether-a-go-go-related gene 3 is the main candidate for the E-4031-sensitive potassium current in the pacemaker interstitial cells of Cajal.
Am. J. Physiol. Gastrointest. Liver Physiol.,
2008
Oct
, 295 (G691-9).
1293
Yontar OC
et al.
Short QT syndrome: a very rare arrhythmogenic entity.
Acta Cardiol,
2008
Oct
, 63 (553-5).
1294
Yeung KS
et al.
Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
,
2008
Oct
, 3 (1501-2).
1295
Wang X
et al.
[Analysis and analyzing mechanisms of HERG channel kinetics]
,
2008
Oct
, 25 (1068-73).
1296
Ravens U
et al.
Role of potassium currents in cardiac arrhythmias.
,
2008
Oct
, 10 (1133-7).
1297
Thai KM
et al.
Classification models for HERG inhibitors by counter-propagation neural networks.
,
2008
Oct
, 72 (279-89).
1298
Zhang DY
et al.
Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels.
Cell. Signal.,
2008
Oct
, 20 (1815-21).
1299
Tang Q
et al.
The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.
Br. J. Pharmacol.,
2008
Oct
, 155 (365-73).
1300
Wu ZY
et al.
Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-á-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2.
Endocrinology,
2008
Oct
, 149 (5061-9).
1301
Waldhauser KM
et al.
Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.
Br. J. Pharmacol.,
2008
Oct
, 155 (585-95).
1302
Otagiri T
et al.
Cardiac ion channel gene mutations in sudden infant death syndrome.
Pediatr. Res.,
2008
Nov
, 64 (482-7).
1303
Crumb W
et al.
Cyamemazine metabolites: effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs.
J. Pharm. Pharmacol.,
2008
Nov
, 60 (1507-13).
1304
Bowlby MR
et al.
hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk.
Curr. Drug Metab.,
2008
Nov
, 9 (965-70).
1305
Kamiya K
et al.
Molecular determinants of hERG channel block by terfenadine and cisapride.
J. Pharmacol. Sci.,
2008
Nov
, 108 (301-7).
1306
Christé G
et al.
A new C-terminal hERG mutation A915fs+47X associated with symptomatic LQT2 and auditory-trigger syncope.
,
2008
Nov
, 5 (1577-86).
1307
Tenenbaum M
et al.
Identification of the gene causing long QT syndrome in an Israeli family.
Isr. Med. Assoc. J.,
2008
Nov
, 10 (809-11).
1308
Wynia-Smith SL
et al.
hERG gating microdomains defined by S6 mutagenesis and molecular modeling.
J. Gen. Physiol.,
2008
Nov
, 132 (507-20).
1309
Perrin MJ
et al.
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
Mol. Pharmacol.,
2008
Nov
, 74 (1443-52).
1310
McPate MJ
et al.
Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.
Br. J. Pharmacol.,
2008
Nov
, 155 (957-66).
1311
Lindegger N
et al.
Look beyond the hERG mutation: a neutral SCN5A variant may turn lidocaine into a threat.
Heart Rhythm,
2008
Nov
, 5 (1575-6).
1312
Lin MT
et al.
In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant.
Heart Rhythm,
2008
Nov
, 5 (1567-74).
1313
1314
Alonso-Ron C
et al.
Thermodynamic and kinetic properties of amino-terminal and S4-S5 loop HERG channel mutants under steady-state conditions.
Biophys. J.,
2008
May
15
, 94 (3893-911).
1315
Schimpf R
et al.
Clinical and molecular genetics of the short QT syndrome.
Curr. Opin. Cardiol.,
2008
May
, 23 (192-8).
1316
Peitersen T
et al.
Computational analysis of the effects of the hERG channel opener NS1643 in a human ventricular cell model.
,
2008
May
, 5 (734-41).
1317
Wang YH
et al.
Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor.
Br. J. Pharmacol.,
2008
May
, 154 (429-39).
1318
Cuypers E
et al.
Gambierol, a toxin produced by the dinoflagellate Gambierdiscus toxicus, is a potent blocker of voltage-gated potassium channels.
Toxicon,
2008
May
, 51 (974-83).
1319
Li H
et al.
HERG K+ channel expression in CD34+/CD38-/CD123(high) cells and primary leukemia cells and analysis of its regulation in leukemia cells.
Int. J. Hematol.,
2008
May
, 87 (387-92).
1320
Mitcheson JS
hERG potassium channels and the structural basis of drug-induced arrhythmias.
Chem. Res. Toxicol.,
2008
May
, 21 (1005-10).
1321
Li Y
et al.
A-kinase anchoring protein targeting of protein kinase A and regulation of HERG channels.
J. Membr. Biol.,
2008
May
, 223 (107-16).
1322
Andrássy G
et al.
Methadone-induced QTc prolongation: is it due to stereoselective block of hERG or to inappropriate QT interval correction?
Clin. Pharmacol. Ther.,
2008
May
, 83 (671; author reply 672).
1323
Johnson JN
et al.
Prevalence of early-onset atrial fibrillation in congenital long QT syndrome.
Heart Rhythm,
2008
May
, 5 (704-9).
1324
Priest BT
et al.
Role of hERG potassium channel assays in drug development.
,
2008
Mar
5
, 2 ().
1325
Slee DH
et al.
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.
J. Med. Chem.,
2008
Mar
27
, 51 (1730-9).
1326
Shamovsky I
et al.
Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.
J. Med. Chem.,
2008
Mar
13
, 51 (1162-78).
1327
Vandendriessche T
et al.
Modulation of voltage-gated Na+ and K+ channels by pumiliotoxin 251D: a "joint venture" alkaloid from arthropods and amphibians.
Toxicon,
2008
Mar
1
, 51 (334-44).
1328
Zebedin E
et al.
Effects of duramycin on cardiac voltage-gated ion channels.
Naunyn Schmiedebergs Arch. Pharmacol.,
2008
Mar
, 377 (87-100).
1329
Claassen S
et al.
Electrophysiological and fluorescence microscopy studies with HERG channel/EGFP fusion proteins.
J. Membr. Biol.,
2008
Mar
, 222 (31-41).
1330
Gordon E
et al.
2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Mol. Pharmacol.,
2008
Mar
, 73 (639-51).
1331
Raschi E
et al.
The hERG K+ channel: target and antitarget strategies in drug development.
Pharmacol. Res.,
2008
Mar
, 57 (181-95).
1332
Mewe M
et al.
Erg K+ channels modulate contractile activity in the bovine epididymal duct.
Am. J. Physiol. Regul. Integr. Comp. Physiol.,
2008
Mar
, 294 (R895-904).
1333
Luo X
et al.
Genomic structure, transcriptional control, and tissue distribution of HERG1 and KCNQ1 genes.
Am. J. Physiol. Heart Circ. Physiol.,
2008
Mar
, 294 (H1371-80).
1334
Gong Q
et al.
A splice site mutation in hERG leads to cryptic splicing in human long QT syndrome.
J. Mol. Cell. Cardiol.,
2008
Mar
, 44 (502-9).
1335
Rhodes TE
et al.
Cardiac potassium channel dysfunction in sudden infant death syndrome.
J. Mol. Cell. Cardiol.,
2008
Mar
, 44 (571-81).
1336
Park SJ
et al.
Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
,
2008
Mar
, 28 (104-11).
1337
Hjaeresen ML
et al.
Chronic electroconvulsive stimulation but not chronic restraint stress modulates mRNA expression of voltage-dependent potassium channels Kv7.2 and Kv11.1 in the rat piriform cortex.
Brain Res.,
2008
Jun
27
, 1217 (179-84).
1338
Abdel-Mottaleb Y
et al.
OdK2, a Kv1.3 channel-selective toxin from the venom of the Iranian scorpion Odonthobuthus doriae.
Toxicon,
2008
Jun
15
, 51 (1424-30).
1339
Kurokawa J
et al.
Acute effects of oestrogen on the guinea pig and human IKr channels and drug-induced prolongation of cardiac repolarization.
J. Physiol. (Lond.),
2008
Jun
15
, 586 (2961-73).
1340
Zhang S
et al.
C101, a novel 4-amino-piperidine derivative selectively blocks N-type calcium channels.
Eur. J. Pharmacol.,
2008
Jun
10
, 587 (42-7).
1341
Jia L
et al.
Support vector machines classification of hERG liabilities based on atom types.
Bioorg. Med. Chem.,
2008
Jun
1
, 16 (6252-60).
1342
Roy J
et al.
Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.
Oncol. Rep.,
2008
Jun
, 19 (1511-6).
1343
Margulis M
et al.
Additive effects of combined application of multiple hERG blockers.
J. Cardiovasc. Pharmacol.,
2008
Jun
, 51 (549-52).
1344
Xu X
et al.
Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD3
Mol. Pharmacol.,
2008
Jun
, 73 (1709-21).
1345
Rajamani S
et al.
Rapid kinetic interactions of ranolazine with HERG K+ current.
J. Cardiovasc. Pharmacol.,
2008
Jun
, 51 (581-9).
1346
Brunner M
et al.
Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome.
J. Clin. Invest.,
2008
Jun
, 118 (2246-59).
1347
Hreiche R
et al.
Drug-induced long QT syndrome in women: review of current evidence and remaining gaps.
,
2008
Jun
, 5 (124-35).
1348
Hancox JC
et al.
Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
Mol. Pharmacol.,
2008
Jun
, 73 (1592-5).
1349
Myokai T
et al.
Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
Mol. Pharmacol.,
2008
Jun
, 73 (1643-51).
1350
Crotti L
et al.
Gene symbol: KCNH2. Disease: Long QT syndrome.
Hum. Genet.,
2008
Jun
, 123 (543).
1351
Crotti L
et al.
Gene symbol: KCNH2. Disease: Long QT syndrome.
Hum. Genet.,
2008
Jun
, 123 (541).
1352
Crotti L
et al.
Gene symbol: KCNH2. Disease: Long QT syndrome.
Hum. Genet.,
2008
Jun
, 123 (540).
1353
Tsai CT
et al.
Molecular genetics of atrial fibrillation.
J. Am. Coll. Cardiol.,
2008
Jul
22
, 52 (241-50).
1354
Stansfeld PJ
et al.
Insight into the mechanism of inactivation and pH sensitivity in potassium channels from molecular dynamics simulations.
Biochemistry,
2008
Jul
15
, 47 (7414-22).
1355
Siu T
et al.
The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
Bioorg. Med. Chem. Lett.,
2008
Jul
15
, 18 (4191-4).
1356
Yoshizumi T
et al.
A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K+ channel.
J. Med. Chem.,
2008
Jul
10
, 51 (4021-9).
1357
Amin AS
et al.
Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome.
J. Clin. Invest.,
2008
Jul
, 118 (2552-61).
1358
Hansen RS
et al.
In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig.
J. Cardiovasc. Pharmacol.,
2008
Jul
, 52 (35-41).
1359
Scherer D
et al.
Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin.
Naunyn Schmiedebergs Arch. Pharmacol.,
2008
Jul
, 378 (73-83).
1361
Shimizu W
Genetics of congenital long QT syndrome and Brugada syndrome.
Future Cardiol,
2008
Jul
, 4 (379-89).
1362
Becucci L
et al.
Incorporation of the HERG potassium channel in a mercury supported lipid bilayer.
,
2008
Jan
31
, 112 (1315-9).
1363
Jo SH
et al.
Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel.
Life Sci.,
2008
Jan
30
, 82 (331-40).
1364
Thomas D
et al.
Doxazosin induces apoptosis of cells expressing hERG K+ channels.
Eur. J. Pharmacol.,
2008
Jan
28
, 579 (98-103).
1365
Zhao J
et al.
Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in vitro and in vivo.
Eur. J. Pharmacol.,
2008
Jan
28
, 579 (50-7).
1366
Whitlock GA
et al.
1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.
Bioorg. Med. Chem. Lett.,
2008
Jan
15
, 18 (596-9).
1367
Albert CM
et al.
Cardiac sodium channel gene variants and sudden cardiac death in women.
Circulation,
2008
Jan
1
, 117 (16-23).
1368
Ding XW
et al.
Overexpression of hERG1 in resected esophageal squamous cell carcinomas: a marker for poor prognosis.
,
2008
Jan
1
, 97 (57-62).
1369
Shao XD
et al.
Expression and significance of HERG protein in gastric cancer.
Cancer Biol. Ther.,
2008
Jan
, 7 (45-50).
1370
Qi ZP
et al.
[Effect of sophocarpine on HERG K+ channels]
Yao Xue Xue Bao,
2008
Jan
, 43 (44-9).
1372
Vaglio M
et al.
A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology.
,
2008
Jan
, 5 (11-8).
1373
Gordon E
et al.
A KCNE2 mutation in a patient with cardiac arrhythmia induced by auditory stimuli and serum electrolyte imbalance.
Cardiovasc. Res.,
2008
Jan
, 77 (98-106).
1374
Jeyaraj D
et al.
I(Kr) channel blockade to unmask occult congenital long QT syndrome.
Heart Rhythm,
2008
Jan
, 5 (2-7).
1375
Gleeson MP
Generation of a set of simple, interpretable ADMET rules of thumb.
J. Med. Chem.,
2008
Feb
28
, 51 (817-34).
1376
Kort ME
et al.
Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.
J. Med. Chem.,
2008
Feb
14
, 51 (407-16).
1377
Wu L
et al.
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone.
Cardiovasc. Res.,
2008
Feb
1
, 77 (481-8).
1378
Mancilla-Simbro C
et al.
Chlorthalidone inhibits the KvLQT1 potassium current in guinea-pig ventricular myocytes and oocytes from Xenopus laevis.
Br. J. Pharmacol.,
2008
Feb
, 153 (448-58).
1380
Christ T
et al.
Electrophysiological profile of propiverine--relationship to cardiac risk.
Naunyn Schmiedebergs Arch. Pharmacol.,
2008
Feb
, 376 (431-40).
1381
Garg D
et al.
Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques.
J. Mol. Graph. Model.,
2008
Feb
, 26 (966-76).
1382
van der Heyden MA
et al.
Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?
Br. J. Pharmacol.,
2008
Feb
, 153 (406-9).
1383
Takemasa H
et al.
Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.
Br. J. Pharmacol.,
2008
Feb
, 153 (439-47).
1384
Teng GQ
et al.
Homozygous missense N629D hERG (KCNH2) potassium channel mutation causes developmental defects in the right ventricle and its outflow tract and embryonic lethality.
Circ. Res.,
2008
Dec
5
, 103 (1483-91).
1385
Jones CD
et al.
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Bioorg. Med. Chem. Lett.,
2008
Dec
15
, 18 (6486-9).
1386
Jones CD
et al.
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.
Bioorg. Med. Chem. Lett.,
2008
Dec
15
, 18 (6369-73).
1387
Mizutani T
et al.
Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.
Bioorg. Med. Chem. Lett.,
2008
Dec
1
, 18 (6041-5).
1388
Methot JL
et al.
SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Bioorg. Med. Chem. Lett.,
2008
Dec
1
, 18 (6104-9).
1389
Mente S
et al.
Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.
Bioorg. Med. Chem. Lett.,
2008
Dec
1
, 18 (6088-92).
1390
Shimizu W
Clinical impact of genetic studies in lethal inherited cardiac arrhythmias.
Circ. J.,
2008
Dec
, 72 (1926-36).
1391
Inanobe A
et al.
In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
J Physiol Sci,
2008
Dec
, 58 (459-70).
1392
Deisemann H
et al.
Effects of common antitussive drugs on the hERG potassium channel current.
J. Cardiovasc. Pharmacol.,
2008
Dec
, 52 (494-9).
1393
Kim YJ
et al.
Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
J. Cardiovasc. Pharmacol.,
2008
Dec
, 52 (485-93).
1394
Yang H
et al.
[Identification of a novel KCNH2 mutation in a family with congenital long QT syndrome and prediction of the secondary structure of its encoding protein]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi,
2008
Dec
, 25 (704-7).
1395
Odening KE
et al.
Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization.
Am. J. Physiol. Heart Circ. Physiol.,
2008
Dec
, 295 (H2264-72).
1396
Tabo M
et al.
Cardiovascular safety profile of MA-2029, a novel motilin receptor antagonist.
,
2008
Dec
, 33 (631-9).
1397
Sakaguchi T
et al.
Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation.
J. Pharmacol. Sci.,
2008
Dec
, 108 (462-71).
1398
Zienciuk A
et al.
[QTc duration in the long QT syndrome type 2 - diagnostic dilemma]
,
2008
Dec
, 66 (1333-7).
1399
Tu DN
et al.
Blockade of the human ether-a-go-go-related gene potassium channel by ketanserin.
,
2008
Aug
25
, 60 (525-34).
1400
Nanduri J
et al.
Mitochondrial reactive oxygen species mediate hypoxic down-regulation of hERG channel protein.
Biochem. Biophys. Res. Commun.,
2008
Aug
22
, 373 (309-14).
1401
Sun DD
et al.
Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels.
Eur. J. Pharmacol.,
2008
Aug
20
, 590 (317-21).
1402
Huo J
et al.
The G604S-hERG mutation alters the biophysical properties and exerts a dominant-negative effect on expression of hERG channels in HEK293 cells.
Pflugers Arch.,
2008
Aug
, 456 (917-28).
1403
Hancox JC
et al.
The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Pharmacol. Ther.,
2008
Aug
, 119 (118-32).
1404
Restano-Cassulini R
et al.
Two novel ergtoxins, blockers of K+-channels, purified from the Mexican scorpion Centruroides elegans elegans.
Neurochem. Res.,
2008
Aug
, 33 (1525-33).
1405
Dumotier BM
et al.
Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis.
Pharmacol. Ther.,
2008
Aug
, 119 (152-9).
1406
Yao X
et al.
Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model.
Br. J. Pharmacol.,
2008
Aug
, 154 (1446-56).
1407
Lu HR
et al.
Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
Br. J. Pharmacol.,
2008
Aug
, 154 (1427-38).
1408
Guasti L
et al.
Identification of a posttranslational mechanism for the regulation of hERG1 K+ channel expression and hERG1 current density in tumor cells.
Mol. Cell. Biol.,
2008
Aug
, 28 (5043-60).
1409
Pollard CE
et al.
Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective.
Br. J. Pharmacol.,
2008
Aug
, 154 (1538-43).
1410
Tu DN
et al.
Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes.
Acta Pharmacol. Sin.,
2008
Aug
, 29 (913-22).
1411
Gintant GA
Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
Pharmacol. Ther.,
2008
Aug
, 119 (199-209).
1412
Biliczki P
et al.
Cellular properties of C-terminal KCNH2 long QT syndrome mutations: description and divergence from clinical phenotypes.
Heart Rhythm,
2008
Aug
, 5 (1159-67).
1413
Wang XP
et al.
[The persistent expression of HERG channel in Xenopus oocyte and alteration of current].
Zhongguo Ying Yong Sheng Li Xue Za Zhi,
2008
Aug
, 24 (329-33).
1414
Masetti M
et al.
Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
,
2008
Apr
15
, 29 (795-808).
1415
Thai KM
et al.
A binary QSAR model for classification of hERG potassium channel blockers.
Bioorg. Med. Chem.,
2008
Apr
1
, 16 (4107-19).
1416
Perry M
et al.
A single amino acid difference between ether-a-go-go- related gene channel subtypes determines differential sensitivity to a small molecule activator.
Mol. Pharmacol.,
2008
Apr
, 73 (1044-51).
1417
Zhang Y
et al.
Single nucleotide polymorphisms and haplotype of four genes encoding cardiac ion channels in Chinese and their association with arrhythmia.
Ann Noninvasive Electrocardiol,
2008
Apr
, 13 (180-90).
1418
Zhao XL
et al.
HERG K+ channel blockade by the novel antiviral drug sophocarpine.
Biol. Pharm. Bull.,
2008
Apr
, 31 (627-32).
1419
Fernandez D
et al.
Structural basis for ether-a-go-go-related gene K+ channel subtype-dependent activation by niflumic acid.
Mol. Pharmacol.,
2008
Apr
, 73 (1159-67).
1420
Recanatini M
et al.
Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations.
,
2008
Apr
, 3 (523-35).
1421
Zeng H
et al.
Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride.
,
2008
Apr
, 6 (235-41).
1422
Piper DR
et al.
Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach.
,
2008
Apr
, 6 (213-23).
1423
Chtcheglova LA
et al.
Localization of the ergtoxin-1 receptors on the voltage sensing domain of hERG K+ channel by AFM recognition imaging.
Pflugers Arch.,
2008
Apr
, 456 (247-54).
1424
Grunnet M
Fetal arrhythmia caused by dysregulation of HERG channels.
Heart Rhythm,
2008
Apr
, 5 (562-4).
1425
Bhuiyan ZA
et al.
Recurrent intrauterine fetal loss due to near absence of HERG: clinical and functional characterization of a homozygous nonsense HERG Q1070X mutation.
Heart Rhythm,
2008
Apr
, 5 (553-61).
1426
Luo T
et al.
Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Anesth. Analg.,
2008
Apr
, 106 (1161-70, table of contents).
1428
Sinner MF
et al.
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG).
Eur. Heart J.,
2008
Apr
, 29 (907-14).
1429
Patel C
et al.
Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome.
Heart Rhythm,
2008
Apr
, 5 (585-90).
1430
Piper DR
et al.
Cooperative interactions between R531 and acidic residues in the voltage sensing module of hERG1 channels.
Cell. Physiol. Biochem.,
2008
, 21 (37-46).
1431
Lundby A
et al.
KCNE3 mutation V17M identified in a patient with lone atrial fibrillation.
Cell. Physiol. Biochem.,
2008
, 21 (47-54).
1433
Jackson HA
et al.
Evolutionary analyses of KCNQ1 and HERG voltage-gated potassium channel sequences reveal location-specific susceptibility and augmented chemical severities of arrhythmogenic mutations.
BMC Evol. Biol.,
2008
, 8 (188).
1434
Lin C
et al.
Extracellular acidification and hyperkalemia induce changes in HERG inhibition by ibutilide.
Cardiology,
2008
, 110 (209-16).
1435
Lin C
et al.
The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition.
Cardiology,
2008
, 110 (145-52).
1436
Raudenská M
et al.
Mutation analysis of candidate genes SCN1B, KCND3 and ANK2 in patients with clinical diagnosis of long QT syndrome.
Physiol Res,
2008
, 57 (857-62).
1437
Koskela J
et al.
Potassium channel KCNH2 K897T polymorphism and cardiac repolarization during exercise test: The Finnish Cardiovascular Study.
Scand. J. Clin. Lab. Invest.,
2008
, 68 (31-8).
1438
Berge KE
et al.
Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers.
Scand. J. Clin. Lab. Invest.,
2008
, 68 (362-8).
1439
Zhang X
et al.
Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations.
BMC Med. Genet.,
2008
, 9 (87).
1440
Drago A
et al.
Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia.
Curr. Med. Chem.,
2008
, 15 (2472-517).
1441
Himmel HM
Mechanisms involved in cardiac sensitization by volatile anesthetics: general applicability to halogenated hydrocarbons?
Crit. Rev. Toxicol.,
2008
, 38 (773-803).
1442
Judd AS
et al.
Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity.
,
2008
, 8 (1152-7).
1443
Price DA
et al.
Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
,
2008
, 8 (1140-51).
1444
Bell IM
et al.
The impact of I(Kr) blockade on medicinal chemistry programs.
,
2008
, 8 (1128-39).
1445
Helliwell RM
Recording hERG potassium currents and assessing the effects of compounds using the whole-cell patch-clamp technique.
Methods Mol. Biol.,
2008
, 491 (279-95).
1447
Lagrutta AA
et al.
The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview.
,
2008
, 8 (1102-12).
1448
Harada N
et al.
Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1.
Kobe J Med Sci,
2008
, 54 (E23-34).
1449
Grunnet M
et al.
Biophysical characterization of the short QT mutation hERG-N588K reveals a mixed gain-and loss-of-function.
Cell. Physiol. Biochem.,
2008
, 22 (611-24).
1450
Brown S
et al.
A highly conserved alanine in the S6 domain of the hERG1 K+ channel is required for normal gating.
Cell. Physiol. Biochem.,
2008
, 22 (601-10).
1451
Banerjee B
et al.
Genomic imbalances in key ion channel genes and telomere shortening in sudden cardiac death victims.
Cytogenet. Genome Res.,
2008
, 122 (350-5).
1452
Ducroq J
et al.
Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
,
2007 Sep-Oct
, 56 (159-70).
1453
Obrezanova O
et al.
Gaussian processes: a method for automatic QSAR modeling of ADME properties.
,
2007 Sep-Oct
, 47 (1847-57).
1454
1455
Latorre R
et al.
ThermoTRP channels as modular proteins with allosteric gating.
Cell Calcium,
2007 Oct-Nov
, 42 (427-38).
1456
Hu D
et al.
Genetic predisposition and cellular basis for ischemia-induced ST-segment changes and arrhythmias.
,
2007 Nov-Dec
, 40 (S26-9).
1457
Donahue JK
et al.
Gene therapy approaches to ventricular tachyarrhythmias.
,
2007 Nov-Dec
, 40 (S187-91).
1458
Abbott GW
et al.
Impact of ancillary subunits on ventricular repolarization.
,
2007 Nov-Dec
, 40 (S42-6).
1459
Meyers NL
et al.
The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.
J. Int. Med. Res.,
2007 Nov-Dec
, 35 (848-66).
1460
Lin MC
et al.
Differences between ion binding to eag and HERG voltage sensors contribute to differential regulation of activation and deactivation gating.
Channels (Austin),
2007 Nov-Dec
, 1 (429-37).
1461
Hosaka Y
et al.
Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Channels (Austin),
2007 May-Jun
, 1 (198-208).
1462
Cvetanovic I
et al.
The effects of quinidine and its chiral isolates on erg-1sm potassium current and correlation with gastrointestinal augmentation.
,
2007 May-Jun
, 14 (269-76).
1463
Deacon M
et al.
Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
,
2007 May-Jun
, 55 (238-47).
1464
Balijepalli RC
et al.
Kv11.1 (ERG1) K+ channels localize in cholesterol and sphingolipid enriched membranes and are modulated by membrane cholesterol.
Channels (Austin),
2007 Jul-Aug
, 1 (263-72).
1465
Yunomae K
et al.
Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.
,
2007 Jan-Feb
, 27 (78-85).
1466
Kim KS
et al.
Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization.
Int. J. Toxicol.,
2007 Jan-Feb
, 26 (25-31).
1467
Fossa AA
et al.
Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants.
,
2007 Jan-Feb
, 55 (78-85).
1468
Newton-Cheh C
et al.
Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study.
Circulation,
2007
Sep
4
, 116 (1128-36).
1469
Johnson SR
et al.
Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR.
Bioorg. Med. Chem.,
2007
Sep
15
, 15 (6182-92).
1470
Hill AP
et al.
The S631A mutation causes a mechanistic switch in the block of hERG channels by CnErg1.
Biophys. J.,
2007
Sep
15
, 93 (L32-4).
1471
Su Z
et al.
Functional consequences of methionine oxidation of hERG potassium channels.
Biochem. Pharmacol.,
2007
Sep
1
, 74 (702-11).
1472
Rutberg J
et al.
Molecular autopsy in the sudden cardiac death of a young woman: a first Canadian report.
,
2007
Sep
, 23 (904-6).
1473
Gouas L
et al.
Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects.
Eur. J. Hum. Genet.,
2007
Sep
, 15 (974-9).
1474
Silvestre JS
et al.
Comparative evaluation of hERG potassium channel blockade by antipsychotics.
,
2007
Sep
, 29 (457-65).
1475
Aizawa Y
et al.
A novel mutation in KCNQ1 associated with a potent dominant negative effect as the basis for the LQT1 form of the long QT syndrome.
J. Cardiovasc. Electrophysiol.,
2007
Sep
, 18 (972-7).
1476
Zhang Y
et al.
A missense mutation (G604S) in the S5/pore region of HERG causes long QT syndrome in a Chinese family with a high incidence of sudden unexpected death.
Eur. J. Pediatr.,
2007
Sep
, 166 (927-33).
1477
Morissette P
et al.
Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
J. Psychopharmacol. (Oxford),
2007
Sep
, 21 (735-41).
1478
Nakamura K
et al.
Anti-KCNH2 antibody-induced long QT syndrome: novel acquired form of long QT syndrome.
J. Am. Coll. Cardiol.,
2007
Oct
30
, 50 (1808-9).
1479
Kawai M
et al.
Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone--a potent NR2B-selective N-methyl D-aspartate (NMDA) antagonist for the treatment of pain.
Bioorg. Med. Chem. Lett.,
2007
Oct
15
, 17 (5558-62).
1480
Kawai M
et al.
Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity.
Bioorg. Med. Chem. Lett.,
2007
Oct
15
, 17 (5533-6).
1481
Cavarra MS
et al.
HERG1 currents in native K562 leukemic cells.
J. Membr. Biol.,
2007
Oct
, 219 (49-61).
1482
Chung SK
et al.
Long QT and Brugada syndrome gene mutations in New Zealand.
,
2007
Oct
, 4 (1306-14).
1483
Bian JS
et al.
Phosphatidylinositol 4,5-bisphosphate interactions with the HERG K(+) channel.
Pflugers Arch.,
2007
Oct
, 455 (105-13).
1484
Toga T
et al.
The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities.
J. Pharmacol. Sci.,
2007
Oct
, 105 (207-10).
1485
Li CL
et al.
[The mechanistic rote of KCNH2 gene L413P and L559H mutations in long QT syndrome]
Zhonghua Nei Ke Za Zhi,
2007
Oct
, 46 (838-41).
1486
Hardman RM
et al.
Activation gating of hERG potassium channels: S6 glycines are not required as gating hinges.
J. Biol. Chem.,
2007
Nov
2
, 282 (31972-81).
1487
Bai X
et al.
Electrophysiological properties of human adipose tissue-derived stem cells.
Am. J. Physiol., Cell Physiol.,
2007
Nov
, 293 (C1539-50).
1488
Schimpf R
et al.
In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study.
J. Cardiovasc. Electrophysiol.,
2007
Nov
, 18 (1157-60).
1489
Dennis A
et al.
hERG channel trafficking: novel targets in drug-induced long QT syndrome.
Biochem. Soc. Trans.,
2007
Nov
, 35 (1060-3).
1490
Scholz EP
et al.
Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656.
,
2007
Nov
, 17 (666-75).
1491
Varga A
et al.
Effect of experimental hypercholesterolaemia on K+ channel alpha-subunit mRNA levels in rabbit hearts.
Eur. J. Pharmacol.,
2007
May
7
, 562 (130-1).
1492
Dinges J
et al.
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
J. Med. Chem.,
2007
May
3
, 50 (2011-29).
1493
Gross MF
et al.
Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
Bioorg. Med. Chem. Lett.,
2007
May
15
, 17 (2849-53).
1494
Tseng GN
et al.
Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.
Biophys. J.,
2007
May
15
, 92 (3524-40).
1495
Iwamoto M
et al.
Transcription factor ERG and joint and articular cartilage formation during mouse limb and spine skeletogenesis.
Dev. Biol.,
2007
May
1
, 305 (40-51).
1496
Mikhail A
et al.
Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.
J. Cardiovasc. Pharmacol.,
2007
May
, 49 (269-74).
1497
Elmedyb P
et al.
Modulation of ERG channels by XE991.
Basic Clin. Pharmacol. Toxicol.,
2007
May
, 100 (316-22).
1498
Schwoerer AP
et al.
Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Anesthesiology,
2007
May
, 106 (967-76).
1500
Lehtonen A
et al.
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Heart Rhythm,
2007
May
, 4 (603-7).
1501
Eap CB
et al.
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.
Clin. Pharmacol. Ther.,
2007
May
, 81 (719-28).
1502
Phartiyal P
et al.
Heteromeric assembly of human ether-à-go-go-related gene (hERG) 1a/1b channels occurs cotranslationally via N-terminal interactions.
J. Biol. Chem.,
2007
Mar
30
, 282 (9874-82).
1503
Lowe J
et al.
A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening.
Bioorg. Med. Chem. Lett.,
2007
Mar
15
, 17 (1675-8).
1504
Waring MJ
et al.
A quantitative assessment of hERG liability as a function of lipophilicity.
Bioorg. Med. Chem. Lett.,
2007
Mar
15
, 17 (1759-64).
1505
Mühlbauer E
et al.
Circadian changes of ether-a-go-go-related-gene (Erg) potassium channel transcripts in the rat pancreas and beta-cell.
Cell. Mol. Life Sci.,
2007
Mar
, 64 (768-80).
1506
Witchel HJ
The hERG potassium channel as a therapeutic target.
Expert Opin. Ther. Targets,
2007
Mar
, 11 (321-36).
1507
Siebrands CC
et al.
Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Anesthesiology,
2007
Mar
, 106 (523-31).
1508
Ohno S
et al.
N- and C-terminal KCNE1 mutations cause distinct phenotypes of long QT syndrome.
,
2007
Mar
, 4 (332-40).
1509
Ly JQ
et al.
Assessing hERG channel inhibition using PatchXpress.
Clin. Lab. Med.,
2007
Mar
, 27 (201-8).
1510
Singleton DH
et al.
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
J. Med. Chem.,
2007
Jun
28
, 50 (2931-41).
1511
Hill AP
et al.
Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1.
Biophys. J.,
2007
Jun
1
, 92 (3915-29).
1512
Cockerill SL
et al.
Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits.
J. Physiol. (Lond.),
2007
Jun
1
, 581 (479-93).
1513
Li H
et al.
Expression and functional role of HERG1, K+ channels in leukemic cells and leukemic stem cells.
J. Huazhong Univ. Sci. Technol. Med. Sci.,
2007
Jun
, 27 (257-60).
1514
Koo SH
et al.
Mutation screening in KCNQ1, HERG, KCNE1, KCNE2 and SCN5A genes in a long QT syndrome family.
Ann. Acad. Med. Singap.,
2007
Jun
, 36 (394-8).
1515
Guo J
et al.
Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes.
J. Pharmacol. Exp. Ther.,
2007
Jun
, 321 (911-20).
1516
Hansen RS
et al.
Pharmacological activation of rapid delayed rectifier potassium current suppresses bradycardia-induced triggered activity in the isolated guinea pig heart.
J. Pharmacol. Exp. Ther.,
2007
Jun
, 321 (996-1002).
1517
Kiehne N
et al.
Mutations in the SCN5A gene: evidence for a link between long QT syndrome and sudden death?
Forensic Sci Int Genet,
2007
Jun
, 1 (170-4).
1518
Gong Q
et al.
Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome.
Circulation,
2007
Jul
3
, 116 (17-24).
1519
Arnaout R
et al.
Zebrafish model for human long QT syndrome.
Proc. Natl. Acad. Sci. U.S.A.,
2007
Jul
3
, 104 (11316-21).
1520
Yabuuchi F
et al.
Reduction of hERG potassium currents by hyperosmolar solutions.
Eur. J. Pharmacol.,
2007
Jul
2
, 566 (222-5).
1521
Guan FY
et al.
[HERG K+ channel, the target of anti-arrhythmias drugs]
Yao Xue Xue Bao,
2007
Jul
, 42 (687-91).
1522
Beery TA
et al.
Neonatal long QT syndrome due to a de novo dominant negative hERG mutation.
Am. J. Crit. Care,
2007
Jul
, 16 (416, 412-5).
1523
Duan JJ
et al.
Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain.
Acta Pharmacol. Sin.,
2007
Jul
, 28 (959-67).
1524
Ocorr K
et al.
Genetic control of heart function and aging in Drosophila.
Trends Cardiovasc. Med.,
2007
Jul
, 17 (177-82).
1525
Diller DJ
et al.
Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation.
J. Comput. Aided Mol. Des.,
2007
Jul
, 21 (379-93).
1526
Saenen JB
et al.
A single hERG mutation underlying a spectrum of acquired and congenital long QT syndrome phenotypes.
J. Mol. Cell. Cardiol.,
2007
Jul
, 43 (63-72).
1527
Drake E
et al.
Brief review: anesthetic implications of long QT syndrome in pregnancy.
,
2007
Jul
, 54 (561-72).
1528
Monassier L
et al.
sigma(2)-receptor ligand-mediated inhibition of inwardly rectifying K(+) channels in the heart.
J. Pharmacol. Exp. Ther.,
2007
Jul
, 322 (341-50).
1529
Lin H
et al.
Overexpression HERG K(+) channel gene mediates cell-growth signals on activation of oncoproteins SP1 and NF-kappaB and inactivation of tumor suppressor Nkx3.1.
J. Cell. Physiol.,
2007
Jul
, 212 (137-47).
1530
Sauer AJ
et al.
Long QT syndrome in adults.
J. Am. Coll. Cardiol.,
2007
Jan
23
, 49 (329-37).
1531
Arnestad M
et al.
Prevalence of long-QT syndrome gene variants in sudden infant death syndrome.
Circulation,
2007
Jan
23
, 115 (361-7).
1532
Tester DJ
et al.
Postmortem long QT syndrome genetic testing for sudden unexplained death in the young.
J. Am. Coll. Cardiol.,
2007
Jan
16
, 49 (240-6).
1533
Chapman H
et al.
The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph.
Eur. J. Pharmacol.,
2007
Jan
12
, 554 (98-105).
1534
Miller TE
et al.
Whole blood RNA offers a rapid, comprehensive approach to genetic diagnosis of cardiovascular diseases.
Genet. Med.,
2007
Jan
, 9 (23-33).
1535
Andresen JM
et al.
Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds.
J. Med. Genet.,
2007
Jan
, 44 (44-50).
1536
Kutteh R
et al.
Molecular dynamics and continuum electrostatics studies of inactivation in the HERG potassium channel.
,
2007
Feb
8
, 111 (1090-8).
1537
Nakajima T
et al.
HERG is protected from pharmacological block by alpha-1,2-glucosyltransferase function.
J. Biol. Chem.,
2007
Feb
23
, 282 (5506-13).
1538
Liverton NJ
et al.
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
J. Med. Chem.,
2007
Feb
22
, 50 (807-19).
1539
Iyengar RR
et al.
An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.
Bioorg. Med. Chem. Lett.,
2007
Feb
15
, 17 (874-8).
1540
Souers AJ
et al.
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.
Bioorg. Med. Chem. Lett.,
2007
Feb
15
, 17 (884-9).
1541
Lengyel C
et al.
Diabetes mellitus attenuates the repolarization reserve in mammalian heart.
Cardiovasc. Res.,
2007
Feb
1
, 73 (512-20).
1542
Meyers KM
et al.
Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists--Increasing selectivity over hERG.
Bioorg. Med. Chem. Lett.,
2007
Feb
1
, 17 (814-8).
1543
Meyers KM
et al.
Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG.
Bioorg. Med. Chem. Lett.,
2007
Feb
1
, 17 (819-22).
1544
Chevalier P
et al.
Torsades de pointes complicating atrioventricular block: evidence for a genetic predisposition.
,
2007
Feb
, 4 (170-4).
1545
Yi H
et al.
Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
J. Proteome Res.,
2007
Feb
, 6 (611-20).
1546
Wang L
et al.
Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
J. Pharmacol. Exp. Ther.,
2007
Feb
, 320 (525-34).
1547
Akyol M
et al.
The common non-synonymous variant G38S of the KCNE1-(minK)-gene is not associated to QT interval in Central European Caucasians: results from the KORA study.
Eur. Heart J.,
2007
Feb
, 28 (305-9).
1548
Siebrands CC
et al.
Inhibition of HERG channels by the local anaesthetic articaine.
,
2007
Feb
, 24 (148-53).
1549
Leong MK
A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
Chem. Res. Toxicol.,
2007
Feb
, 20 (217-26).
1550
Wanke E
et al.
Toxins interacting with ether-à-go-go-related gene voltage-dependent potassium channels.
Toxicon,
2007
Feb
, 49 (239-48).
1551
Arnestad M
et al.
A mitochondrial DNA polymorphism associated with cardiac arrhythmia investigated in sudden infant death syndrome.
Acta Paediatr.,
2007
Feb
, 96 (206-10).
1552
Zhang Y
et al.
[Effects of matrine, oxymatrine and resveratrol on HERG channel expression]
Yao Xue Xue Bao,
2007
Feb
, 42 (139-44).
1553
Li Y
et al.
[Functional expression of congenital long QT syndrome related HERG mutation A561V in vitro]
,
2007
Feb
, 35 (143-6).
1556
Tang Q
et al.
The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells.
Biochem. Pharmacol.,
2007
Dec
3
, 74 (1596-607).
1557
Lu HR
et al.
In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Eur. J. Pharmacol.,
2007
Dec
22
, 577 (222-32).
1558
Kelemen K
et al.
Green tea flavonoid epigallocatechin-3-gallate (EGCG) inhibits cardiac hERG potassium channels.
Biochem. Biophys. Res. Commun.,
2007
Dec
21
, 364 (429-35).
1559
Couderc JP
et al.
Impaired T-amplitude adaptation to heart rate characterizes I(Kr) inhibition in the congenital and acquired forms of the long QT syndrome.
J. Cardiovasc. Electrophysiol.,
2007
Dec
, 18 (1299-305).
1560
Scholz EP
et al.
Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.
Naunyn Schmiedebergs Arch. Pharmacol.,
2007
Dec
, 376 (275-84).
1561
Gongadze N
et al.
Prolong QT interval and "torsades de pointes" associated with different group of drugs.
Georgian Med News,
2007
Dec
, (45-9).
1562
Perry M
et al.
Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.
Proc. Natl. Acad. Sci. U.S.A.,
2007
Aug
21
, 104 (13827-32).
1563
Pillozzi S
et al.
VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome.
Blood,
2007
Aug
15
, 110 (1238-50).
1564
Walker VE
et al.
Co-chaperone FKBP38 promotes HERG trafficking.
J. Biol. Chem.,
2007
Aug
10
, 282 (23509-16).
1565
Stansfeld PJ
et al.
Drug block of the hERG potassium channel: insight from modeling.
Proteins,
2007
Aug
1
, 68 (568-80).
1566
Duncan RS
et al.
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.
Biochem. Pharmacol.,
2007
Aug
1
, 74 (425-37).
1567
Stork D
et al.
State dependent dissociation of HERG channel inhibitors.
Br. J. Pharmacol.,
2007
Aug
, 151 (1368-76).
1568
Kimura K
et al.
Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
,
2007
Aug
, 32 (217-30).
1569
Hu D
et al.
Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction.
,
2007
Aug
, 4 (1072-80).
1570
Elmedyb P
et al.
Activation of ERG2 potassium channels by the diphenylurea NS1643.
Neuropharmacology,
2007
Aug
, 53 (283-94).
1571
Danielsson C
et al.
Polytherapy with hERG-blocking antiepileptic drugs: increased risk for embryonic cardiac arrhythmia and teratogenicity.
Birth Defects Res. Part A Clin. Mol. Teratol.,
2007
Aug
, 79 (595-603).
1572
Zhang M
et al.
APETx1 from sea anemone Anthopleura elegantissima is a gating modifier peptide toxin of the human ether-a-go-go- related potassium channel.
Mol. Pharmacol.,
2007
Aug
, 72 (259-68).
1573
Xiao J
et al.
MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts.
J. Biol. Chem.,
2007
Apr
27
, 282 (12363-7).
1574
Du L
et al.
A novel structure-based virtual screening model for the hERG channel blockers.
Biochem. Biophys. Res. Commun.,
2007
Apr
20
, 355 (889-94).
1575
Judd AS
et al.
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.
Bioorg. Med. Chem. Lett.,
2007
Apr
15
, 17 (2365-71).
1576
Jo SH
et al.
Maprotiline block of the human ether-a-go-go-related gene (HERG) K+ channel.
Arch. Pharm. Res.,
2007
Apr
, 30 (453-60).
1577
Gavaghan CL
et al.
Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data.
J. Comput. Aided Mol. Des.,
2007
Apr
, 21 (189-206).
1578
Watanabe E
et al.
Upregulation of KCNE1 induces QT interval prolongation in patients with chronic heart failure.
Circ. J.,
2007
Apr
, 71 (471-8).
1579
Kim CS
et al.
Inhibitory effects of coronary vasodilator papaverine on heterologously-expressed HERG currents in Xenopus oocytes.
Acta Pharmacol. Sin.,
2007
Apr
, 28 (503-10).
1580
Um SY
et al.
Differential association between HERG and KCNE1 or KCNE2.
PLoS ONE,
2007
, 2 (e933).
1581
Bai Y
et al.
Sphingolipid metabolite ceramide causes metabolic perturbation contributing to HERG K+ channel dysfunction.
Cell. Physiol. Biochem.,
2007
, 20 (429-40).
1582
Bai Y
et al.
Phospholipid lysophosphatidylcholine as a metabolic trigger and HERG as an ionic pathway for extracellular K accumulation and "short QT syndrome" in acute myocardial ischemia.
Cell. Physiol. Biochem.,
2007
, 20 (417-28).
1583
Lin C
et al.
The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.
Cardiology,
2007
, 108 (18-27).
1584
Bankston JR
et al.
A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response.
PLoS ONE,
2007
, 2 (e1258).
1585
Thai KM
et al.
Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
Curr. Med. Chem.,
2007
, 14 (3003-26).
1586
Chen MX
et al.
Improved functional expression of recombinant human ether-a-go-go (hERG) K+ channels by cultivation at reduced temperature.
BMC Biotechnol.,
2007
, 7 (93).
1587
Qiu Y
et al.
JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
Int. J. Impot. Res.,
2006 Sep-Oct
, 18 (477-83).
1588
Bridgland-Taylor MH
et al.
Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
,
2006 Sep-Oct
, 54 (189-99).
1589
Hanson LA
et al.
ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
,
2006 Sep-Oct
, 54 (116-29).
1590
Du X
et al.
Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells.
,
2006 Sep-Oct
, 54 (164-72).
1591
Ekins S
et al.
Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms.
Xenobiotica,
2006 Oct-Nov
, 36 (877-901).
1592
Cheng HC
et al.
Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval.
,
2006 Nov-Dec
, 54 (278-87).
1593
Yoshida K
et al.
Quantitative structure-activity relationship studies on inhibition of HERG potassium channels.
,
2006 May-Jun
, 46 (1371-8).
1594
Hoffmann P
et al.
Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
,
2006 Mar-Apr
, 53 (87-105).
1595
Murphy SM
et al.
Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
,
2006 Jul-Aug
, 54 (42-55).
1596
1597
Song M
et al.
Development and evaluation of an in silico model for hERG binding.
,
2006 Jan-Feb
, 46 (392-400).
1598
Bottino D
et al.
Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Prog. Biophys. Mol. Biol.,
2006 Jan-Apr
, 90 (414-43).
1599
Gómez-Varela D
et al.
Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide.
FEBS Lett.,
2006
Sep
18
, 580 (5059-66).
1600
Price DA
et al.
Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
Bioorg. Med. Chem. Lett.,
2006
Sep
1
, 16 (4633-7).
1601
Millat G
et al.
Spectrum of pathogenic mutations and associated polymorphisms in a cohort of 44 unrelated patients with long QT syndrome.
Clin. Genet.,
2006
Sep
, 70 (214-27).
1602
Siebrands CC
et al.
Long QT 1 mutation KCNQ1A344V increases local anesthetic sensitivity of the slowly activating delayed rectifier potassium current.
Anesthesiology,
2006
Sep
, 105 (511-20).
1603
Zhang Y
et al.
Restoring depressed HERG K+ channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits.
Am. J. Physiol. Heart Circ. Physiol.,
2006
Sep
, 291 (H1446-55).
1604
McPate MJ
et al.
Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.
J. Mol. Cell. Cardiol.,
2006
Sep
, 41 (563-6).
1605
Hurley KM
et al.
M-like K+ currents in type I hair cells and calyx afferent endings of the developing rat utricle.
J. Neurosci.,
2006
Oct
4
, 26 (10253-69).
1606
Heradien MJ
et al.
Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation?
J. Am. Coll. Cardiol.,
2006
Oct
3
, 48 (1410-5).
1607
Lau JF
et al.
Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.
Bioorg. Med. Chem. Lett.,
2006
Oct
15
, 16 (5303-8).
1608
Choe CU
et al.
C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon.
Hum. Mol. Genet.,
2006
Oct
1
, 15 (2888-902).
1609
Oliveira JS
et al.
BcIV, a new paralyzing peptide obtained from the venom of the sea anemone Bunodosoma caissarum. A comparison with the Na+ channel toxin BcIII.
Biochim. Biophys. Acta,
2006
Oct
, 1764 (1592-600).
1610
Ohmoto M
et al.
Taste receptor cells express voltage-dependent potassium channels in a cell age-specific manner.
Chem. Senses,
2006
Oct
, 31 (739-46).
1611
Hansen RS
et al.
Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea].
Mol. Pharmacol.,
2006
Oct
, 70 (1319-29).
1612
Betge S
et al.
[Long QT syndrome causing grand mal epilepsy: case report, pedigree, therapeutic options, and review of the literature]
,
2006
Oct
, 77 (1210-7).
1614
Ohya S
[Molecular pharmacological studies on potassium channels and their regulatory molecules]
Yakugaku Zasshi,
2006
Oct
, 126 (945-53).
1615
Lu LX
et al.
Short QT syndrome: a case report and review of literature.
,
2006
Oct
, 71 (115-21).
1616
Zünkler BJ
Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
Pharmacol. Ther.,
2006
Oct
, 112 (12-37).
1617
Lynch JK
et al.
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.
J. Med. Chem.,
2006
Nov
2
, 49 (6569-84).
1618
Aronov AM
Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
J. Med. Chem.,
2006
Nov
16
, 49 (6917-21).
1619
Wu S
et al.
Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers.
Bioorg. Med. Chem. Lett.,
2006
Nov
15
, 16 (5859-63).
1620
Fluxe A
et al.
Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers.
Bioorg. Med. Chem. Lett.,
2006
Nov
15
, 16 (5855-8).
1621
Tseng GN
Linkage between 'disruption of inactivation' and 'reduction of K+ selectivity' among hERG mutants in the S5-P linker region.
J. Physiol. (Lond.),
2006
Nov
15
, 577 (459-60; author reply 461-2).
1622
Zhu BY
et al.
Inhibitory effect of carboxylic acid group on hERG binding.
Bioorg. Med. Chem. Lett.,
2006
Nov
1
, 16 (5507-12).
1623
Zeng H
et al.
Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
J. Pharmacol. Exp. Ther.,
2006
Nov
, 319 (957-62).
1624
Tutor AS
et al.
Association of 14-3-3 proteins to beta1-adrenergic receptors modulates Kv11.1 K+ channel activity in recombinant systems.
Mol. Biol. Cell,
2006
Nov
, 17 (4666-74).
1625
Limberis JT
et al.
Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Clin. Exp. Pharmacol. Physiol.,
2006
Nov
, 33 (1059-65).
1626
Lastraioli E
et al.
hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus.
J. Cell. Physiol.,
2006
Nov
, 209 (398-404).
1627
Sasano T
et al.
Molecular ablation of ventricular tachycardia after myocardial infarction.
Nat. Med.,
2006
Nov
, 12 (1256-8).
1628
Hancox JC
et al.
Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.
Br. J. Pharmacol.,
2006
Nov
, 149 (457-9).
1629
Rajamani S
et al.
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Br. J. Pharmacol.,
2006
Nov
, 149 (481-9).
1630
Ferrer T
et al.
The S4-S5 linker directly couples voltage sensor movement to the activation gate in the human ether-a'-go-go-related gene (hERG) K+ channel.
J. Biol. Chem.,
2006
May
5
, 281 (12858-64).
1631
Choe H
et al.
A novel hypothesis for the binding mode of HERG channel blockers.
Biochem. Biophys. Res. Commun.,
2006
May
26
, 344 (72-8).
1632
Diness TG
et al.
Frequency-dependent modulation of KCNQ1 and HERG1 potassium channels.
Biochem. Biophys. Res. Commun.,
2006
May
19
, 343 (1224-33).
1633
Farid R
et al.
New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.
Bioorg. Med. Chem.,
2006
May
1
, 14 (3160-73).
1634
Coi A
et al.
Prediction of hERG potassium channel affinity by the CODESSA approach.
Bioorg. Med. Chem.,
2006
May
1
, 14 (3153-9).
1635
Xu H
et al.
Glycosylation of the osmoresponsive transient receptor potential channel TRPV4 on Asn-651 influences membrane trafficking.
Am. J. Physiol. Renal Physiol.,
2006
May
, 290 (F1103-9).
1636
Guo J
et al.
Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
J. Pharmacol. Exp. Ther.,
2006
May
, 317 (865-74).
1637
Kamiya K
et al.
Molecular determinants of HERG channel block.
Mol. Pharmacol.,
2006
May
, 69 (1709-16).
1638
Restano-Cassulini R
et al.
Species diversity and peptide toxins blocking selectivity of ether-a-go-go-related gene subfamily K+ channels in the central nervous system.
Mol. Pharmacol.,
2006
May
, 69 (1673-83).
1639
Fedida D
et al.
The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers.
J. Cardiovasc. Electrophysiol.,
2006
May
, 17 Suppl 1 (S71-S78).
1640
Sun H
et al.
Chronic inhibition of cardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking.
J. Biol. Chem.,
2006
Mar
3
, 281 (5877-84).
1641
Storey NM
et al.
Rapid signaling at the plasma membrane by a nuclear receptor for thyroid hormone.
Proc. Natl. Acad. Sci. U.S.A.,
2006
Mar
28
, 103 (5197-201).
1642
Gentile S
et al.
Rac GTPase signaling through the PP5 protein phosphatase.
Proc. Natl. Acad. Sci. U.S.A.,
2006
Mar
28
, 103 (5202-6).
1643
Sanguinetti MC
et al.
hERG potassium channels and cardiac arrhythmia.
Nature,
2006
Mar
23
, 440 (463-9).
1644
Vyas H
et al.
Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response.
Circulation,
2006
Mar
21
, 113 (1385-92).
1645
Raab CE
et al.
Synthesis of the first sulfur-35-labeled hERG radioligand.
Bioorg. Med. Chem. Lett.,
2006
Mar
15
, 16 (1692-5).
1646
Duncan RS
et al.
Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652.
Biochem. Biophys. Res. Commun.,
2006
Mar
10
, 341 (500-6).
1647
Ok D
et al.
Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers.
Bioorg. Med. Chem. Lett.,
2006
Mar
1
, 16 (1358-61).
1648
Kawakami K
et al.
Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.
Br. J. Pharmacol.,
2006
Mar
, 147 (642-52).
1649
Koo SH
et al.
Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore.
,
2006
Mar
, 61 (301-8).
1650
de Castro MP
et al.
Protein distribution of Kcnq1, Kcnh2, and Kcne3 potassium channel subunits during mouse embryonic development.
,
2006
Mar
, 288 (304-15).
1651
Modell SM
et al.
The long QT syndrome family of cardiac ion channelopathies: a HuGE review.
Genet. Med.,
2006
Mar
, 8 (143-55).
1652
Katchman AN
et al.
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
J. Pharmacol. Exp. Ther.,
2006
Mar
, 316 (1098-106).
1653
Zhang S
Isolation and characterization of I(Kr) in cardiac myocytes by Cs+ permeation.
Am. J. Physiol. Heart Circ. Physiol.,
2006
Mar
, 290 (H1038-49).
1654
Rajamani S
et al.
Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr).
Am. J. Physiol. Heart Circ. Physiol.,
2006
Mar
, 290 (H1278-88).
1655
Sun H
An accurate and interpretable bayesian classification model for prediction of HERG liability.
,
2006
Mar
, 1 (315-22).
1656
Sarzani R
et al.
The functional HERG variant 897T is associated with Conn's adenoma.
J. Hypertens.,
2006
Mar
, 24 (479-87).
1657
Clarke CE
et al.
Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels.
J. Physiol. (Lond.),
2006
Jun
1
, 573 (291-304).
1658
Crumb WJ
et al.
Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.
Pharm. Res.,
2006
Jun
, 23 (1133-43).
1659
Kiesecker C
et al.
Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels.
Naunyn Schmiedebergs Arch. Pharmacol.,
2006
Jun
, 373 (212-20).
1660
Locke GR
et al.
Gastrointestinal symptoms in families of patients with an SCN5A-encoded cardiac channelopathy: evidence of an intestinal channelopathy.
Am. J. Gastroenterol.,
2006
Jun
, 101 (1299-304).
1661
Liu WL
et al.
[Novel mutations of potassium channel KCNQ1 S145L and KCNH2 Y475C genes in Chinese pedigrees of long QT syndrome]
Zhonghua Nei Ke Za Zhi,
2006
Jun
, 45 (463-6).
1662
She HR
et al.
[Electrophysiological characterization of long QT syndrome associated mutations V630A and N633S]
,
2006
Jun
, 34 (523-7).
1663
Dubus E
et al.
In silico classification of HERG channel blockers: a knowledge-based strategy.
,
2006
Jun
, 1 (622-30).
1664
Lee SY
et al.
Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine.
Br. J. Pharmacol.,
2006
Jun
, 148 (499-509).
1665
Ro S
et al.
Template switching within exons 3 and 4 of KV11.1 (HERG) gives rise to a 5' truncated cDNA.
Biochem. Biophys. Res. Commun.,
2006
Jul
14
, 345 (1342-9).
1666
Struijk JJ
et al.
Classification of the long-QT syndrome based on discriminant analysis of T-wave morphology.
,
2006
Jul
, 44 (543-9).
1667
Gang H
et al.
Na+ permeation and block of hERG potassium channels.
J. Gen. Physiol.,
2006
Jul
, 128 (55-71).
1668
Patel ND
et al.
The heterogeneous spectrum of the long QT syndrome.
Eur. J. Intern. Med.,
2006
Jul
, 17 (235-40).
1669
Wang X
et al.
Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway.
FASEB J.,
2006
Jul
, 20 (1531-3).
1670
Vandenberg JI
et al.
Temperature dependence of human ether-a-go-go-related gene K+ currents.
Am. J. Physiol., Cell Physiol.,
2006
Jul
, 291 (C165-75).
1671
Wisialowski T
et al.
Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability.
J. Pharmacol. Exp. Ther.,
2006
Jul
, 318 (352-9).
1672
Tester DJ
et al.
Allelic dropout in long QT syndrome genetic testing: a possible mechanism underlying false-negative results.
Heart Rhythm,
2006
Jul
, 3 (815-21).
1673
Tester DJ
et al.
Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing.
Heart Rhythm,
2006
Jul
, 3 (800-5).
1674
Anderson CL
et al.
Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
Circulation,
2006
Jan
24
, 113 (365-73).
1675
Abdel-Mottaleb Y
et al.
A novel toxin from the venom of the scorpion Tityus trivittatus, is the first member of a new alpha-KTX subfamily.
FEBS Lett.,
2006
Jan
23
, 580 (592-6).
1676
Su Z
et al.
Block of hERG channel by ziprasidone: biophysical properties and molecular determinants.
Biochem. Pharmacol.,
2006
Jan
12
, 71 (278-86).
1677
Yamada M
et al.
The effects of sevoflurane and propofol on QT interval and heterologously expressed human ether-a-go-go related gene currents in Xenopus oocytes.
Anesth. Analg.,
2006
Jan
, 102 (98-103).
1678
Rodriguez-Menchaca A
et al.
Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels.
J. Cardiovasc. Pharmacol.,
2006
Jan
, 47 (21-9).
1679
Rudy Y
Modelling and imaging cardiac repolarization abnormalities.
J. Intern. Med.,
2006
Jan
, 259 (91-106).
1680
Ridley JM
et al.
Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
J. Mol. Cell. Cardiol.,
2006
Jan
, 40 (107-18).
1681
Furuzono S
et al.
Inherent pacemaker function of duodenal GIST.
Eur. J. Cancer,
2006
Jan
, 42 (243-8).
1682
Linna EH
et al.
Functional significance of KCNH2 (HERG) K897T polymorphism for cardiac repolarization assessed by analysis of T-wave morphology.
Ann Noninvasive Electrocardiol,
2006
Jan
, 11 (57-62).
1683
Hansen RS
et al.
Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643).
Mol. Pharmacol.,
2006
Jan
, 69 (266-77).
1684
Koopmann TT
et al.
Long QT syndrome caused by a large duplication in the KCNH2 (HERG) gene undetectable by current polymerase chain reaction-based exon-scanning methodologies.
Heart Rhythm,
2006
Jan
, 3 (52-5).
1685
Crumb W
et al.
Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs.
Eur. J. Pharmacol.,
2006
Feb
27
, 532 (270-8).
1686
Harvey AJ
et al.
A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.
J. Med. Chem.,
2006
Feb
23
, 49 (1433-41).
1687
Gong Q
et al.
Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome.
J. Biol. Chem.,
2006
Feb
17
, 281 (4069-74).
1688
Möller C
et al.
Effects of estradiol on cardiac ion channel currents.
Eur. J. Pharmacol.,
2006
Feb
17
, 532 (44-9).
1689
Ferrer-Villada T
et al.
Inhibition of cardiac HERG potassium channels by antidepressant maprotiline.
Eur. J. Pharmacol.,
2006
Feb
15
, 531 (1-8).
1690
Kirchberger NM
et al.
Effects of TRH on heteromeric rat erg1a/1b K+ channels are dominated by the rerg1b subunit.
J. Physiol. (Lond.),
2006
Feb
15
, 571 (27-42).
1691
Slack M
et al.
Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay.
,
2006
Feb
, 11 (57-64).
1692
Ding M
et al.
Application of cryopreserved cells to HERG screening using a non-radioactive Rb+ efflux assay.
,
2006
Feb
, 4 (83-8).
1693
Perry M
et al.
Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.
Mol. Pharmacol.,
2006
Feb
, 69 (509-19).
1694
Novotný T
et al.
[Mutational analysis of LQT genes in individuals with drug induced QT interval prolongation]
,
2006
Feb
, 52 (116-8).
1695
Trepakova ES
et al.
Flunarizine is a highly potent inhibitor of cardiac hERG potassium current.
J. Cardiovasc. Pharmacol.,
2006
Feb
, 47 (211-20).
1696
Chaudhary KW
et al.
Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.
,
2006
Feb
, 4 (73-82).
1697
Casis O
et al.
Mechanism of action of a novel human ether-a-go-go-related gene channel activator.
Mol. Pharmacol.,
2006
Feb
, 69 (658-65).
1698
Tian M
et al.
Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents.
Br. J. Pharmacol.,
2006
Feb
, 147 (289-97).
1699
De Bruin ML
et al.
Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data.
,
2006
Feb
, 15 (99-105).
1700
Rudy Y
et al.
Computational biology in the study of cardiac ion channels and cell electrophysiology.
Q. Rev. Biophys.,
2006
Feb
, 39 (57-116).
1701
Stansfeld PJ
et al.
Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.
Expert Opin Drug Metab Toxicol,
2006
Feb
, 2 (81-94).
1702
Cockerill SL
et al.
Direct block of human ether-a-go-go-related gene potassium channels by caffeine.
J. Pharmacol. Exp. Ther.,
2006
Feb
, 316 (860-8).
1703
Fossa AA
et al.
QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization.
J. Pharmacol. Exp. Ther.,
2006
Feb
, 316 (498-506).
1704
Milnes JT
et al.
hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656.
Biochem. Biophys. Res. Commun.,
2006
Dec
8
, 351 (273-80).
1705
Zünkler BJ
et al.
Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels.
Toxicology,
2006
Dec
7
, 228 (239-48).
1706
Lu HR
et al.
In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Eur. J. Pharmacol.,
2006
Dec
28
, 553 (229-39).
1707
Chen SZ
et al.
[Erythromycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs]
Zhonghua Yi Xue Za Zhi,
2006
Dec
19
, 86 (3353-7).
1708
Saenen JB
et al.
Modulation of HERG gating by a charge cluster in the N-terminal proximal domain.
Biophys. J.,
2006
Dec
15
, 91 (4381-91).
1709
Walker DP
et al.
Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists.
Bioorg. Med. Chem.,
2006
Dec
15
, 14 (8219-48).
1710
Li Y
et al.
[Construction of eukaryotic expression vector of congenital long QT syndrome related HERG gene A561V mutation and its expression in HEK293 cells]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi,
2006
Dec
, 23 (627-30).
1711
Waldhauser KM
et al.
Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives.
J. Pharmacol. Exp. Ther.,
2006
Dec
, 319 (1413-23).
1712
Lawrence CL
et al.
A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.
Br. J. Pharmacol.,
2006
Dec
, 149 (845-60).
1713
Shin WH
et al.
Electrophysiological effects of brompheniramine on cardiac ion channels and action potential.
Pharmacol. Res.,
2006
Dec
, 54 (414-20).
1714
Lamarca V
et al.
K+ channels involved in contractility of rabbit small intestine.
J. Physiol. Biochem.,
2006
Dec
, 62 (227-36).
1715
Couderc JP
et al.
Repolarization morphology in adult LQT2 carriers with borderline prolonged QTc interval.
Heart Rhythm,
2006
Dec
, 3 (1460-6).
1716
Jamieson C
et al.
Medicinal chemistry of hERG optimizations: Highlights and hang-ups.
J. Med. Chem.,
2006
Aug
24
, 49 (5029-46).
1717
Ekins S
et al.
Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
J. Med. Chem.,
2006
Aug
24
, 49 (5059-71).
1718
Kim MD
et al.
Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine.
Eur. J. Pharmacol.,
2006
Aug
21
, 544 (82-90).
1719
Scholz EP
et al.
In vitro modulation of HERG channels by organochlorine solvent trichlormethane as potential explanation for proarrhythmic effects of chloroform.
Toxicol. Lett.,
2006
Aug
20
, 165 (156-66).
1720
Roepke TK
et al.
The KCNE2 potassium channel ancillary subunit is essential for gastric acid secretion.
J. Biol. Chem.,
2006
Aug
18
, 281 (23740-7).
1721
Alberati D
et al.
Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with improved metabolic stability.
Bioorg. Med. Chem. Lett.,
2006
Aug
15
, 16 (4311-5).
1722
McBriar MD
et al.
Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 antagonists: impacting hERG liability via aryl modifications.
Bioorg. Med. Chem. Lett.,
2006
Aug
15
, 16 (4262-5).
1723
Gepp MM
et al.
Determination of hERG channel blockers using a decision tree.
Bioorg. Med. Chem.,
2006
Aug
1
, 14 (5325-32).
1724
Matsuda T
et al.
Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 channel.
J. Pharmacol. Sci.,
2006
Aug
, 101 (303-10).
1725
1726
Ridley JM
et al.
Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
FEBS Lett.,
2006
Apr
3
, 580 (1999-2005).
1727
Huscroft IT
et al.
1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.
Bioorg. Med. Chem. Lett.,
2006
Apr
1
, 16 (2008-12).
1728
Garbaccio RM
et al.
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.
Bioorg. Med. Chem. Lett.,
2006
Apr
1
, 16 (1780-3).
1729
Jo SH
et al.
Chemical modification of the human ether-a-go-go-related gene (HERG) K+ current by the amino-group reagent trinitrobenzene sulfonic acid.
Arch. Pharm. Res.,
2006
Apr
, 29 (310-7).
1730
Seierstad M
et al.
A QSAR model of HERG binding using a large, diverse, and internally consistent training set.
,
2006
Apr
, 67 (284-96).
1731
Itoh H
et al.
Arrhythmogenesis in the short-QT syndrome associated with combined HERG channel gating defects: a simulation study.
Circ. J.,
2006
Apr
, 70 (502-8).
1732
Kuryshev YA
et al.
Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents.
Mol. Pharmacol.,
2006
Apr
, 69 (1216-25).
1733
Alexandrou AJ
et al.
Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Br. J. Pharmacol.,
2006
Apr
, 147 (905-16).
1734
Sotkis HV
et al.
[Identification of E-4031-sensitive potassium current component in murine P19 embryonic carcinoma cell line differentiated in cardiomyocytes]
,
2006
, 52 (49-61).
1735
Lawson K
et al.
Modulation of potassium channels as a therapeutic approach.
Curr. Pharm. Des.,
2006
, 12 (459-70).
1736
Robertson GA
et al.
HERG trafficking and pharmacological rescue of LQTS-2 mutant channels.
Handb Exp Pharmacol,
2006
, (349-55).
1737
Bundis F
et al.
Involvement of Golgin-160 in cell surface transport of renal ROMK channel: co-expression of Golgin-160 increases ROMK currents.
Cell. Physiol. Biochem.,
2006
, 17 (1-12).
1738
Gintant GA
et al.
Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Toxicol Pathol,
2006
, 34 (81-90).
1739
Furihata Y
et al.
Cardiovascular effects of KUR-1246, a new tetrahydronaphthalen derivative beta2-adrenoceptor agonist and a selective uterine relaxant.
,
2006
, 56 (18-24).
1740
Aydar E
et al.
Expression and functional characterization of the human ether-à-go-go-related gene (HERG) K+ channel cardiac splice variant in Xenopus laevis oocytes.
J. Membr. Biol.,
2006
, 211 (115-26).
1741
Tatemichi S
et al.
Cardiovascular effects of the selective alphalA-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction.
,
2006
, 56 (682-7).
1742
Maier G
et al.
Upregulation of HERG channels by the serum and glucocorticoid inducible kinase isoform SGK3.
Cell. Physiol. Biochem.,
2006
, 18 (177-86).
1743
Thomas D
et al.
The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Curr. Pharm. Des.,
2006
, 12 (2271-83).
1744
Seop Kim D
et al.
Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxacin and balofloxacin.
,
2006
, 29 (303-12).
1745
Fodstad H
et al.
Molecular characterization of two founder mutations causing long QT syndrome and identification of compound heterozygous patients.
Ann. Med.,
2006
, 38 (294-304).
1746
Bencherif M
et al.
Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors.
J. Mol. Neurosci.,
2006
, 30 (17-8).
1747
Liang XJ
et al.
Different roles for K+ channels in cisplatin-resistant cell lines argue against a critical role for these channels in cisplatin resistance.
Anticancer Res.,
2005 Nov-Dec
, 25 (4113-22).
1748
Lin C
et al.
A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels.
,
2005 Jul-Aug
, 12 (328-36).
1749
Ducroq J
et al.
Additive effects of ziprasidone and D,L-sotalol on the action potential in rabbit Purkinje fibres and on the hERG potassium current.
,
2005 Jul-Aug
, 52 (115-22).
1750
Guo L
et al.
Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
,
2005 Jul-Aug
, 52 (123-35).
1751
Yao JA
et al.
Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature.
,
2005 Jul-Aug
, 52 (146-53).
1752
Wible BA
et al.
HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
,
2005 Jul-Aug
, 52 (136-45).
1753
Norinder U
In silico modelling of ADMET-a minireview of work from 2000 to 2004.
,
2005 Feb-Apr
, 16 (1-11).
1754
Anson BD
et al.
Blockade of HERG channels by HIV protease inhibitors.
Lancet,
2005 Feb 19-25
, 365 (682-6).
1755
Shim SH
et al.
Gene sequencing in neonates and infants with the long QT syndrome.
Genet. Test.,
2005
Winter
, 9 (281-4).
1756
Csanády M
et al.
[The long QT syndrome from the bedside to molecular genetic laboratory. The history of the first described Hungarian family]
,
2005
Sep
25
, 146 (2011-6).
1757
Nie L
et al.
Expression and functional phenotype of mouse ERG K+ channels in the inner ear: potential role in K+ regulation in the inner ear.
J. Neurosci.,
2005
Sep
21
, 25 (8671-9).
1758
Yao X
et al.
Propranolol inhibits the human ether-a-go-go-related gene potassium channels.
Eur. J. Pharmacol.,
2005
Sep
20
, 519 (208-11).
1759
Fernandez D
et al.
Molecular mapping of a site for Cd2+-induced modification of human ether-à-go-go-related gene (hERG) channel activation.
J. Physiol. (Lond.),
2005
Sep
15
, 567 (737-55).
1760
Lin J
et al.
Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels.
Mol. Pharmacol.,
2005
Sep
, 68 (855-65).
1761
Zhou J
et al.
Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
Mol. Pharmacol.,
2005
Sep
, 68 (876-84).
1762
Gómez R
et al.
Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels.
Br. J. Pharmacol.,
2005
Sep
, 146 (146-61).
1763
Masi A
et al.
hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines.
Br. J. Cancer,
2005
Oct
3
, 93 (781-92).
1764
Berge KE
et al.
[DNA-based diagnostics of long QT syndrome]
Tidsskr. Nor. Laegeforen.,
2005
Oct
20
, 125 (2783-6).
1765
Guasti L
et al.
Expression pattern of the ether-a-go-go-related (ERG) family proteins in the adult mouse central nervous system: evidence for coassembly of different subunits.
J. Comp. Neurol.,
2005
Oct
17
, 491 (157-74).
1766
Zhang M
et al.
Interactions between charged residues in the transmembrane segments of the voltage-sensing domain in the hERG channel.
J. Membr. Biol.,
2005
Oct
, 207 (169-81).
1767
Chapman H
et al.
Downregulation of the HERG (KCNH2) K(+) channel by ceramide: evidence for ubiquitin-mediated lysosomal degradation.
J. Cell. Sci.,
2005
Nov
15
, 118 (5325-34).
1768
Jiang M
et al.
Dynamic conformational changes of extracellular S5-P linkers in the hERG channel.
J. Physiol. (Lond.),
2005
Nov
15
, 569 (75-89).
1769
Gouas L
et al.
Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population.
Eur. J. Hum. Genet.,
2005
Nov
, 13 (1213-22).
1770
Chen X
et al.
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Br. J. Pharmacol.,
2005
Nov
, 146 (792-9).
1771
Guizy M
et al.
{Omega}-3 and {omega}-6 polyunsaturated fatty acids block HERG channels.
Am. J. Physiol., Cell Physiol.,
2005
Nov
, 289 (C1251-60).
1772
Dorr P
et al.
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Antimicrob. Agents Chemother.,
2005
Nov
, 49 (4721-32).
1773
Grunnet M
et al.
Functional assessment of compound mutations in the KCNQ1 and KCNH2 genes associated with long QT syndrome.
,
2005
Nov
, 2 (1238-49).
1774
Fitzgerald PT
et al.
Drug-induced torsades de pointes: the evolving role of pharmacogenetics.
,
2005
Nov
, 2 (S30-7).
1775
Ando H
et al.
Coupled K+-water flux through the HERG potassium channel measured by an osmotic pulse method.
J. Gen. Physiol.,
2005
Nov
, 126 (529-38).
1776
Osterberg F
et al.
Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods.
FEBS Lett.,
2005
May
23
, 579 (2939-44).
1777
Höfner G
et al.
NMDA-NR2B subtype selectivity of stereoisomeric 2-(1,2,3,4-tetrahydro-1-isoquinolyl)ethanol derivatives.
Bioorg. Med. Chem. Lett.,
2005
May
2
, 15 (2231-4).
1778
Gong Q
et al.
Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway.
J. Biol. Chem.,
2005
May
13
, 280 (19419-25).
1779
Tester DJ
et al.
Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing.
,
2005
May
, 2 (507-17).
1780
Kim CS
et al.
Modulating effect of ginseng saponins on heterologously expressed HERG currents in Xenopus oocytes.
Acta Pharmacol. Sin.,
2005
May
, 26 (551-8).
1781
Haugan K
et al.
The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress.
J. Cardiovasc. Electrophysiol.,
2005
May
, 16 (537-45).
1782
Choi SY
et al.
Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
J. Pharmacol. Exp. Ther.,
2005
May
, 313 (888-95).
1783
Cordes JS
et al.
Pentamidine reduces hERG expression to prolong the QT interval.
Br. J. Pharmacol.,
2005
May
, 145 (15-23).
1784
Eckhardt LL
et al.
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
Br. J. Pharmacol.,
2005
May
, 145 (3-4).
1785
Tarantino P
et al.
Effect of trazodone on hERG channel current and QT-interval.
Eur. J. Pharmacol.,
2005
Mar
7
, 510 (75-85).
1786
Zhang HC
et al.
Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
J. Med. Chem.,
2005
Mar
24
, 48 (1725-8).
1787
Rajamani R
et al.
A two-state homology model of the hERG K+ channel: application to ligand binding.
Bioorg. Med. Chem. Lett.,
2005
Mar
15
, 15 (1737-41).
1788
Hofer AM
Another dimension to calcium signaling: a look at extracellular calcium.
J. Cell. Sci.,
2005
Mar
1
, 118 (855-62).
1789
Rossenbacker T
et al.
Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome.
Circulation,
2005
Mar
1
, 111 (961-8).
1790
Danielsson BR
et al.
Phenytoin teratogenicity: hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism.
Birth Defects Res. Part A Clin. Mol. Teratol.,
2005
Mar
, 73 (146-53).
1791
Recanatini M
et al.
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Med Res Rev,
2005
Mar
, 25 (133-66).
1792
Kikuchi K
et al.
Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Br. J. Pharmacol.,
2005
Mar
, 144 (840-8).
1793
Lin C
et al.
The influence of extracellular acidosis on the effect of IKr blockers.
J. Cardiovasc. Pharmacol. Ther.,
2005
Mar
, 10 (67-76).
1794
Pandini A
et al.
Conservation and specialization in PAS domain dynamics.
Protein Eng. Des. Sel.,
2005
Mar
, 18 (127-37).
1795
Persson F
et al.
Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009.
J. Cardiovasc. Electrophysiol.,
2005
Mar
, 16 (329-41).
1796
Sanguinetti MC
et al.
Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Trends Pharmacol. Sci.,
2005
Mar
, 26 (119-24).
1797
Shao XD
et al.
The potent inhibitory effects of cisapride, a specific blocker for human ether-a-go-go-related gene (HERG) channel, on gastric cancer cells.
Cancer Biol. Ther.,
2005
Mar
, 4 (295-301).
1798
Dubin AE
et al.
Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp.
,
2005
Mar
, 10 (168-81).
1799
Kang J
et al.
Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Mol. Pharmacol.,
2005
Mar
, 67 (827-36).
1800
De Bruin ML
et al.
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
Eur. Heart J.,
2005
Mar
, 26 (590-7).
1801
Seebohm G
Activators of cation channels: potential in treatment of channelopathies.
Mol. Pharmacol.,
2005
Mar
, 67 (585-8).
1802
de Gortari P
et al.
Acute administration of alcohol modulates pyroglutamyl amino peptidase II activity and mRNA levels in rat limbic regions.
Neurochem. Int.,
2005
Mar
, 46 (347-56).
1803
Tobita M
et al.
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Bioorg. Med. Chem. Lett.,
2005
Jun
2
, 15 (2886-90).
1804
Du R
et al.
[Relationship between congenital long QT syndrome and Brugada syndrome gene mutation]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao,
2005
Jun
, 27 (289-94).
1805
Scholz EP
et al.
Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation.
Naunyn Schmiedebergs Arch. Pharmacol.,
2005
Jun
, 371 (516-25).
1806
Cherubini A
et al.
Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integrins and modulate adhesion-dependent signaling.
Mol. Biol. Cell,
2005
Jun
, 16 (2972-83).
1807
Dorn A
et al.
Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition.
,
2005
Jun
, 10 (339-47).
1808
Jonker DM
et al.
A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Clin. Pharmacol. Ther.,
2005
Jun
, 77 (572-82).
1809
Pihl J
et al.
Microfluidic gradient-generating device for pharmacological profiling.
Anal. Chem.,
2005
Jul
1
, 77 (3897-903).
1810
Akhavan A
et al.
Identification of the cyclic-nucleotide-binding domain as a conserved determinant of ion-channel cell-surface localization.
J. Cell. Sci.,
2005
Jul
1
, 118 (2803-12).
1811
Shang YP
et al.
A novel splice mutation of HERG in a Chinese family with long QT syndrome.
,
2005
Jul
, 6 (626-30).
1812
Persson F
et al.
Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009.
J. Cardiovasc. Pharmacol.,
2005
Jul
, 46 (7-17).
1813
Siebrands CC
et al.
Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656.
Anesthesiology,
2005
Jul
, 103 (102-12).
1814
Shushi L
et al.
Clinical, genetic, and electrophysiologic characteristics of a new PAS-domain HERG mutation (M124R) causing Long QT syndrome.
Ann Noninvasive Electrocardiol,
2005
Jul
, 10 (334-41).
1815
Wolpert C
et al.
Clinical characteristics and treatment of short QT syndrome.
,
2005
Jul
, 3 (611-7).
1816
Delisle BP
et al.
Intragenic suppression of trafficking-defective KCNH2 channels associated with long QT syndrome.
Mol. Pharmacol.,
2005
Jul
, 68 (233-40).
1817
Shah RR
et al.
Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.
Heart Rhythm,
2005
Jul
, 2 (758-72).
1818
Kikuchi K
et al.
Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer.
Circulation,
2005
Jan
25
, 111 (264-70).
1819
Aronov AM
Predictive in silico modeling for hERG channel blockers.
Drug Discov. Today,
2005
Jan
15
, 10 (149-55).
1820
Royer A
et al.
Expression of human ERG K+ channels in the mouse heart exerts anti-arrhythmic activity.
Cardiovasc. Res.,
2005
Jan
1
, 65 (128-37).
1821
Kuryshev YA
et al.
Pentamidine-induced long QT syndrome and block of hERG trafficking.
J. Pharmacol. Exp. Ther.,
2005
Jan
, 312 (316-23).
1822
Ramakers C
et al.
Molecular and electrical characterization of the canine cardiac ventricular septum.
J. Mol. Cell. Cardiol.,
2005
Jan
, 38 (153-61).
1823
Wolpert C
et al.
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.
J. Cardiovasc. Electrophysiol.,
2005
Jan
, 16 (54-8).
1824
Walker BD
et al.
Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
,
2005
Jan
, 21 (33-8).
1825
Berecki G
et al.
HERG channel (dys)function revealed by dynamic action potential clamp technique.
Biophys. J.,
2005
Jan
, 88 (566-78).
1826
Danielsson BR
et al.
Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents.
Epilepsy Res.,
2005
Jan
, 63 (17-25).
1827
Kim EJ
et al.
Electrophysiological safety of DW-286a, a novel fluoroquinolone antibiotic agent.
,
2005
Jan
, 24 (19-25).
1828
Piper DR
et al.
Regional specificity of human ether-a'-go-go-related gene channel activation and inactivation gating.
J. Biol. Chem.,
2005
Feb
25
, 280 (7206-17).
1829
O'Brien SE
et al.
Greater than the sum of its parts: combining models for useful ADMET prediction.
J. Med. Chem.,
2005
Feb
24
, 48 (1287-91).
1830
Zitron E
et al.
QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids.
Circulation,
2005
Feb
22
, 111 (835-8).
1831
Yang W
et al.
Discovery and structure-activity relationships of 2-benzylpyrrolidine-substituted aryloxypropanols as calcium-sensing receptor antagonists.
Bioorg. Med. Chem. Lett.,
2005
Feb
15
, 15 (1225-8).
1832
Christiansen M
et al.
Mutations in the HERG K+-ion channel: a novel link between long QT syndrome and sudden infant death syndrome.
Am. J. Cardiol.,
2005
Feb
1
, 95 (433-4).
1833
Yamaguchi M
et al.
Compound heterozygosity for mutations Asp611-->Tyr in KCNQ1 and Asp609-->Gly in KCNH2 associated with severe long QT syndrome.
Clin. Sci.,
2005
Feb
, 108 (143-50).
1834
Aydin A
et al.
Single nucleotide polymorphism map of five long-QT genes.
J. Mol. Med.,
2005
Feb
, 83 (159-65).
1835
Dupuis DS
et al.
Effect of beta-adrenoceptor blockers on human ether-a-go-go-related gene (HERG) potassium channels.
Basic Clin. Pharmacol. Toxicol.,
2005
Feb
, 96 (123-30).
1836
Calderone V
et al.
Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
J. Pharm. Pharmacol.,
2005
Feb
, 57 (151-61).
1837
Sorota S
et al.
Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.
,
2005
Feb
, 3 (47-57).
1838
Yu L
et al.
Nuclear magnetic resonance structural studies of a potassium channel-charybdotoxin complex.
Biochemistry,
2005
Dec
6
, 44 (15834-41).
1839
Napolitano C
et al.
Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice.
JAMA,
2005
Dec
21
, 294 (2975-80).
1840
Subbiah RN
et al.
Tryptophan scanning mutagenesis of the HERG K+ channel: the S4 domain is loosely packed and likely to be lipid exposed.
J. Physiol. (Lond.),
2005
Dec
1
, 569 (367-79).
1841
Verkerk AO
et al.
Role of sequence variations in the human ether-a-go-go-related gene (HERG, KCNH2) in the Brugada syndrome.
Cardiovasc. Res.,
2005
Dec
1
, 68 (441-53).
1842
Jalaie M
et al.
QT interval prolongation: and the beat goes on.
,
2005
Dec
, 5 (1083-91).
1843
Guthrie H
et al.
A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
,
2005
Dec
, 10 (832-40).
1844
Kim SW
et al.
In vivo targeting of ERG potassium channels in mice and dogs by a positron-emitting analogue of fluoroclofilium.
Exp. Mol. Med.,
2005
Aug
31
, 37 (269-75).
1845
Crotti L
et al.
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome.
Circulation,
2005
Aug
30
, 112 (1251-8).
1846
McPate MJ
et al.
The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.
Biochem. Biophys. Res. Commun.,
2005
Aug
26
, 334 (441-9).
1847
Cordeiro JM
et al.
Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome.
Cardiovasc. Res.,
2005
Aug
15
, 67 (498-509).
1849
Paulussen AD
et al.
HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency.
Cardiovasc. Res.,
2005
Aug
15
, 67 (467-75).
1850
Shimizu W
The long QT syndrome: therapeutic implications of a genetic diagnosis.
Cardiovasc. Res.,
2005
Aug
15
, 67 (347-56).
1851
Ehrlich JR
et al.
Atrial fibrillation-associated minK38G/S polymorphism modulates delayed rectifier current and membrane localization.
Cardiovasc. Res.,
2005
Aug
15
, 67 (520-8).
1852
Miranda P
et al.
Specificity of TRH receptor coupling to G-proteins for regulation of ERG K+ channels in GH3 rat anterior pituitary cells.
J. Physiol. (Lond.),
2005
Aug
1
, 566 (717-36).
1853
Cianchetta G
et al.
Predictive models for hERG potassium channel blockers.
Bioorg. Med. Chem. Lett.,
2005
Aug
1
, 15 (3637-42).
1854
Szabó G
et al.
Asymmetrical distribution of ion channels in canine and human left-ventricular wall: epicardium versus midmyocardium.
Pflugers Arch.,
2005
Aug
, 450 (307-16).
1855
Chen SZ
et al.
HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
Cancer Chemother. Pharmacol.,
2005
Aug
, 56 (212-20).
1856
Chagot B
et al.
Solution structure of APETx2, a specific peptide inhibitor of ASIC3 proton-gated channels.
Protein Sci.,
2005
Aug
, 14 (2003-10).
1857
Chen SZ
et al.
[Correlation of HERG K+ channel protein expression to chemosensitivity of tumor cells to doxorubicin and its modulation by erythromycin]
Ai Zheng,
2005
Aug
, 24 (924-9).
1858
1859
Schneider J
et al.
Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs.
Eur. J. Pharmacol.,
2005
Apr
4
, 512 (53-60).
1860
Priori SG
et al.
A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene.
Circ. Res.,
2005
Apr
15
, 96 (800-7).
1861
Sturm P
et al.
Extracellular potassium effects are conserved within the rat erg K+ channel family.
J. Physiol. (Lond.),
2005
Apr
15
, 564 (329-45).
1862
Hirdes W
et al.
Fast erg K+ currents in rat embryonic serotonergic neurones.
J. Physiol. (Lond.),
2005
Apr
1
, 564 (33-49).
1863
Pfeufer A
et al.
Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study.
Circ. Res.,
2005
Apr
1
, 96 (693-701).
1864
Dilaveris PE
Molecular predictors of drug-induced prolongation of the QT interval.
Curr Med Chem Cardiovasc Hematol Agents,
2005
Apr
, 3 (105-18).
1865
Eun JS
et al.
Effects of oxypeucedanin on hKv1.5 and action potential duration.
Biol. Pharm. Bull.,
2005
Apr
, 28 (657-60).
1866
Claassen S
et al.
Comparison of the effects of metoclopramide and domperidone on HERG channels.
Pharmacology,
2005
Apr
, 74 (31-6).
1867
Kim I
et al.
Postnatal development of E-4031-sensitive potassium current in rat carotid chemoreceptor cells.
J. Appl. Physiol.,
2005
Apr
, 98 (1469-77).
1868
Hong K
et al.
Short QT syndrome and atrial fibrillation caused by mutation in KCNH2.
J. Cardiovasc. Electrophysiol.,
2005
Apr
, 16 (394-6).
1869
Anantharam A
et al.
Does hERG coassemble with a beta subunit? Evidence for roles of MinK and MiRP1.
Novartis Found. Symp.,
2005
, 266 (100-12; discussion 112-7, 155-8).
1870
Robertson GA
et al.
Gating and assembly of heteromeric hERG1a/1b channels underlying I(Kr) in the heart.
Novartis Found. Symp.,
2005
, 266 (4-15; discussion 15-8, 44-5).
1871
Vaz RJ
et al.
Human ether-a-go-go related gene (HERG): a chemist's perspective.
,
2005
, 43 (1-18).
1872
Tseng GN
et al.
Structure-function studies of the outer mouth and voltage sensor domain of hERG.
Novartis Found. Symp.,
2005
, 266 (19-35; discussion 35-45).
1873
Shimizu W
et al.
Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.
Curr. Pharm. Des.,
2005
, 11 (1561-72).
1874
Piper DR
et al.
Voltage sensor movement in the hERG K+ channel.
Novartis Found. Symp.,
2005
, 266 (46-52; discussion 52-6, 95-9).
1875
Ficker E
et al.
HERG channel trafficking.
Novartis Found. Symp.,
2005
, 266 (57-69; discussion 70-4, 95-9).
1876
Kagan A
et al.
Dynamic control of hERG/I(Kr) by PKA-mediated interactions with 14-3-3.
Novartis Found. Symp.,
2005
, 266 (75-89; discussion 89-99).
1877
Furlan F
et al.
Interneurons transiently express the ERG K+ channels during development of mouse spinal networks in vitro.
Neuroscience,
2005
, 135 (1179-92).
1878
Shah RR
Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Novartis Found. Symp.,
2005
, 266 (251-80; discussion 280-5).
1879
1880
Brown AM
HERG block, QT liability and sudden cardiac death.
Novartis Found. Symp.,
2005
, 266 (118-31; discussion 131-5, 155-8).
1881
Mitcheson J
et al.
Structural determinants for high-affinity block of hERG potassium channels.
Novartis Found. Symp.,
2005
, 266 (136-50; discussion 150-8).
1882
Sanguinetti MC
et al.
Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Novartis Found. Symp.,
2005
, 266 (159-66; discussion 166-70).
1883
Recanatini M
et al.
In silico modelling--pharmacophores and hERG channel models.
Novartis Found. Symp.,
2005
, 266 (171-81; discussion 181-5).
1884
Schwartz PJ
The long QT syndrome: a clinical counterpart of hERG mutations.
Novartis Found. Symp.,
2005
, 266 (186-98; discussion 198-203).
1885
Arcangeli A
Expression and role of hERG channels in cancer cells.
Novartis Found. Symp.,
2005
, 266 (225-32; discussion 232-4).
1886
Kim KS
et al.
The phenothiazine drugs inhibit hERG potassium channels.
,
2005
, 28 (303-13).
1887
Kii Y
et al.
QT PRODACT: evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles.
J. Pharmacol. Sci.,
2005
, 99 (449-57).
1888
Keller SH
et al.
Long QT syndrome-associated I593R mutation in HERG potassium channel activates ER stress pathways.
Cell Biochem. Biophys.,
2005
, 43 (365-77).
1889
Chatrath R
et al.
Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome.
Pediatr Cardiol,
2004 Sep-Oct
, 25 (459-65).
1890
Kirsch GE
et al.
Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.
,
2004 Sep-Oct
, 50 (93-101).
1891
Aptula AO
et al.
Prediction of hERG K+ blocking potency: application of structural knowledge.
,
2004 Oct-Dec
, 15 (399-411).
1892
1893
Korolkova YV
et al.
Unique interaction of scorpion toxins with the hERG channel.
J. Mol. Recognit.,
2004 May-Jun
, 17 (209-17).
1894
Patt S
et al.
Expression of ether à go-go potassium channels in human gliomas.
Neurosci. Lett.,
2004
Sep
30
, 368 (249-53).
1895
Zhang L
et al.
An intronic mutation causes long QT syndrome.
J. Am. Coll. Cardiol.,
2004
Sep
15
, 44 (1283-91).
1896
Priori SG
et al.
Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers.
JAMA,
2004
Sep
15
, 292 (1341-4).
1898
Gögelein H
et al.
Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.
Naunyn Schmiedebergs Arch. Pharmacol.,
2004
Sep
, 370 (183-92).
1899
Kanters JK
et al.
T wave morphology analysis distinguishes between KvLQT1 and HERG mutations in long QT syndrome.
Heart Rhythm,
2004
Sep
, 1 (285-92).
1900
Jones EM
et al.
Cardiac IKr channels minimally comprise hERG 1a and 1b subunits.
J. Biol. Chem.,
2004
Oct
22
, 279 (44690-4).
1901
Dustan Sarazan R
et al.
Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
Eur. J. Pharmacol.,
2004
Oct
19
, 502 (163-7).
1902
Choi G
et al.
Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes.
Circulation,
2004
Oct
12
, 110 (2119-24).
1903
Finlayson K
et al.
Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Eur. J. Pharmacol.,
2004
Oct
1
, 500 (129-42).
1904
Rezazadeh S
et al.
Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay.
,
2004
Oct
, 9 (588-97).
1905
Testai L
et al.
Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.
Curr. Med. Chem.,
2004
Oct
, 11 (2691-706).
1906
Bains W
et al.
HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study.
Prog. Biophys. Mol. Biol.,
2004
Oct
, 86 (205-33).
1907
Tao H
et al.
Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds.
,
2004
Oct
, 2 (497-506).
1908
Opdal SH
et al.
The sudden infant death syndrome gene: does it exist?
Pediatrics,
2004
Oct
, 114 (e506-12).
1909
Zehelein J
et al.
Identification and characterisation of a novel KCNQ1 mutation in a family with Romano-Ward syndrome.
Biochim. Biophys. Acta,
2004
Nov
5
, 1690 (185-92).
1910
Abriel H
et al.
Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.
,
2004
Nov
27
, 134 (685-94).
1911
Bilchick K
et al.
Temporal repolarization lability differences among genotyped patients with the long QT syndrome.
Am. J. Cardiol.,
2004
Nov
15
, 94 (1312-6).
1912
Davie C
et al.
Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
J. Cardiovasc. Electrophysiol.,
2004
Nov
, 15 (1302-9).
1913
Yang Y
et al.
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation.
Am. J. Hum. Genet.,
2004
Nov
, 75 (899-905).
1914
Kim EJ
et al.
Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent.
,
2004
Nov
, 27 (295-307).
1915
Witchel HJ
et al.
The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Mol. Pharmacol.,
2004
Nov
, 66 (1201-12).
1916
Bellocq C
et al.
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2.
Mol. Pharmacol.,
2004
Nov
, 66 (1093-102).
1917
Bian JS
et al.
Molecular analysis of PIP2 regulation of HERG and IKr.
Am. J. Physiol. Heart Circ. Physiol.,
2004
Nov
, 287 (H2154-63).
1918
Arcangeli A
et al.
Physical and functional interaction between integrins and hERG potassium channels.
Biochem. Soc. Trans.,
2004
Nov
, 32 (826-7).
1919
Sun Z
et al.
Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
J. Mol. Cell. Cardiol.,
2004
Nov
, 37 (1031-9).
1920
Chugh SS
et al.
Postmortem molecular screening in unexplained sudden death.
J. Am. Coll. Cardiol.,
2004
May
5
, 43 (1625-9).
1921
Yuill KH
et al.
Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation.
Biochem. Biophys. Res. Commun.,
2004
May
28
, 318 (556-61).
1922
Bellocq C
et al.
Mutation in the KCNQ1 gene leading to the short QT-interval syndrome.
Circulation,
2004
May
25
, 109 (2394-7).
1923
Clark RB
et al.
A rapidly activating delayed rectifier K+ current regulates pacemaker activity in adult mouse sinoatrial node cells.
Am. J. Physiol. Heart Circ. Physiol.,
2004
May
, 286 (H1757-66).
1924
Lee SY
et al.
Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.
J. Cardiovasc. Pharmacol.,
2004
May
, 43 (706-14).
1925
Thomas D
et al.
Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
Naunyn Schmiedebergs Arch. Pharmacol.,
2004
May
, 369 (462-72).
1926
Gessner G
et al.
Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents.
Mol. Pharmacol.,
2004
May
, 65 (1120-9).
1927
Dong DL
et al.
Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Basic Clin. Pharmacol. Toxicol.,
2004
May
, 94 (209-12).
1928
Yang BF
et al.
Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Acta Pharmacol. Sin.,
2004
May
, 25 (554-60).
1929
Ridley JM
et al.
Lidoflazine is a high affinity blocker of the HERG K(+)channel.
J. Mol. Cell. Cardiol.,
2004
May
, 36 (701-5).
1930
Hiramatsu M
et al.
Block of HERG current expressed in HEK293 cells by the Na+-channel blocker cibenzoline.
,
2004
May
, 19 (137-43).
1931
Lupoglazoff JM
et al.
Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations.
J. Am. Coll. Cardiol.,
2004
Mar
3
, 43 (826-30).
1932
Huys I
et al.
BmTx3, a scorpion toxin with two putative functional faces separately active on A-type K+ and HERG currents.
Biochem. J.,
2004
Mar
15
, 378 (745-52).
1933
Fernandez D
et al.
Physicochemical features of the HERG channel drug binding site.
J. Biol. Chem.,
2004
Mar
12
, 279 (10120-7).
1934
Teng S
et al.
Clinical and electrophysiological characterization of a novel mutation R863X in HERG C-terminus associated with long QT syndrome.
J. Mol. Med.,
2004
Mar
, 82 (189-96).
1935
Kang J
et al.
Cardiac ion channel effects of tolterodine.
J. Pharmacol. Exp. Ther.,
2004
Mar
, 308 (935-40).
1936
Thu-Thuy LT
et al.
Long-term follow-up of notched T waves in female patients with LQT2 (HERG) mutations.
,
2004
Mar
, 45 (243-50).
1937
Martin RL
et al.
The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block.
J. Cardiovasc. Pharmacol.,
2004
Mar
, 43 (369-79).
1938
Paulussen AD
et al.
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients.
J. Mol. Med.,
2004
Mar
, 82 (182-8).
1939
Peukert S
et al.
Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.
Bioorg. Med. Chem. Lett.,
2004
Jun
7
, 14 (2823-7).
1940
Tsujimae K
et al.
Comparison of kinetic properties of quinidine and dofetilide block of HERG channels.
Eur. J. Pharmacol.,
2004
Jun
16
, 493 (29-40).
1941
Wang S
et al.
Activation properties of Kv4.3 channels: time, voltage and [K+]o dependence.
J. Physiol. (Lond.),
2004
Jun
15
, 557 (705-17).
1943
Hua F
et al.
Suppression of electrical alternans by overexpression of HERG in canine ventricular myocytes.
Am. J. Physiol. Heart Circ. Physiol.,
2004
Jun
, 286 (H2342-51).
1944
Thomas D
et al.
Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
Br. J. Pharmacol.,
2004
Jun
, 142 (485-94).
1945
Anson BD
et al.
Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels.
Am. J. Physiol. Heart Circ. Physiol.,
2004
Jun
, 286 (H2434-41).
1946
Lian JF
et al.
[Long QT syndrome gene diagnosis by haplotype analysis]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi,
2004
Jun
, 21 (272-3).
1947
Subbiah RN
et al.
Molecular basis of slow activation of the human ether-a-go-go related gene potassium channel.
J. Physiol. (Lond.),
2004
Jul
15
, 558 (417-31).
1948
Suzuki T
et al.
Selective expression of HERG and Kv2 channels influences proliferation of uterine cancer cells.
Int. J. Oncol.,
2004
Jul
, 25 (153-9).
1949
Ficker E
et al.
Mechanisms of arsenic-induced prolongation of cardiac repolarization.
Mol. Pharmacol.,
2004
Jul
, 66 (33-44).
1950
Tsai HF
et al.
Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension.
Antimicrob. Agents Chemother.,
2004
Jul
, 48 (2483-9).
1951
Thomas D
et al.
Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, I(Kr), and the underlying hERG ion channel.
Basic Res. Cardiol.,
2004
Jul
, 99 (279-87).
1952
Sharma D
et al.
Characterization of a KCNQ1/KVLQT1 polymorphism in Asian families with LQT2: implications for genetic testing.
J. Mol. Cell. Cardiol.,
2004
Jul
, 37 (79-89).
1953
Chiu PJ
et al.
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
J. Pharmacol. Sci.,
2004
Jul
, 95 (311-9).
1954
Conti M
Targeting K+ channels for cancer therapy.
J. Exp. Ther. Oncol.,
2004
Jul
, 4 (161-6).
1955
Youm JB
et al.
Modulation of HERG channel inactivation by external cations.
Eur. Biophys. J.,
2004
Jul
, 33 (360-9).
1956
Ehrlich JR
et al.
KvLQT1 modulates the distribution and biophysical properties of HERG. A novel alpha-subunit interaction between delayed rectifier currents.
J. Biol. Chem.,
2004
Jan
9
, 279 (1233-41).
1957
Drolet B
et al.
Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents.
Circulation,
2004
Jan
6
, 109 (26-9).
1958
Brugada R
et al.
Sudden death associated with short-QT syndrome linked to mutations in HERG.
Circulation,
2004
Jan
6
, 109 (30-5).
1959
Fraley ME
et al.
Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding.
Bioorg. Med. Chem. Lett.,
2004
Jan
19
, 14 (351-5).
1960
Traebert M
et al.
Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.
Eur. J. Pharmacol.,
2004
Jan
19
, 484 (41-8).
1961
Lastraioli E
et al.
herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells.
Cancer Res.,
2004
Jan
15
, 64 (606-11).
1962
Friederich P
et al.
Local anaesthetic sensitivities of cloned HERG channels from human heart: comparison with HERG/MiRP1 and HERG/MiRP1 T8A.
,
2004
Jan
, 92 (93-101).
1963
Varró A
et al.
Theoretical possibilities for the development of novel antiarrhythmic drugs.
Curr. Med. Chem.,
2004
Jan
, 11 (1-11).
1964
Su Z
et al.
Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel.
J. Mol. Cell. Cardiol.,
2004
Jan
, 36 (151-60).
1965
Fossa AA
et al.
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.
Eur. J. Pharmacol.,
2004
Feb
20
, 486 (209-21).
1966
Teng G
et al.
Prolonged repolarization and triggered activity induced by adenoviral expression of HERG N629D in cardiomyocytes derived from stem cells.
Cardiovasc. Res.,
2004
Feb
1
, 61 (268-77).
1967
Kobori A
et al.
Additional gene variants reduce effectiveness of beta-blockers in the LQT1 form of long QT syndrome.
J. Cardiovasc. Electrophysiol.,
2004
Feb
, 15 (190-9).
1968
Wang J
et al.
Potential mechanisms for the enhancement of HERG K+ channel function by phospholipid metabolites.
Br. J. Pharmacol.,
2004
Feb
, 141 (586-99).
1969
Cheng JH
et al.
Two components of delayed rectifier K+ current in heart: molecular basis, functional diversity, and contribution to repolarization.
Acta Pharmacol. Sin.,
2004
Feb
, 25 (137-45).
1970
Bilodeau MT
et al.
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
J. Med. Chem.,
2004
Dec
2
, 47 (6363-72).
1971
Ridley JM
et al.
High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Biochem. Biophys. Res. Commun.,
2004
Dec
17
, 325 (883-91).
1972
Thomas D
et al.
Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X).
Cardiovasc. Res.,
2004
Dec
1
, 64 (467-76).
1973
Subbiah RN
et al.
Inherited cardiac arrhythmia syndromes: what have they taught us about arrhythmias and anti-arrhythmic therapy?
Clin. Exp. Pharmacol. Physiol.,
2004
Dec
, 31 (906-12).
1974
Sánchez-Chapula JA
et al.
Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Naunyn Schmiedebergs Arch. Pharmacol.,
2004
Dec
, 370 (484-91).
1975
Zhang M
et al.
Gating charges in the activation and inactivation processes of the HERG channel.
J. Gen. Physiol.,
2004
Dec
, 124 (703-18).
1976
Kiesecker C
et al.
Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action.
Naunyn Schmiedebergs Arch. Pharmacol.,
2004
Dec
, 370 (423-35).
1977
Sasano T
et al.
Novel C-terminus frameshift mutation, 1122fs/147, of HERG in LQT2: additional amino acids generated by frameshift cause accelerated inactivation.
J. Mol. Cell. Cardiol.,
2004
Dec
, 37 (1205-11).
1978
Thomas D
et al.
Activation of cardiac human ether-a-go-go related gene potassium currents is regulated by alpha(1A)-adrenoceptors.
J. Mol. Med.,
2004
Dec
, 82 (826-37).
1979
Saegusa N
et al.
Inhibitory effects of AMP 579, a novel cardioprotective adenosine A1/A2A receptor agonist, on native IKr and cloned HERG current.
Naunyn Schmiedebergs Arch. Pharmacol.,
2004
Dec
, 370 (492-9).
1980
Gong Q
et al.
Defective assembly and trafficking of mutant HERG channels with C-terminal truncations in long QT syndrome.
J. Mol. Cell. Cardiol.,
2004
Dec
, 37 (1225-33).
1981
Chun KR
et al.
Expression of the IKr components KCNH2 (rERG) and KCNE2 (rMiRP1) during late rat heart development.
Exp. Mol. Med.,
2004
Aug
31
, 36 (367-71).
1982
Hirdes W
et al.
Muscarinic modulation of erg potassium current.
J. Physiol. (Lond.),
2004
Aug
15
, 559 (67-84).
1983
Petersen CI
et al.
In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia.
Proc. Natl. Acad. Sci. U.S.A.,
2004
Aug
10
, 101 (11773-8).
1984
Frénal K
et al.
Exploring structural features of the interaction between the scorpion toxinCnErg1 and ERG K+ channels.
Proteins,
2004
Aug
1
, 56 (367-75).
1985
Mullins FM
et al.
Functional interaction between extracellular sodium, potassium and inactivation gating in HERG channels.
J. Physiol. (Lond.),
2004
Aug
1
, 558 (729-44).
1986
Hayashi K
et al.
Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Clin. Sci.,
2004
Aug
, 107 (175-82).
1987
Gong Q
et al.
Pharmacological rescue of trafficking defective HERG channels formed by coassembly of wild-type and long QT mutant N470D subunits.
Am. J. Physiol. Heart Circ. Physiol.,
2004
Aug
, 287 (H652-8).
1988
Schram G
et al.
Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.
Br. J. Pharmacol.,
2004
Aug
, 142 (1300-8).
1989
Perry M
et al.
Structural determinants of HERG channel block by clofilium and ibutilide.
Mol. Pharmacol.,
2004
Aug
, 66 (240-9).
1990
Zitron E
et al.
Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.
Naunyn Schmiedebergs Arch. Pharmacol.,
2004
Aug
, 370 (146-56).
1991
McCauley JA
et al.
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.
J. Med. Chem.,
2004
Apr
8
, 47 (2089-96).
1992
Westenskow P
et al.
Compound mutations: a common cause of severe long-QT syndrome.
Circulation,
2004
Apr
20
, 109 (1834-41).
1993
Wang J
et al.
Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator.
J. Biol. Chem.,
2004
Apr
2
, 279 (13289-92).
1994
Liu GX
et al.
Single-channel recordings of a rapid delayed rectifier current in adult mouse ventricular myocytes: basic properties and effects of divalent cations.
J. Physiol. (Lond.),
2004
Apr
15
, 556 (401-13).
1995
Tamargo J
et al.
Pharmacology of cardiac potassium channels.
Cardiovasc. Res.,
2004
Apr
1
, 62 (9-33).
1996
Rasmussen HB
et al.
Subcellular localization of the delayed rectifier K(+) channels KCNQ1 and ERG1 in the rat heart.
Am. J. Physiol. Heart Circ. Physiol.,
2004
Apr
, 286 (H1300-9).
1997
Winston NJ
et al.
Expression and role of the ether-à-go-go-related (MERG1A) potassium-channel protein during preimplantation mouse development.
Biol. Reprod.,
2004
Apr
, 70 (1070-9).
1998
Vandenberg JI
et al.
The HERG K+ channel: progress in understanding the molecular basis of its unusual gating kinetics.
Eur. Biophys. J.,
2004
Apr
, 33 (89-97).
1999
Fodstad H
et al.
Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland.
Ann. Med.,
2004
, 36 Suppl 1 (53-63).
2000
Han H
et al.
HERG K channel conductance promotes H2O2-induced apoptosis in HEK293 cells: cellular mechanisms.
Cell. Physiol. Biochem.,
2004
, 14 (121-34).
2001
Charpentier F
et al.
Cardiac channelopathies: from men to mice.
Ann. Med.,
2004
, 36 Suppl 1 (28-34).
2002
Thomas D
et al.
Modulation of HERG potassium channel function by drug action.
Ann. Med.,
2004
, 36 Suppl 1 (41-6).
2003
Bian JS
et al.
S641 contributes HERG K+ channel inactivation.
Cell Biochem. Biophys.,
2004
, 41 (25-40).
2004
Joshi A
et al.
Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.
,
2004
, 37 Suppl (7-14).
2005
Meyer T
et al.
Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.
,
2004
, 27 (763-72).
2006
Danielsson BR
et al.
Phenytoin and phenobarbital inhibit human HERG potassium channels.
Epilepsy Res.,
2003 Jun-Jul
, 55 (147-57).
2007
Finley MR
et al.
Structural and functional basis for the long QT syndrome: relevance to veterinary patients.
J. Vet. Intern. Med.,
2003 Jul-Aug
, 17 (473-88).
2008
Piper DR
et al.
Gating currents associated with intramembrane charge displacement in HERG potassium channels.
Proc. Natl. Acad. Sci. U.S.A.,
2003
Sep
2
, 100 (10534-9).
2009
Delisle BP
et al.
Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C.
J. Biol. Chem.,
2003
Sep
12
, 278 (35749-54).
2010
Paavonen KJ
et al.
Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG).
Cardiovasc. Res.,
2003
Sep
1
, 59 (603-11).
2011
Liu W
et al.
Mutation analysis of potassium channel genes KCNQ1 and KCNH2 in patients with long QT syndrome.
Chin. Med. J.,
2003
Sep
, 116 (1333-5).
2012
Borlak J
et al.
Hallmarks of ion channel gene expression in end-stage heart failure.
FASEB J.,
2003
Sep
, 17 (1592-608).
2013
Wu LM
et al.
Effects of Na+ channel blocker, pilsicainide, on HERG current expressed in HEK-293 cells.
J. Cardiovasc. Pharmacol.,
2003
Sep
, 42 (410-8).
2014
Mitcheson JS
et al.
Molecular determinants of high-affinity drug binding to HERG channels.
,
2003
Sep
, 6 (667-74).
2015
Witzenbichler B
et al.
[18-year old patient with anti-epileptic therapy and sudden cardiac death]
Z Kardiol,
2003
Sep
, 92 (747-53).
2016
Akar FG
et al.
Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure.
Circ. Res.,
2003
Oct
3
, 93 (638-45).
2017
Torres AM
et al.
Structure of the HERG K+ channel S5P extracellular linker: role of an amphipathic alpha-helix in C-type inactivation.
J. Biol. Chem.,
2003
Oct
24
, 278 (42136-48).
2018
Fedida D
et al.
Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.
Circ. Res.,
2003
Oct
17
, 93 (744-51).
2019
Laohakunakorn P
et al.
Bidirectional ventricular tachycardia and channelopathy.
Am. J. Cardiol.,
2003
Oct
15
, 92 (991-5).
2020
Akhavan A
et al.
Identification of a COOH-terminal segment involved in maturation and stability of human ether-a-go-go-related gene potassium channels.
J. Biol. Chem.,
2003
Oct
10
, 278 (40105-12).
2021
Angelo K
et al.
A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1.
Pflugers Arch.,
2003
Oct
, 447 (55-63).
2022
Kutchinsky J
et al.
Characterization of potassium channel modulators with QPatch automated patch-clamp technology: system characteristics and performance.
,
2003
Oct
, 1 (685-93).
2023
Zicha S
et al.
Molecular basis of species-specific expression of repolarizing K+ currents in the heart.
Am. J. Physiol. Heart Circ. Physiol.,
2003
Oct
, 285 (H1641-9).
2024
Zolotoy AB
et al.
Physicochemical determinants for drug induced blockade of HERG potassium channels: effect of charge and charge shielding.
Curr Med Chem Cardiovasc Hematol Agents,
2003
Oct
, 1 (225-41).
2025
Brendel J
et al.
Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.
Curr Med Chem Cardiovasc Hematol Agents,
2003
Oct
, 1 (273-87).
2026
Lee K
et al.
IKr channel blockers: novel antiarrhythmic agents.
Curr Med Chem Cardiovasc Hematol Agents,
2003
Oct
, 1 (203-23).
2027
Papa M
et al.
Expression pattern of the ether-a-gogo-related (ERG) K+ channel-encoding genes ERG1, ERG2, and ERG3 in the adult rat central nervous system.
J. Comp. Neurol.,
2003
Nov
3
, 466 (119-35).
2028
Etheridge SP
et al.
A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations.
J. Am. Coll. Cardiol.,
2003
Nov
19
, 42 (1777-82).
2029
Thomas D
et al.
Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing.
Cardiovasc. Res.,
2003
Nov
1
, 60 (235-41).
2030
Thomas D
et al.
Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.
Br. J. Pharmacol.,
2003
Nov
, 140 (996-1002).
2031
Scholz EP
et al.
Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
Naunyn Schmiedebergs Arch. Pharmacol.,
2003
Nov
, 368 (404-14).
2032
Lee K
et al.
Differential recovery of action potential duration and HERG currents from the effects of two methanesulfonamide class III antiarrhythmic agents, KCB-328 and dofetilide.
J. Cardiovasc. Pharmacol.,
2003
Nov
, 42 (648-55).
2033
Zareba W
et al.
Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.
J. Cardiovasc. Electrophysiol.,
2003
Nov
, 14 (1149-53).
2034
Priori SG
et al.
Risk stratification in the long-QT syndrome.
N. Engl. J. Med.,
2003
May
8
, 348 (1866-74).
2035
Pearlstein RA
et al.
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
Bioorg. Med. Chem. Lett.,
2003
May
19
, 13 (1829-35).
2036
Zhang S
et al.
Modulation of human ether-à-go-go-related K+ (HERG) channel inactivation by Cs+ and K+.
J. Physiol. (Lond.),
2003
May
1
, 548 (691-702).
2037
Johnson WH
et al.
Clinical, genetic, and biophysical characterization of a homozygous HERG mutation causing severe neonatal long QT syndrome.
Pediatr. Res.,
2003
May
, 53 (744-8).
2038
Zhang M
et al.
BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1.
Biophys. J.,
2003
May
, 84 (3022-36).
2039
Sánchez-Chapula JA
et al.
Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain.
Mol. Pharmacol.,
2003
May
, 63 (1051-8).
2040
Torres AM
et al.
Solution structure of CnErg1 (Ergtoxin), a HERG specific scorpion toxin.
FEBS Lett.,
2003
Mar
27
, 539 (138-42).
2041
Zhang Y
et al.
Impairment of human ether-à-go-go-related gene (HERG) K+ channel function by hypoglycemia and hyperglycemia. Similar phenotypes but different mechanisms.
J. Biol. Chem.,
2003
Mar
21
, 278 (10417-26).
2042
Milan DJ
et al.
Drugs that induce repolarization abnormalities cause bradycardia in zebrafish.
Circulation,
2003
Mar
18
, 107 (1355-8).
2043
Kaufman ES
et al.
Is restoration of intracellular trafficking clinically feasible in the long QT syndrome?: The example of HERG mutations.
J. Cardiovasc. Electrophysiol.,
2003
Mar
, 14 (320-2).
2044
Teng GQ
et al.
[K(+)](o)-dependent change in conformation of the HERG1 long QT mutation N629D channel results in partial reversal of the in vitro disease phenotype.
Cardiovasc. Res.,
2003
Mar
, 57 (642-50).
2045
Ishii K
et al.
Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency.
Cardiovasc. Res.,
2003
Mar
, 57 (651-9).
2046
Parr E
et al.
ERG K+ channels modulate the electrical and contractile activities of gallbladder smooth muscle.
Am. J. Physiol. Gastrointest. Liver Physiol.,
2003
Mar
, 284 (G392-8).
2047
Arias C
et al.
Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
Cardiovasc. Res.,
2003
Mar
, 57 (660-9).
2048
Lees-Miller JP
et al.
Selective knockout of mouse ERG1 B potassium channel eliminates I(Kr) in adult ventricular myocytes and elicits episodes of abrupt sinus bradycardia.
Mol. Cell. Biol.,
2003
Mar
, 23 (1856-62).
2049
Picard S
et al.
QT interval prolongation and cardiac risk assessment for novel drugs.
,
2003
Mar
, 4 (303-8).
2050
Friesen RW
et al.
Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
J. Med. Chem.,
2003
Jun
5
, 46 (2413-26).
2051
Ridley JM
et al.
Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.
Biochem. Biophys. Res. Commun.,
2003
Jun
27
, 306 (388-93).
2052
Ficker E
et al.
Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG.
Circ. Res.,
2003
Jun
27
, 92 (e87-100).
2053
Ridley JM
et al.
Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine.
J. Physiol. (Lond.),
2003
Jun
15
, 549 (667-72).
2054
Zünkler BJ
et al.
Effects of lomefloxacin and norfloxacin on pancreatic beta-cell ATP-sensitive K(+) channels.
Life Sci.,
2003
Jun
13
, 73 (429-35).
2055
Liu J
et al.
Negative charges in the transmembrane domains of the HERG K channel are involved in the activation- and deactivation-gating processes.
J. Gen. Physiol.,
2003
Jun
, 121 (599-614).
2056
Farrelly AM
et al.
Expression and function of KCNH2 (HERG) in the human jejunum.
Am. J. Physiol. Gastrointest. Liver Physiol.,
2003
Jun
, 284 (G883-95).
2057
Wang J
et al.
Saxitoxin is a gating modifier of HERG K+ channels.
J. Gen. Physiol.,
2003
Jun
, 121 (583-98).
2058
Drolet B
et al.
Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
J. Cardiovasc. Pharmacol.,
2003
Jun
, 41 (934-7).
2059
Thomas D
et al.
The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
Br. J. Pharmacol.,
2003
Jun
, 139 (567-74).
2060
Inoue M
et al.
Q-T peak dispersion in congenital long QT syndrome: possible marker of mutation of HERG.
Circ. J.,
2003
Jun
, 67 (495-8).
2061
Nakaya H
[Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels]
Nippon Yakurigaku Zasshi,
2003
Jun
, 121 (384-92).
2062
Amos GJ
et al.
Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52.
J. Cardiovasc. Electrophysiol.,
2003
Jun
, 14 (651-8).
2063
Zareba W
et al.
Modulating effects of age and gender on the clinical course of long QT syndrome by genotype.
J. Am. Coll. Cardiol.,
2003
Jul
2
, 42 (103-9).
2064
Milnes JT
et al.
Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin.
FEBS Lett.,
2003
Jul
17
, 547 (20-6).
2065
Thomas D
et al.
Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein.
Cardiovasc. Res.,
2003
Jul
1
, 59 (14-26).
2066
Bezzina CR
et al.
A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization.
Cardiovasc. Res.,
2003
Jul
1
, 59 (27-36).
2067
Diochot S
et al.
APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels.
Mol. Pharmacol.,
2003
Jul
, 64 (59-69).
2068
Thomas D
et al.
Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen.
Naunyn Schmiedebergs Arch. Pharmacol.,
2003
Jul
, 368 (41-8).
2069
Netzer R
et al.
HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery.
,
2003
Jul
, 6 (462-9).
2070
Mitcheson JS
Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.
Br. J. Pharmacol.,
2003
Jul
, 139 (883-4).
2071
Milnes JT
et al.
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
Br. J. Pharmacol.,
2003
Jul
, 139 (887-98).
2072
Crociani O
et al.
Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells.
J. Biol. Chem.,
2003
Jan
31
, 278 (2947-55).
2073
Gómez-Varela D
et al.
Relevance of the proximal domain in the amino-terminus of HERG channels for regulation by a phospholipase C-coupled hormone receptor.
FEBS Lett.,
2003
Jan
30
, 535 (125-30).
2074
Shoeb F
et al.
Cloning and functional characterization of the smooth muscle ether-a-go-go-related gene K+ channel. Potential role of a conserved amino acid substitution in the S4 region.
J. Biol. Chem.,
2003
Jan
24
, 278 (2503-14).
2075
Mühlbauer E
et al.
Ethanol differently affects stress protein and HERG K+ channel expression in SH-SY5Y cells.
Eur. J. Pharmacol.,
2003
Jan
17
, 459 (121-9).
2076
Zhang Y
et al.
Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity.
FEBS Lett.,
2003
Jan
16
, 534 (125-32).
2077
Kang J
et al.
Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channels.
Eur. J. Pharmacol.,
2003
Jan
1
, 458 (25-9).
2078
Gessner G
et al.
Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241.
Br. J. Pharmacol.,
2003
Jan
, 138 (161-71).
2079
Tristani-Firouzi M
et al.
Structural determinants and biophysical properties of HERG and KCNQ1 channel gating.
J. Mol. Cell. Cardiol.,
2003
Jan
, 35 (27-35).
2080
Wang J
et al.
Functional and pharmacological properties of canine ERG potassium channels.
Am. J. Physiol. Heart Circ. Physiol.,
2003
Jan
, 284 (H256-67).
2081
Liu XK
et al.
In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits.
Cardiovasc. Res.,
2003
Jan
, 57 (28-36).
2082
Jenke M
et al.
C-terminal domains implicated in the functional surface expression of potassium channels.
EMBO J.,
2003
Feb
3
, 22 (395-403).
2083
D'Amico M
et al.
A HERG current sustains a cardiac-type action potential in neuroblastoma S cells.
Biochem. Biophys. Res. Commun.,
2003
Feb
28
, 302 (101-8).
2084
Caballero R
et al.
Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels.
Circulation,
2003
Feb
18
, 107 (889-95).
2085
Peukert S
et al.
Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
J. Med. Chem.,
2003
Feb
13
, 46 (486-98).
2086
Gullo F
et al.
ERG K+ channel blockade enhances firing and epinephrine secretion in rat chromaffin cells: the missing link to LQT2-related sudden death?
FASEB J.,
2003
Feb
, 17 (330-2).
2087
Shimizu H
et al.
Interaction between tetraethylammonium and permeant cations at the inactivation gate of the HERG potassium channel.
Jpn. J. Physiol.,
2003
Feb
, 53 (25-34).
2088
Witchel HJ
et al.
Psychotropic drugs, cardiac arrhythmia, and sudden death.
,
2003
Feb
, 23 (58-77).
2089
Moreno I
et al.
Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization.
J. Pharmacol. Exp. Ther.,
2003
Feb
, 304 (862-73).
2090
Bauer CK
et al.
HERG K(+) currents in human prolactin-secreting adenoma cells.
Pflugers Arch.,
2003
Feb
, 445 (589-600).
2091
Kiss L
et al.
High throughput ion-channel pharmacology: planar-array-based voltage clamp.
,
2003
Feb
, 1 (127-35).
2092
Witchel HJ
et al.
Antipsychotics, HERG and sudden death.
Br J Psychiatry,
2003
Feb
, 182 (171-2).
2093
Ning L
et al.
Denaturing high-performance liquid chromatography quickly and reliably detects cardiac ion channel mutations in long QT syndrome.
Genet. Test.,
2003
Fall
, 7 (249-53).
2094
Langheinrich U
et al.
Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia.
Toxicol. Appl. Pharmacol.,
2003
Dec
15
, 193 (370-82).
2095
Hurst RS
et al.
Dopamine receptor agonists differ in their actions on cardiac ion channels.
Eur. J. Pharmacol.,
2003
Dec
15
, 482 (31-7).
2096
Danielsson BR
et al.
Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia.
Toxicol. Appl. Pharmacol.,
2003
Dec
1
, 193 (168-76).
2097
Polvani S
et al.
Developmentally regulated expression of the mouse homologues of the potassium channel encoding genes m-erg1, m-erg2 and m-erg3.
Gene Expr. Patterns,
2003
Dec
, 3 (767-76).
2098
Kupershmidt S
et al.
The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines.
FASEB J.,
2003
Dec
, 17 (2263-5).
2099
Mizuno H
et al.
Cardiovascular assessment of ER-118585, a selective phosphodiesterase 5 inhibitor.
Biol. Pharm. Bull.,
2003
Dec
, 26 (1661-7).
2100
Park KH
et al.
N-Glycosylation-dependent block is a novel mechanism for drug-induced cardiac arrhythmia.
FASEB J.,
2003
Dec
, 17 (2308-9).
2101
Ackerman MJ
et al.
Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome.
Mayo Clin. Proc.,
2003
Dec
, 78 (1479-87).
2102
Stanat SJ
et al.
Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel.
Mol. Cell. Biochem.,
2003
Dec
, 254 (1-7).
2103
Keseru GM
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Bioorg. Med. Chem. Lett.,
2003
Aug
18
, 13 (2773-5).
2104
Lu Y
et al.
Mutant MiRP1 subunits modulate HERG K+ channel gating: a mechanism for pro-arrhythmia in long QT syndrome type 6.
J. Physiol. (Lond.),
2003
Aug
15
, 551 (253-62).
2105
Ninomiya T
et al.
Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6.2).
J. Cardiovasc. Pharmacol.,
2003
Aug
, 42 (161-8).
2106
Anantharam A
et al.
RNA interference reveals that endogenous Xenopus MinK-related peptides govern mammalian K+ channel function in oocyte expression studies.
J. Biol. Chem.,
2003
Apr
4
, 278 (11739-45).
2107
Sugiyama A
et al.
Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems.
Eur. J. Pharmacol.,
2003
Apr
11
, 466 (137-46).
2108
Redfern WS
et al.
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Cardiovasc. Res.,
2003
Apr
1
, 58 (32-45).
2109
Hajdu P
et al.
Drug- and mutagenesis-induced changes in the selectivity filter of a cardiac two-pore background K+ channel.
Cardiovasc. Res.,
2003
Apr
1
, 58 (46-54).
2110
Avossa D
et al.
Spinal circuits formation: a study of developmentally regulated markers in organotypic cultures of embryonic mouse spinal cord.
Neuroscience,
2003
, 122 (391-405).
2111
Osanai S
et al.
Effect of HERG-like potassium channel blocker on the carotid body chemoreception.
Adv. Exp. Med. Biol.,
2003
, 536 (117-22).
2112
Bett GC
et al.
Functionally-distinct proton-binding in HERG suggests the presence of two binding sites.
Cell Biochem. Biophys.,
2003
, 39 (183-93).
2113
Witchel HJ
et al.
Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes.
,
2002 Sep-Oct
, 48 (65-80).
2115
Chen J
et al.
Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.
Proc. Natl. Acad. Sci. U.S.A.,
2002
Sep
17
, 99 (12461-6).
2116
Wang H
et al.
HERG K+ channel, a regulator of tumor cell apoptosis and proliferation.
Cancer Res.,
2002
Sep
1
, 62 (4843-8).
2117
Zitron E
et al.
Bertosamil blocks HERG potassium channels in their open and inactivated states.
Br. J. Pharmacol.,
2002
Sep
, 137 (221-8).
2118
Pillozzi S
et al.
HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors.
Leukemia,
2002
Sep
, 16 (1791-8).
2119
Ohya S
et al.
Functional and molecular identification of ERG channels in murine portal vein myocytes.
Am. J. Physiol., Cell Physiol.,
2002
Sep
, 283 (C866-77).
2120
Mbai M
et al.
The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels.
Cardiovasc. Res.,
2002
Sep
, 55 (799-805).
2121
Moss AJ
T-wave patterns associated with the hereditary long QT syndrome.
,
2002
Sep
, 6 (311-5).
2122
Malykhina AP
et al.
Fenamate-induced enhancement of heterologously expressed HERG currents in Xenopus oocytes.
Eur. J. Pharmacol.,
2002
Oct
11
, 452 (269-77).
2123
Li J
et al.
Kinetic modulation of HERG potassium channels by the volatile anesthetic halothane.
Anesthesiology,
2002
Oct
, 97 (921-30).
2124
Mullins FM
et al.
Extracellular sodium interacts with the HERG channel at an outer pore site.
J. Gen. Physiol.,
2002
Oct
, 120 (517-37).
2125
Angelo K
et al.
KCNE5 induces time- and voltage-dependent modulation of the KCNQ1 current.
Biophys. J.,
2002
Oct
, 83 (1997-2006).
2126
Korolkova YV
et al.
New binding site on common molecular scaffold provides HERG channel specificity of scorpion toxin BeKm-1.
J. Biol. Chem.,
2002
Nov
8
, 277 (43104-9).
2127
Scherer CR
et al.
The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.
Br. J. Pharmacol.,
2002
Nov
, 137 (892-900).
2128
Liu J
et al.
Structural and functional role of the extracellular s5-p linker in the HERG potassium channel.
J. Gen. Physiol.,
2002
Nov
, 120 (723-37).
2129
Jongbloed R
et al.
DHPLC analysis of potassium ion channel genes in congenital long QT syndrome.
Hum. Mutat.,
2002
Nov
, 20 (382-91).
2130
Bertaso F
et al.
Expression of voltage-gated K+ channels in human atrium.
Basic Res. Cardiol.,
2002
Nov
, 97 (424-33).
2131
Katchman AN
et al.
Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.
J. Pharmacol. Exp. Ther.,
2002
Nov
, 303 (688-94).
2132
Cherubini A
et al.
HERG K+ channels and beta1 integrins interact through the assembly of a macromolecular complex.
Ann. N. Y. Acad. Sci.,
2002
Nov
, 973 (559-61).
2133
Roche O
et al.
A virtual screening method for prediction of the HERG potassium channel liability of compound libraries.
Chembiochem,
2002
May
3
, 3 (455-9).
2134
Gima K
et al.
Ionic current basis of electrocardiographic waveforms: a model study.
Circ. Res.,
2002
May
3
, 90 (889-96).
2135
Tristani-Firouzi M
et al.
Interactions between S4-S5 linker and S6 transmembrane domain modulate gating of HERG K+ channels.
J. Biol. Chem.,
2002
May
24
, 277 (18994-9000).
2136
Smith GA
et al.
Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells.
J. Biol. Chem.,
2002
May
24
, 277 (18528-34).
2137
Gómez-Varela D
et al.
Influence of amino-terminal structures on kinetic transitions between several closed and open states in human erg K+ channels.
J. Membr. Biol.,
2002
May
15
, 187 (117-33).
2138
Pardo-López L
et al.
Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule.
J. Biol. Chem.,
2002
May
10
, 277 (16403-11).
2139
Lupoglazoff JM
et al.
[Homozygotous mutation of the SCN5A gene responsible for congenital long QT syndrome with 2/1 atrioventricular block]
Arch Mal Coeur Vaiss,
2002
May
, 95 (440-6).
2140
Ekins S
et al.
Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.
J. Pharmacol. Exp. Ther.,
2002
May
, 301 (427-34).
2141
Azarbayjani F
et al.
Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs?
Epilepsia,
2002
May
, 43 (457-68).
2142
Wei Z
et al.
Protein kinase A-mediated phosphorylation of HERG potassium channels in a human cell line.
Chin. Med. J.,
2002
May
, 115 (668-76).
2143
Pannaccione A
et al.
Histidines 578 and 587 in the S5-S6 linker of the human Ether-a-gogo Related Gene-1 K+ channels confer sensitivity to reactive oxygen species.
J. Biol. Chem.,
2002
Mar
15
, 277 (8912-9).
2144
Akar FG
et al.
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome.
Circulation,
2002
Mar
12
, 105 (1247-53).
2145
Selyanko AA
et al.
Dominant-negative subunits reveal potassium channel families that contribute to M-like potassium currents.
J. Neurosci.,
2002
Mar
1
, 22 (RC212).
2146
Jespersen T
et al.
Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes.
BioTechniques,
2002
Mar
, 32 (536-8, 540).
2147
Smith PL
et al.
Fast and slow voltage sensor movements in HERG potassium channels.
J. Gen. Physiol.,
2002
Mar
, 119 (275-93).
2148
Abbott GW
et al.
Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism.
FASEB J.,
2002
Mar
, 16 (390-400).
2149
Sánchez-Chapula JA
et al.
Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
J. Biol. Chem.,
2002
Jun
28
, 277 (23587-95).
2150
Rajamani S
et al.
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
Circulation,
2002
Jun
18
, 105 (2830-5).
2151
Ottschytsch N
et al.
Obligatory heterotetramerization of three previously uncharacterized Kv channel alpha-subunits identified in the human genome.
Proc. Natl. Acad. Sci. U.S.A.,
2002
Jun
11
, 99 (7986-91).
2152
Calderone V
et al.
[Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval]
Minerva Med.,
2002
Jun
, 93 (181-97).
2153
Chachin M
et al.
[Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system]
Nippon Yakurigaku Zasshi,
2002
Jun
, 119 (345-51).
2154
Kupershmidt S
et al.
Defective human Ether-à-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus.
J. Biol. Chem.,
2002
Jul
26
, 277 (27442-8).
2155
Grunnet M
et al.
KCNE4 is an inhibitory subunit to the KCNQ1 channel.
J. Physiol. (Lond.),
2002
Jul
1
, 542 (119-30).
2156
Park JB
et al.
Open channel block by KCB-328 [1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane hydrochloride] of the heterologously expressed human ether-a-go-go-related gene K+ channels.
J. Pharmacol. Exp. Ther.,
2002
Jul
, 302 (314-9).
2157
Volberg WA
et al.
Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.
J. Pharmacol. Exp. Ther.,
2002
Jul
, 302 (320-7).
2158
Nastainczyk W
et al.
A short-chain peptide toxin isolated from Centruroides sculpturatus scorpion venom inhibits ether-à-go-go-related gene K(+) channels.
Toxicon,
2002
Jul
, 40 (1053-8).
2159
Paul AA
et al.
Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.
Br. J. Pharmacol.,
2002
Jul
, 136 (717-29).
2160
Finley MR
et al.
Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart.
Am. J. Physiol. Heart Circ. Physiol.,
2002
Jul
, 283 (H126-38).
2161
Gong Q
et al.
Role of glycosylation in cell surface expression and stability of HERG potassium channels.
Am. J. Physiol. Heart Circ. Physiol.,
2002
Jul
, 283 (H77-84).
2162
Iannini PB
Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.
,
2002
Jul
, 1 (121-8).
2163
Pardo-López L
et al.
Mapping the receptor site for ergtoxin, a specific blocker of ERG channels.
FEBS Lett.,
2002
Jan
2
, 510 (45-9).
2164
Bachmann A
et al.
Inhibition of cardiac potassium currents by pentobarbital.
Naunyn Schmiedebergs Arch. Pharmacol.,
2002
Jan
, 365 (29-37).
2165
Benhorin J
et al.
Variable expression of long QT syndrome among gene carriers from families with five different HERG mutations.
Ann Noninvasive Electrocardiol,
2002
Jan
, 7 (40-6).
2166
Karle CA
et al.
An ion channel 'addicted' to ether, alcohol and cocaine: the HERG potassium channel.
Cardiovasc. Res.,
2002
Jan
, 53 (6-8).
2167
O'leary ME
Inhibition of HERG potassium channels by cocaethylene: a metabolite of cocaine and ethanol.
Cardiovasc. Res.,
2002
Jan
, 53 (59-67).
2168
Verheijck EE
et al.
Atrio-sinus interaction demonstrated by blockade of the rapid delayed rectifier current.
Circulation,
2002
Feb
19
, 105 (880-5).
2169
Moss AJ
et al.
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel.
Circulation,
2002
Feb
19
, 105 (794-9).
2170
Conrath CE
et al.
Gender differences in the long QT syndrome: effects of beta-adrenoceptor blockade.
Cardiovasc. Res.,
2002
Feb
15
, 53 (770-6).
2171
Ficker E
et al.
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
J. Biol. Chem.,
2002
Feb
15
, 277 (4989-98).
2172
Witchel HJ
et al.
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.
FEBS Lett.,
2002
Feb
13
, 512 (59-66).
2173
Thomas D
et al.
The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.
J. Pharmacol. Exp. Ther.,
2002
Feb
, 300 (543-8).
2174
Weerapura M
et al.
Dofetilide block involves interactions with open and inactivated states of HERG channels.
Pflugers Arch.,
2002
Feb
, 443 (520-31).
2175
Ohya S
et al.
Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle.
Am. J. Physiol. Gastrointest. Liver Physiol.,
2002
Feb
, 282 (G277-87).
2176
Baxter DF
et al.
A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels.
,
2002
Feb
, 7 (79-85).
2177
Roti EC
et al.
Interaction with GM130 during HERG ion channel trafficking. Disruption by type 2 congenital long QT syndrome mutations. Human Ether-à-go-go-Related Gene.
J. Biol. Chem.,
2002
Dec
6
, 277 (47779-85).
2178
Paulussen A
et al.
A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency.
J. Biol. Chem.,
2002
Dec
13
, 277 (48610-6).
2179
Kushida S
et al.
Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.
Eur. J. Pharmacol.,
2002
Dec
13
, 457 (19-27).
2180
Liu W
et al.
KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population.
Hum. Mutat.,
2002
Dec
, 20 (475-6).
2181
Gonzalez T
et al.
Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block.
Br. J. Pharmacol.,
2002
Dec
, 137 (1269-79).
2182
Wimmers S
et al.
Biophysical properties of heteromultimeric erg K+ channels.
Pflugers Arch.,
2002
Dec
, 445 (423-30).
2183
Pietilä E
et al.
Association between HERG K897T polymorphism and QT interval in middle-aged Finnish women.
J. Am. Coll. Cardiol.,
2002
Aug
7
, 40 (511-4).
2184
Cavalli A
et al.
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
J. Med. Chem.,
2002
Aug
29
, 45 (3844-53).
2185
Kongsamut S
et al.
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
Eur. J. Pharmacol.,
2002
Aug
16
, 450 (37-41).
2186
Becchetti A
et al.
The functional properties of the human ether-à-go-go-like (HELK2) K+ channel.
Eur. J. Neurosci.,
2002
Aug
, 16 (415-28).
2187
Isbrandt D
et al.
Identification and functional characterization of a novel KCNE2 (MiRP1) mutation that alters HERG channel kinetics.
J. Mol. Med.,
2002
Aug
, 80 (524-32).
2188
Xu X
et al.
Increasing I(Ks) corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy.
Am. J. Physiol. Heart Circ. Physiol.,
2002
Aug
, 283 (H664-70).
2189
Yang P
et al.
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.
Circulation,
2002
Apr
23
, 105 (1943-8).
2190
Cayabyab FS
et al.
Regulation of an ERG K+ current by Src tyrosine kinase.
J. Biol. Chem.,
2002
Apr
19
, 277 (13673-81).
2191
Kagan A
et al.
14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity.
EMBO J.,
2002
Apr
15
, 21 (1889-98).
2192
Weerapura M
et al.
A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?
J. Physiol. (Lond.),
2002
Apr
1
, 540 (15-27).
2193
Leurs R
et al.
H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects.
Clin. Exp. Allergy,
2002
Apr
, 32 (489-98).
2194
Hayashi K
et al.
Characterization of a novel missense mutation E637K in the pore-S6 loop of HERG in a patient with long QT syndrome.
Cardiovasc. Res.,
2002
Apr
, 54 (67-76).
2195
Cheng CS
et al.
A high-throughput HERG potassium channel function assay: an old assay with a new look.
,
2002
, 28 (177-91).
2196
De Ponti F
et al.
Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
,
2002
, 25 (263-86).
2197
Sauviat MP
et al.
[Cardiotoxicity of lindane, a gamma isomer of hexachlorocyclohexane]
J. Soc. Biol.,
2002
, 196 (339-48).
2198
Fontana L
et al.
Long-term modulation of HERG channel gating in hypoxia.
Biochem. Biophys. Res. Commun.,
2001
Sep
7
, 286 (857-62).
2199
Chen J
et al.
The S4-S5 linker couples voltage sensing and activation of pacemaker channels.
Proc. Natl. Acad. Sci. U.S.A.,
2001
Sep
25
, 98 (11277-82).
2200
Finlayson K
et al.
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
Eur. J. Pharmacol.,
2001
Oct
26
, 430 (147-8).
2201
Ishii K
et al.
An amino acid residue whose change by mutation affects drug binding to the HERG channel.
FEBS Lett.,
2001
Oct
12
, 506 (191-5).
2202
Pond AL
et al.
ERG proteins and functional cardiac I(Kr) channels in rat, mouse, and human heart.
Trends Cardiovasc. Med.,
2001
Oct
, 11 (286-94).
2203
Ferreira S
et al.
Effects of cocaine and its major metabolites on the HERG-encoded potassium channel.
J. Pharmacol. Exp. Ther.,
2001
Oct
, 299 (220-6).
2204
Kang J
et al.
Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.
J. Pharmacol. Exp. Ther.,
2001
Oct
, 299 (290-6).
2205
Tang W
et al.
Development and evaluation of high throughput functional assay methods for HERG potassium channel.
,
2001
Oct
, 6 (325-31).
2206
Perkiömäki JS
et al.
Heart rate variability in patients with congenital long QT syndrome.
Ann Noninvasive Electrocardiol,
2001
Oct
, 6 (298-304).
2207
Franco D
et al.
Divergent expression of delayed rectifier K(+) channel subunits during mouse heart development.
Cardiovasc. Res.,
2001
Oct
, 52 (65-75).
2208
Wang J
et al.
Phospholipid metabolite 1-palmitoyl-lysophosphatidylcholine enhances human ether-a-go-go-related gene (HERG) K(+) channel function.
Circulation,
2001
Nov
27
, 104 (2645-8).
2209
Taglialatela M
et al.
Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells by some second-generation H(1) receptor antagonists through blockade of store-operated Ca(2+) channels (SOCs).
Biochem. Pharmacol.,
2001
Nov
1
, 62 (1229-38).
2210
Larsen LA
et al.
Automated mutation screening using dideoxy fingerprinting and capillary array electrophoresis.
Hum. Mutat.,
2001
Nov
, 18 (451-7).
2211
Ko YL
et al.
Linkage and mutation analysis in two Taiwanese families with long QT syndrome.
J. Formos. Med. Assoc.,
2001
Nov
, 100 (767-71).
2212
Imai T
et al.
Effects of different types of K+ channel modulators on the spontaneous myogenic contraction of guinea-pig urinary bladder smooth muscle.
Acta Physiol. Scand.,
2001
Nov
, 173 (323-33).
2213
Yang T
et al.
Drug block of I(kr): model systems and relevance to human arrhythmias.
J. Cardiovasc. Pharmacol.,
2001
Nov
, 38 (737-44).
2214
Bachmann A
et al.
Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Naunyn Schmiedebergs Arch. Pharmacol.,
2001
Nov
, 364 (472-8).
2215
Cui J
et al.
Analysis of the cyclic nucleotide binding domain of the HERG potassium channel and interactions with KCNE2.
J. Biol. Chem.,
2001
May
18
, 276 (17244-51).
2216
Thomas D
et al.
High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
J. Pharmacol. Exp. Ther.,
2001
May
, 297 (753-61).
2218
Vandenberg JI
et al.
HERG K+ channels: friend and foe.
Trends Pharmacol. Sci.,
2001
May
, 22 (240-6).
2219
Chevalier P
et al.
Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates.
Cardiovasc. Res.,
2001
May
, 50 (386-98).
2220
Clancy CE
et al.
Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death.
Cardiovasc. Res.,
2001
May
, 50 (301-13).
2221
Zhang S
et al.
Cocaine blocks HERG, but not KvLQT1+minK, potassium channels.
Mol. Pharmacol.,
2001
May
, 59 (1069-76).
2222
Lupoglazoff JM
et al.
[T wave abnormalities on Holter monitoring of congenital long QT syndrome: phenotypic marker of a mutation of LQT2 (HERG)]
Arch Mal Coeur Vaiss,
2001
May
, 94 (470-8).
2223
Zehelein J
et al.
Molecular cloning and expression of cERG, the ether à go-go-related gene from canine myocardium.
Pflugers Arch.,
2001
May
, 442 (188-91).
2224
Kamiya K
et al.
Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current.
Circulation,
2001
Mar
6
, 103 (1317-24).
2225
Korolkova YV
et al.
An ERG channel inhibitor from the scorpion Buthus eupeus.
J. Biol. Chem.,
2001
Mar
30
, 276 (9868-76).
2226
Brundel BJ
et al.
Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels.
J. Am. Coll. Cardiol.,
2001
Mar
1
, 37 (926-32).
2227
Johnson JP
et al.
A novel extracellular calcium sensing mechanism in voltage-gated potassium ion channels.
J. Neurosci.,
2001
Jun
15
, 21 (4143-53).
2228
Wainger BJ
et al.
Molecular mechanism of cAMP modulation of HCN pacemaker channels.
Nature,
2001
Jun
14
, 411 (805-10).
2229
Ohyama H
et al.
Inhibition of cardiac delayed rectifier K+ currents by an antisense oligodeoxynucleotide against IsK (minK) and over-expression of IsK mutant D77N in neonatal mouse hearts.
Pflugers Arch.,
2001
Jun
, 442 (329-35).
2230
De Backer MD
et al.
Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray.
Antimicrob. Agents Chemother.,
2001
Jun
, 45 (1660-70).
2231
Mazhari R
et al.
Molecular interactions between two long-QT syndrome gene products, HERG and KCNE2, rationalized by in vitro and in silico analysis.
Circ. Res.,
2001
Jul
6
, 89 (33-8).
2232
Lupoglazoff JM
et al.
Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block.
Circ. Res.,
2001
Jul
20
, 89 (E16-21).
2233
Saganich MJ
et al.
Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain.
J. Neurosci.,
2001
Jul
1
, 21 (4609-24).
2234
Aydar E
et al.
Functional characterization of the C-terminus of the human ether-à-go-go-related gene K(+) channel (HERG).
J. Physiol. (Lond.),
2001
Jul
1
, 534 (1-14).
2235
Shuba YM
et al.
Testosterone-mediated modulation of HERG blockade by proarrhythmic agents.
Biochem. Pharmacol.,
2001
Jul
1
, 62 (41-9).
2236
Yamakura T
et al.
Differential effects of general anesthetics on G protein-coupled inwardly rectifying and other potassium channels.
Anesthesiology,
2001
Jul
, 95 (144-53).
2237
Schwartz PJ
et al.
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.
Circulation,
2001
Jan
2
, 103 (89-95).
2238
Bajanowski T
et al.
Prolonged QT interval and sudden infant death--report of two cases.
Forensic Sci. Int.,
2001
Jan
1
, 115 (147-53).
2239
Kang J
et al.
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.
Mol. Pharmacol.,
2001
Jan
, 59 (122-6).
2240
Wimmers S
et al.
Erg1, erg2 and erg3 K channel subunits are able to form heteromultimers.
Pflugers Arch.,
2001
Jan
, 441 (450-5).
2241
Paul AA
et al.
Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Biochem. Biophys. Res. Commun.,
2001
Feb
9
, 280 (1243-50).
2242
Brundel BJ
et al.
Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation.
Circulation,
2001
Feb
6
, 103 (684-90).
2243
Lupoglazoff JM
et al.
Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations.
Circulation,
2001
Feb
27
, 103 (1095-101).
2244
Finlayson K
et al.
[3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?
Eur. J. Pharmacol.,
2001
Feb
2
, 412 (203-12).
2245
Hofmann G
et al.
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1.
J. Biol. Chem.,
2001
Feb
16
, 276 (4923-31).
2246
Yoshida H
et al.
Bradycardia-induced long QT syndrome caused by a de novo missense mutation in the S2-S3 inner loop of HERG.
Am. J. Med. Genet.,
2001
Feb
1
, 98 (348-52).
2247
Karle CA
et al.
Antiarrhythmic drug carvedilol inhibits HERG potassium channels.
Cardiovasc. Res.,
2001
Feb
1
, 49 (361-70).
2248
O'Leary ME
Inhibition of human ether-a-go-go potassium channels by cocaine.
Mol. Pharmacol.,
2001
Feb
, 59 (269-77).
2249
González T
et al.
Effects of bupivacaine and a novel local anesthetic, IQB-9302, on human cardiac K+ channels.
J. Pharmacol. Exp. Ther.,
2001
Feb
, 296 (573-83).
2250
Li BX
et al.
Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes.
Acta Pharmacol. Sin.,
2001
Feb
, 22 (125-31).
2251
Bian J
et al.
HERG K(+) channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate.
Circ. Res.,
2001
Dec
7
, 89 (1168-76).
2252
Lu Y
et al.
Effects of premature stimulation on HERG K(+) channels.
J. Physiol. (Lond.),
2001
Dec
15
, 537 (843-51).
2253
Potet F
et al.
Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel.
J. Pharmacol. Exp. Ther.,
2001
Dec
, 299 (1007-12).
2254
Paul AA
et al.
Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes.
J. Pharm. Pharmacol.,
2001
Dec
, 53 (1671-8).
2255
Ficker E
et al.
Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Mol. Pharmacol.,
2001
Dec
, 60 (1343-8).
2256
Huang FD
et al.
Long-QT syndrome-associated missense mutations in the pore helix of the HERG potassium channel.
Circulation,
2001
Aug
28
, 104 (1071-5).
2257
Kang J
et al.
The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel.
Biochem. Biophys. Res. Commun.,
2001
Aug
24
, 286 (499-504).
2258
Larsen LA
et al.
Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome.
Clin. Chem.,
2001
Aug
, 47 (1390-5).
2259
Kamiya K
et al.
Open channel block of HERG K(+) channels by vesnarinone.
Mol. Pharmacol.,
2001
Aug
, 60 (244-53).
2260
Moschèn
et al.
Effects of gallium and mercury ions on transport systems.
J. Dent. Res.,
2001
Aug
, 80 (1753-7).
2261
Hoppe UC
et al.
Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1.
Proc. Natl. Acad. Sci. U.S.A.,
2001
Apr
24
, 98 (5335-40).
2262
Hondeghem LM
et al.
Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
Circulation,
2001
Apr
17
, 103 (2004-13).
2263
Schledermann W
et al.
Modulation of rat erg1, erg2, erg3 and HERG K+ currents by thyrotropin-releasing hormone in anterior pituitary cells via the native signal cascade.
J. Physiol. (Lond.),
2001
Apr
1
, 532 (143-63).
2264
Bérubé J
et al.
Hydrogen peroxide modifies the kinetics of HERG channel expressed in a mammalian cell line.
J. Pharmacol. Exp. Ther.,
2001
Apr
, 297 (96-102).
2265
Towbin JA
et al.
Genotype and severity of long QT syndrome.
Drug Metab. Dispos.,
2001
Apr
, 29 (574-9).
2266
Caballero R
et al.
Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization.
Mol. Pharmacol.,
2001
Apr
, 59 (825-36).
2267
Mergenthaler J
et al.
Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel.
Naunyn Schmiedebergs Arch. Pharmacol.,
2001
Apr
, 363 (472-80).
2268
Kaufman ES
et al.
Electrocardiographic prediction of abnormal genotype in congenital long QT syndrome: experience in 101 related family members.
J. Cardiovasc. Electrophysiol.,
2001
Apr
, 12 (455-61).
2269
Osypenko VM
et al.
[Effects of sex hormones on HERG potassium channels expressed in Xenopus oocytes]
,
2001
, 47 (24-31).
2270
Osypenko VM
et al.
[Blockade of HERG K+ channels expressed in Xenopus oocytes by antipsychotic agents]
,
2001
, 47 (17-25).
2271
Allan WC
et al.
Long QT syndrome in children: the value of rate corrected QT interval and DNA analysis as screening tests in the general population.
,
2001
, 8 (173-7).
2272
Osypenko VM
et al.
[Testosterone modulation of HERG potassium channel blockade induced by neuroleptics]
,
2001
, 47 (11-8).
2273
Antzelevitch C
Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
,
2001
, 34 Suppl (177-81).
2274
Li H
et al.
Current concepts in long QT syndrome.
Pediatr Cardiol,
2000 Nov-Dec
, 21 (542-50).
2275
Drici MD
et al.
Cardiac K+ channels and drug-acquired long QT syndrome.
Therapie,
2000 Jan-Feb
, 55 (185-93).
2276
Georgijević Milić L
[Molecular genetics in the hereditary form of long QT syndrome]
Med. Pregl.,
2000 Jan-Feb
, 53 (51-4).
2277
Chouabe C
et al.
Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs.
Therapie,
2000 Jan-Feb
, 55 (195-202).
2278
Nakajima T
et al.
Characterization of S818L mutation in HERG C-terminus in LQT2. Modification of activation-deactivation gating properties.
FEBS Lett.,
2000
Sep
15
, 481 (197-203).
2279
Tinel N
et al.
M-type KCNQ2-KCNQ3 potassium channels are modulated by the KCNE2 subunit.
FEBS Lett.,
2000
Sep
1
, 480 (137-41).
2280
Yang IC
et al.
Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels.
J. Pharmacol. Exp. Ther.,
2000
Sep
, 294 (955-62).
2281
Buckley NA
et al.
Cardiovascular adverse effects of antipsychotic drugs.
,
2000
Sep
, 23 (215-28).
2282
Mitcheson JS
et al.
A structural basis for drug-induced long QT syndrome.
Proc. Natl. Acad. Sci. U.S.A.,
2000
Oct
24
, 97 (12329-33).
2283
Bischoff U
et al.
Effects of fluoroquinolones on HERG currents.
Eur. J. Pharmacol.,
2000
Oct
20
, 406 (341-3).
2284
Drolet B
et al.
Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders.
Circulation,
2000
Oct
17
, 102 (1883-5).
2285
Ficker E
et al.
Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome.
Am. J. Physiol. Heart Circ. Physiol.,
2000
Oct
, 279 (H1748-56).
2286
Walker BD
et al.
Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel.
Cardiovasc. Res.,
2000
Oct
, 48 (44-58).
2287
Witchel HJ
et al.
Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Clin. Exp. Pharmacol. Physiol.,
2000
Oct
, 27 (753-66).
2288
Numaguchi H
et al.
Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
Circ. Res.,
2000
Nov
24
, 87 (1012-8).
2289
Taglialatela M
et al.
Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine.
Br. J. Pharmacol.,
2000
Nov
, 131 (1081-8).
2290
Kuryshev YA
et al.
Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.
J. Pharmacol. Exp. Ther.,
2000
Nov
, 295 (614-20).
2291
Ulens C
et al.
Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation.
FEBS Lett.,
2000
May
26
, 474 (111-5).
2292
Emmi A
et al.
Do glia have heart? Expression and functional role for ether-a-go-go currents in hippocampal astrocytes.
J. Neurosci.,
2000
May
15
, 20 (3915-25).
2293
Hayashi K
et al.
Identical twins with long QT syndrome associated with a missense mutation in the S4 region of the HERG.
,
2000
May
, 41 (399-404).
2294
Paulussen A
et al.
Analysis of the human KCNH2(HERG) gene: identification and characterization of a novel mutation Y667X associated with long QT syndrome and a non-pathological 9 bp insertion.
Hum. Mutat.,
2000
May
, 15 (483).
2295
Bowles NE
et al.
The "final common pathway" hypothesis and inherited cardiovascular disease. The role of cytoskeletal proteins in dilated cardiomyopathy.
,
2000
May
, 25 (168-75).
2296
Tamargo J
Drug-induced torsade de pointes: from molecular biology to bedside.
Jpn. J. Pharmacol.,
2000
May
, 83 (1-19).
2297
Stramba-Badiale M
et al.
Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: a key to sudden death during sleep?
Ital Heart J,
2000
May
, 1 (323-8).
2298
Kuryshev YA
et al.
KChAP as a chaperone for specific K(+) channels.
Am. J. Physiol., Cell Physiol.,
2000
May
, 278 (C931-41).
2299
Kang J
et al.
High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide.
Eur. J. Pharmacol.,
2000
Mar
31
, 392 (137-40).
2300
Lees-Miller JP
et al.
Novel gain-of-function mechanism in K(+) channel-related long-QT syndrome: altered gating and selectivity in the HERG1 N629D mutant.
Circ. Res.,
2000
Mar
17
, 86 (507-13).
2301
Robertson GA
LQT2 : amplitude reduction and loss of selectivity in the tail that wags the HERG channel.
Circ. Res.,
2000
Mar
17
, 86 (492-3).
2302
Caballero R
et al.
Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents.
Circulation,
2000
Mar
14
, 101 (1199-205).
2303
Mitcheson JS
et al.
Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
J. Gen. Physiol.,
2000
Mar
, 115 (229-40).
2304
Overholt JL
et al.
HERG-Like potassium current regulates the resting membrane potential in glomus cells of the rabbit carotid body.
J. Neurophysiol.,
2000
Mar
, 83 (1150-7).
2305
Wulfsen I
et al.
Expression of mRNA for voltage-dependent and inward-rectifying K channels in GH3/B6 cells and rat pituitary.
J. Neuroendocrinol.,
2000
Mar
, 12 (263-72).
2306
St-Pierre J
et al.
The distinct HERG missense mutation L564P causes long QT syndrome in one French Canadian family.
Can J Cardiol,
2000
Mar
, 16 (307-12).
2307
Cui J
et al.
Cyclic AMP regulates the HERG K(+) channel by dual pathways.
Curr. Biol.,
2000
Jun
1
, 10 (671-4).
2308
Sanchez-Chapula JA
et al.
Altered gating of HERG potassium channels by cobalt and lanthanum.
Pflugers Arch.,
2000
Jun
, 440 (264-74).
2309
Wang J
et al.
Dynamic control of deactivation gating by a soluble amino-terminal domain in HERG K(+) channels.
J. Gen. Physiol.,
2000
Jun
, 115 (749-58).
2310
Jahr S
et al.
New missense mutation (G626V) in the predicted selectivity filter of the HERG channel associated with familial long QT syndrome.
Hum. Mutat.,
2000
Jun
, 15 (584).
2311
Piippo K
et al.
Homozygosity for a HERG potassium channel mutation causes a severe form of long QT syndrome: identification of an apparent founder mutation in the Finns.
J. Am. Coll. Cardiol.,
2000
Jun
, 35 (1919-25).
2312
Laitinen P
et al.
Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects.
Hum. Mutat.,
2000
Jun
, 15 (580-1).
2313
Hancox JC
et al.
Psychotropic drugs, HERG, and the heart.
Lancet,
2000
Jul
29
, 356 (428).
2314
Geelen P
et al.
Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
Circulation,
2000
Jul
18
, 102 (275-7).
2315
Weerapura M
et al.
State-dependent barium block of wild-type and inactivation-deficient HERG channels in Xenopus oocytes.
J. Physiol. (Lond.),
2000
Jul
15
, 526 Pt 2 (265-78).
2316
Chiang CE
et al.
The long QT syndromes: genetic basis and clinical implications.
J. Am. Coll. Cardiol.,
2000
Jul
, 36 (1-12).
2317
Kiehn J
Regulation of the cardiac repolarizing HERG potassium channel by protein kinase A.
Trends Cardiovasc. Med.,
2000
Jul
, 10 (205-9).
2318
Crociani O
et al.
erg gene(s) expression during development of the nervous and muscular system of quail embryos.
Mech. Dev.,
2000
Jul
, 95 (239-43).
2319
Cavero I
et al.
Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.
,
2000
Jul
, 1 (947-73).
2320
Viloria CG
et al.
Differential effects of amino-terminal distal and proximal domains in the regulation of human erg K(+) channel gating.
Biophys. J.,
2000
Jul
, 79 (231-46).
2321
Katayama Y
et al.
Inhibitory effects of vesnarinone on cloned cardiac delayed rectifier K(+) channels expressed in a mammalian cell line.
J. Pharmacol. Exp. Ther.,
2000
Jul
, 294 (339-46).
2322
Fleischhauer R
et al.
Ultrafast inactivation causes inward rectification in a voltage-gated K(+) channel from Caenorhabditis elegans.
J. Neurosci.,
2000
Jan
15
, 20 (511-20).
2323
Schroeder BC
et al.
A constitutively open potassium channel formed by KCNQ1 and KCNE3.
Nature,
2000
Jan
13
, 403 (196-9).
2324
Terai T
et al.
Effects of external acidosis on HERG current expressed in Xenopus oocytes.
J. Mol. Cell. Cardiol.,
2000
Jan
, 32 (11-21).
2325
Crumb WJ
Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.
J. Pharmacol. Exp. Ther.,
2000
Jan
, 292 (261-4).
2326
Pond AL
et al.
Expression of distinct ERG proteins in rat, mouse, and human heart. Relation to functional I(Kr) channels.
J. Biol. Chem.,
2000
Feb
25
, 275 (5997-6006).
2327
Lees-Miller JP
et al.
Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites.
Mol. Pharmacol.,
2000
Feb
, 57 (367-74).
2328
Larsen LA
et al.
Long QT syndrome with a high mortality rate caused by a novel G572R missense mutation in KCNH2.
Clin. Genet.,
2000
Feb
, 57 (125-30).
2329
Tinel N
et al.
KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel.
EMBO J.,
2000
Dec
1
, 19 (6326-30).
2330
Rosati B
et al.
Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: the role of HERG K(+) channels in firing and release.
FASEB J.,
2000
Dec
, 14 (2601-10).
2331
Higashida H
et al.
Both linopirdine- and WAY123,398-sensitive components of I K(M,ng) are modulated by cyclic ADP ribose in NG108-15 cells.
Pflugers Arch.,
2000
Dec
, 441 (228-34).
2332
January CT
et al.
Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2.
J. Cardiovasc. Electrophysiol.,
2000
Dec
, 11 (1413-8).
2333
Gögelein H
et al.
Inhibition of IKs channels by HMR 1556.
Naunyn Schmiedebergs Arch. Pharmacol.,
2000
Dec
, 362 (480-8).
2334
Cherubini A
et al.
HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium.
Br. J. Cancer,
2000
Dec
, 83 (1722-9).
2335
Ficker E
et al.
Retention in the endoplasmic reticulum as a mechanism of dominant-negative current suppression in human long QT syndrome.
J. Mol. Cell. Cardiol.,
2000
Dec
, 32 (2327-37).
2336
Shimizu W
et al.
Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome.
Circulation,
2000
Aug
8
, 102 (706-12).
2337
Tie H
et al.
Inhibition of HERG potassium channels by the antimalarial agent halofantrine.
Br. J. Pharmacol.,
2000
Aug
, 130 (1967-75).
2338
Kagan A
et al.
The dominant negative LQT2 mutation A561V reduces wild-type HERG expression.
J. Biol. Chem.,
2000
Apr
14
, 275 (11241-8).
2339
Vereecke J
et al.
The effect of external pH on the delayed rectifying K+ current in cardiac ventricular myocytes.
Pflugers Arch.,
2000
Apr
, 439 (739-51).
2340
Dai DZ
Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic therapy.
Acta Pharmacol. Sin.,
2000
Apr
, 21 (289-95).
2341
Jo SH
et al.
Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline.
Br. J. Pharmacol.,
2000
Apr
, 129 (1474-80).
2342
Burashnikov A
et al.
Block of I(Ks) does not induce early afterdepolarization activity but promotes beta-adrenergic agonist-induced delayed afterdepolarization activity.
J. Cardiovasc. Electrophysiol.,
2000
Apr
, 11 (458-65).
2343
Leenhardt A
et al.
[Present concepts of congenital long QT syndrome]
Arch Mal Coeur Vaiss,
2000
Apr
, 93 (17-21).
2344
Overholt JL
et al.
Chemosensing at the carotid body. Involvement of a HERG-like potassium current in glomus cells.
Adv. Exp. Med. Biol.,
2000
, 475 (241-8).
2345
Thomas D
et al.
Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A.
J. Biol. Chem.,
1999
Sep
24
, 274 (27457-62).
2346
Hoorntje T
et al.
Homozygous premature truncation of the HERG protein : the human HERG knockout.
Circulation,
1999
Sep
21
, 100 (1264-7).
2347
Selyanko AA
et al.
Two types of K(+) channel subunit, Erg1 and KCNQ2/3, contribute to the M-like current in a mammalian neuronal cell.
J. Neurosci.,
1999
Sep
15
, 19 (7742-56).
2348
Walker BD
et al.
Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.
Br. J. Pharmacol.,
1999
Sep
, 128 (444-50).
2349
Swan H
et al.
Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects.
J. Am. Coll. Cardiol.,
1999
Sep
, 34 (823-9).
2350
Teschemacher AG
et al.
Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.
Br. J. Pharmacol.,
1999
Sep
, 128 (479-85).
2351
Wang HZ
et al.
Inactivation gating determines nicotine blockade of human HERG channels.
Am. J. Physiol.,
1999
Sep
, 277 (H1081-8).
2352
Yoshida H
et al.
Characterization of a novel missense mutation in the pore of HERG in a patient with long QT syndrome.
J. Cardiovasc. Electrophysiol.,
1999
Sep
, 10 (1262-70).
2353
Lee-Chen GJ
et al.
Romano-Ward long QT syndrome: identification of a HERG mutation in a Taiwanese kindred.
J. Formos. Med. Assoc.,
1999
Sep
, 98 (649-52).
2354
Wattanasirichaigoon D
et al.
Sodium channel abnormalities are infrequent in patients with long QT syndrome: identification of two novel SCN5A mutations.
Am. J. Med. Genet.,
1999
Oct
29
, 86 (470-6).
2355
Zhou Z
et al.
Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects.
J. Biol. Chem.,
1999
Oct
29
, 274 (31123-6).
2356
Jiang M
et al.
Mechanism for the effects of extracellular acidification on HERG-channel function.
Am. J. Physiol.,
1999
Oct
, 277 (H1283-92).
2357
Robbins J
et al.
Genetic variation affecting heart rate in Drosophila melanogaster.
Genet. Res.,
1999
Oct
, 74 (121-8).
2358
Sepp R
et al.
[Molecular genetics of the long QT syndrome: clinical aspects]
,
1999
Nov
21
, 140 (2633-8).
2359
Roden DM
et al.
A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology.
Cardiovasc. Res.,
1999
Nov
, 44 (242-6).
2360
Nakajima T
et al.
Voltage-shift of the current activation in HERG S4 mutation (R534C) in LQT2.
Cardiovasc. Res.,
1999
Nov
, 44 (283-93).
2361
Johnson JP
et al.
Enhancement of HERG K+ currents by Cd2+ destabilization of the inactivated state.
Biophys. J.,
1999
Nov
, 77 (2534-41).
2362
Furutani M
et al.
Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel.
Circulation,
1999
May
4
, 99 (2290-4).
2363
Zhang S
et al.
Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.
Circ. Res.,
1999
May
14
, 84 (989-98).
2364
Viswanathan PC
et al.
Pause induced early afterdepolarizations in the long QT syndrome: a simulation study.
Cardiovasc. Res.,
1999
May
, 42 (530-42).
2365
Walker BD
et al.
Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate.
Br. J. Pharmacol.,
1999
May
, 127 (243-51).
2366
Berthet M
et al.
C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence.
Circulation,
1999
Mar
23
, 99 (1464-70).
2367
Chen Q
et al.
Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome.
Circulation,
1999
Mar
16
, 99 (1344-7).
2368
Sansom MS
Ion channels: structure of a molecular brake.
Curr. Biol.,
1999
Mar
11
, 9 (R173-5).
2369
Nuss HB
et al.
Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes.
J. Clin. Invest.,
1999
Mar
, 103 (889-96).
2370
Pancrazio JJ
et al.
A role for inwardly rectifying K+ channels in differentiation of NG108-15 neuroblastoma x glioma cells.
J. Neurobiol.,
1999
Mar
, 38 (466-74).
2371
Kiehn J
et al.
Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
Naunyn Schmiedebergs Arch. Pharmacol.,
1999
Mar
, 359 (212-9).
2372
Chachin M
et al.
Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible effect on HERG channel.
Eur. J. Pharmacol.,
1999
Jun
25
, 374 (457-60).
2373
Jo SH
et al.
Blockade of HERG channels expressed in Xenopus oocytes by external H+.
Pflugers Arch.,
1999
Jun
, 438 (23-9).
2374
Zhou Z
et al.
Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole.
J. Cardiovasc. Electrophysiol.,
1999
Jun
, 10 (836-43).
2375
Fan JS
et al.
Effects of outer mouth mutations on hERG channel function: a comparison with similar mutations in the Shaker channel.
Biophys. J.,
1999
Jun
, 76 (3128-40).
2376
Schäfer R
et al.
The erg-like potassium current in rat lactotrophs.
J. Physiol. (Lond.),
1999
Jul
15
, 518 ( Pt 2) (401-16).
2377
Yap YG
et al.
Arrhythmogenic mechanisms of non-sedating antihistamines.
Clin. Exp. Allergy,
1999
Jul
, 29 Suppl 3 (174-81).
2378
Kiehn J
et al.
Pathways of HERG inactivation.
Am. J. Physiol.,
1999
Jul
, 277 (H199-210).
2379
Anumonwo JM
et al.
Proton and zinc effects on HERG currents.
Biophys. J.,
1999
Jul
, 77 (282-98).
2380
Taglialatela M
et al.
Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity.
Clin. Exp. Allergy,
1999
Jul
, 29 Suppl 3 (182-9).
2381
Meves H
et al.
Separation of M-like current and ERG current in NG108-15 cells.
Br. J. Pharmacol.,
1999
Jul
, 127 (1213-23).
2382
Schwarz JR
et al.
Ionic mechanisms underlying TRH-induced prolactin secretion in rat lactotrophs.
,
1999
Jan
, 85 (195-204).
2383
Diochot S
et al.
Effects of phrixotoxins on the Kv4 family of potassium channels and implications for the role of Ito1 in cardiac electrogenesis.
Br. J. Pharmacol.,
1999
Jan
, 126 (251-63).
2384
El-Sherif N
et al.
The long QT syndrome and torsade de pointes.
Pacing Clin Electrophysiol,
1999
Jan
, 22 (91-110).
2385
Petrecca K
et al.
N-linked glycosylation sites determine HERG channel surface membrane expression.
J. Physiol. (Lond.),
1999
Feb
15
, 515 ( Pt 1) (41-8).
2386
Sanguinetti MC
et al.
Mutations of the S4-S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes.
J. Physiol. (Lond.),
1999
Feb
1
, 514 ( Pt 3) (667-75).
2387
Tan HL
et al.
Long-term (subacute) potassium treatment in congenital HERG-related long QT syndrome (LQTS2).
J. Cardiovasc. Electrophysiol.,
1999
Feb
, 10 (229-33).
2388
Po SS
et al.
Modulation of HERG potassium channels by extracellular magnesium and quinidine.
J. Cardiovasc. Pharmacol.,
1999
Feb
, 33 (181-5).
2389
Wilde AA
et al.
Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1).
J. Am. Coll. Cardiol.,
1999
Feb
, 33 (327-32).
2390
Shimizu W
et al.
Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome.
J. Cardiovasc. Electrophysiol.,
1999
Feb
, 10 (154-64).
2391
Davis MW
et al.
A mutation in the C. elegans EXP-2 potassium channel that alters feeding behavior.
Science,
1999
Dec
24
, 286 (2501-4).
2392
Drolet B
et al.
Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current.
J. Cardiovasc. Electrophysiol.,
1999
Dec
, 10 (1597-604).
2393
Dun W
et al.
Allosteric effects of mutations in the extracellular S5-P loop on the gating and ion permeation properties of the hERG potassium channel.
Pflugers Arch.,
1999
Dec
, 439 (141-9).
2394
Akbarali HI
et al.
Role of HERG-like K(+) currents in opossum esophageal circular smooth muscle.
Am. J. Physiol.,
1999
Dec
, 277 (C1284-90).
2395
Jiang M
et al.
Use-dependent 'agonist' effect of azimilide on the HERG channel.
J. Pharmacol. Exp. Ther.,
1999
Dec
, 291 (1324-36).
2396
Taglialatela M
et al.
Modulation of the K(+) channels encoded by the human ether-a-gogo-related gene-1 (hERG1) by nitric oxide.
Mol. Pharmacol.,
1999
Dec
, 56 (1298-308).
2397
Ulens C
et al.
Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents.
Cardiovasc. Res.,
1999
Dec
, 44 (568-78).
2398
Wang H
et al.
Inactivation block of the HERG human cardiac K+ channels by RP58866.
Br. J. Pharmacol.,
1999
Aug
, 127 (1899-907).
2399
Bérubé J
et al.
Modulation of HERG potassium channel properties by external pH.
Pflugers Arch.,
1999
Aug
, 438 (419-22).
2400
Bianchi L
et al.
Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome.
Hum. Mol. Genet.,
1999
Aug
, 8 (1499-507).
2401
Arcangeli A
et al.
Modulation of HERG current and herg gene expression during retinoic acid treatment of human neuroblastoma cells: potentiating effects of BDNF.
J. Neurobiol.,
1999
Aug
, 40 (214-25).
2402
Chen J
et al.
Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation.
J. Biol. Chem.,
1999
Apr
9
, 274 (10113-8).
2403
Ganetzky B
et al.
The eag family of K+ channels in Drosophila and mammals.
Ann. N. Y. Acad. Sci.,
1999
Apr
30
, 868 (356-69).
2404
Sanguinetti MC
Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia.
Ann. N. Y. Acad. Sci.,
1999
Apr
30
, 868 (406-13).
2405
Matsuoka R
et al.
A mitochondrial DNA mutation cosegregates with the pathophysiological U wave.
Biochem. Biophys. Res. Commun.,
1999
Apr
2
, 257 (228-33).
2406
Abbott GW
et al.
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
Cell,
1999
Apr
16
, 97 (175-87).
2407
Trudeau MC
et al.
Functional analysis of a mouse brain Elk-type K+ channel.
J. Neurosci.,
1999
Apr
15
, 19 (2906-18).
2408
Ho WK
et al.
Blockade of HERG channels expressed in Xenopus laevis oocytes by external divalent cations.
Biophys. J.,
1999
Apr
, 76 (1959-71).
2409
Johnson JP
et al.
Human ether-à-go-go-related gene K+ channel gating probed with extracellular ca2+. Evidence for two distinct voltage sensors.
J. Gen. Physiol.,
1999
Apr
, 113 (565-80).
2410
Shimizu W
et al.
Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome.
,
1999
, 32 Suppl (177-84).
2411
Mitcheson JS
et al.
Biophysical properties and molecular basis of cardiac rapid and slow delayed rectifier potassium channels.
Cell. Physiol. Biochem.,
1999
, 9 (201-16).
2412
Antzelevitch C
et al.
Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome.
,
1999
, 32 Suppl (158-65).
2413
Jongbloed RJ
et al.
Novel KCNQ1 and HERG missense mutations in Dutch long-QT families.
Hum. Mutat.,
1999
, 13 (301-10).
2414
Waldegger S
et al.
Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed in Xenopus oocytes.
Cell. Physiol. Biochem.,
1999
, 9 (81-9).
2415
Lai LP
et al.
Changes in the mRNA levels of delayed rectifier potassium channels in human atrial fibrillation.
Cardiology,
1999
, 92 (248-55).
2416
Kiehn J
et al.
HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways.
J. Biol. Chem.,
1998
Sep
25
, 273 (25285-91).
2417
Babij P
et al.
Inhibition of cardiac delayed rectifier K+ current by overexpression of the long-QT syndrome HERG G628S mutation in transgenic mice.
Circ. Res.,
1998
Sep
21
, 83 (668-78).
2418
Barros F
et al.
Modulation of human erg K+ channel gating by activation of a G protein-coupled receptor and protein kinase C.
J. Physiol. (Lond.),
1998
Sep
1
, 511 ( Pt 2) (333-46).
2419
Wang Q
et al.
The molecular basis of long QT syndrome and prospects for therapy.
,
1998
Sep
, 4 (382-8).
2420
Kääb S
et al.
Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density.
Circulation,
1998
Oct
6
, 98 (1383-93).
2421
Kupershmidt S
et al.
A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current.
J. Biol. Chem.,
1998
Oct
16
, 273 (27231-5).
2422
Chouabe C
et al.
HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers.
Mol. Pharmacol.,
1998
Oct
, 54 (695-703).
2424
Rosati B
et al.
Sulfonylureas blockade of neural and cardiac HERG channels.
FEBS Lett.,
1998
Nov
27
, 440 (125-30).
2425
Morais Cabral JH
et al.
Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain.
Cell,
1998
Nov
25
, 95 (649-55).
2426
Shimizu W
et al.
Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Circulation,
1998
Nov
24
, 98 (2314-22).
2427
Wang J
et al.
Regulation of deactivation by an amino terminal domain in human ether-à-go-go-related gene potassium channels.
J. Gen. Physiol.,
1998
Nov
, 112 (637-47).
2428
Hancox JC
et al.
Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential.
Pflugers Arch.,
1998
Nov
, 436 (843-53).
2429
Zou A
et al.
A mutation in the pore region of HERG K+ channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation.
J. Physiol. (Lond.),
1998
May
15
, 509 ( Pt 1) (129-37).
2430
Bosch RF
et al.
Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes.
Cardiovasc. Res.,
1998
May
, 38 (441-50).
2431
Arcangeli A
et al.
Long-term exposure to retinoic acid induces the expression of IRK1 channels in HERG channel-endowed neuroblastoma cells.
Biochem. Biophys. Res. Commun.,
1998
Mar
27
, 244 (706-11).
2432
Ho WK
et al.
Voltage-dependent blockade of HERG channels expressed in Xenopus oocytes by external Ca2+ and Mg2+.
J. Physiol. (Lond.),
1998
Mar
15
, 507 ( Pt 3) (631-8).
2433
Ackerman MJ
The long QT syndrome: ion channel diseases of the heart.
Mayo Clin. Proc.,
1998
Mar
, 73 (250-69).
2434
Satler CA
et al.
Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome.
Hum. Genet.,
1998
Mar
, 102 (265-72).
2435
Mitrovic N
et al.
Independent versus coupled inactivation in sodium channels. Role of the domain 2 S4 segment.
J. Gen. Physiol.,
1998
Mar
, 111 (451-62).
2436
Nagai R
et al.
[Molecular genetics of cardiovascular diseases]
Rinsho Byori,
1998
Mar
, 46 (249-57).
2437
Taglialatela M
et al.
Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications.
Biochem. Pharmacol.,
1998
Jun
1
, 55 (1741-6).
2438
Fung D
et al.
RsaI and MaeI intragenic RFLPs in the human HERG gene.
Clin. Genet.,
1998
Jun
, 53 (504).
2439
Pennefather PS
et al.
Idiosyncratic gating of HERG-like K+ channels in microglia.
J. Gen. Physiol.,
1998
Jun
, 111 (795-805).
2440
Zhou W
et al.
HERG-like K+ channels in microglia.
J. Gen. Physiol.,
1998
Jun
, 111 (781-94).
2441
Kanters JK
et al.
Novel donor splice site mutation in the KVLQT1 gene is associated with long QT syndrome.
J. Cardiovasc. Electrophysiol.,
1998
Jun
, 9 (620-4).
2442
Splawski I
et al.
Genomic structure of three long QT syndrome genes: KVLQT1, HERG, and KCNE1.
Genomics,
1998
Jul
1
, 51 (86-97).
2443
Taglialatela M
et al.
Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines.
Mol. Pharmacol.,
1998
Jul
, 54 (113-21).
2444
Lipka LJ
et al.
Differential effects of bupivacaine on cardiac K channels: role of channel inactivation and subunit composition in drug-channel interaction.
J. Cardiovasc. Electrophysiol.,
1998
Jul
, 9 (727-42).
2446
Duggal P
et al.
Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome.
Circulation,
1998
Jan
20
, 97 (142-6).
2447
Busch AE
et al.
Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action.
Br. J. Pharmacol.,
1998
Jan
, 123 (23-30).
2448
Zhou Z
et al.
Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.
Biophys. J.,
1998
Jan
, 74 (230-41).
2449
Ficker E
et al.
Molecular determinants of dofetilide block of HERG K+ channels.
Circ. Res.,
1998
Feb
23
, 82 (386-95).
2450
Bianchi L
et al.
herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells?
Cancer Res.,
1998
Feb
15
, 58 (815-22).
2451
Wang Q
et al.
Genetics, molecular mechanisms and management of long QT syndrome.
Ann. Med.,
1998
Feb
, 30 (58-65).
2452
Hancox JC
et al.
Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation.
Biochem. Biophys. Res. Commun.,
1998
Dec
30
, 253 (719-24).
2453
Engeland B
et al.
Cloning and functional expression of rat ether-à-go-go-like K+ channel genes.
J. Physiol. (Lond.),
1998
Dec
15
, 513 ( Pt 3) (647-54).
2454
Wattanasirichaigoon D
et al.
Molecular genetics of long-QT syndrome.
Curr. Opin. Pediatr.,
1998
Dec
, 10 (628-34).
2455
Nakajima T
et al.
Novel mechanism of HERG current suppression in LQT2: shift in voltage dependence of HERG inactivation.
Circ. Res.,
1998
Aug
24
, 83 (415-22).
2456
Herzberg IM
et al.
Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels.
J. Physiol. (Lond.),
1998
Aug
15
, 511 ( Pt 1) (3-14).
2457
Zhou Z
et al.
HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects.
J. Biol. Chem.,
1998
Aug
14
, 273 (21061-6).
2458
Rampe D
et al.
The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
J. Pharmacol. Exp. Ther.,
1998
Aug
, 286 (788-93).
2459
Eder C
Ion channels in microglia (brain macrophages).
Am. J. Physiol.,
1998
Aug
, 275 (C327-42).
2460
Dumaine R
et al.
Blockade of HERG and Kv1.5 by ketoconazole.
J. Pharmacol. Exp. Ther.,
1998
Aug
, 286 (727-35).
2461
Ackerman MJ
et al.
A novel mutation in KVLQT1 is the molecular basis of inherited long QT syndrome in a near-drowning patient's family.
Pediatr. Res.,
1998
Aug
, 44 (148-53).
2462
Li H
et al.
New mutations in the KVLQT1 potassium channel that cause long-QT syndrome.
Circulation,
1998
Apr
7
, 97 (1264-9).
2463
Meyer R
et al.
Characterization of an eag-like potassium channel in human neuroblastoma cells.
J. Physiol. (Lond.),
1998
Apr
1
, 508 ( Pt 1) (49-56).
2464
Itoh T
et al.
Genomic organization and mutational analysis of HERG, a gene responsible for familial long QT syndrome.
Hum. Genet.,
1998
Apr
, 102 (435-9).
2465
Vincent GM
The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
Annu. Rev. Med.,
1998
, 49 (263-74).
2466
Bauer CK
et al.
RERG is a molecular correlate of the inward-rectifying K current in clonal rat pituitary cells.
Recept. Channels,
1998
, 6 (19-29).
2467
Akimoto K
et al.
Novel missense mutation (G601S) of HERG in a Japanese long QT syndrome family.
Hum. Mutat.,
1998
, Suppl 1 (S184-6).
2468
Benhorin J
et al.
Identification of a new SCN5A mutation, D1840G, associated with the long QT syndrome. Mutations in brief no. 153. Online.
Hum. Mutat.,
1998
, 12 (72).
2469
Shen CT
et al.
Multi-undulant T-U-wave, sinus bradycardia and long QT syndrome: a possible phenotype of mutant genes controlling the inward potassium rectifiers.
,
1997 Jul-Aug
, 38 (267-75).
2470
Suessbrich H
et al.
Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241.
FEBS Lett.,
1997
Sep
8
, 414 (435-8).
2471
Jiang M
et al.
Suppression of slow delayed rectifier current by a truncated isoform of KvLQT1 cloned from normal human heart.
J. Biol. Chem.,
1997
Sep
26
, 272 (24109-12).
2472
van den Berg MH
et al.
The long QT syndrome: a novel missense mutation in the S6 region of the KVLQT1 gene.
Hum. Genet.,
1997
Sep
, 100 (356-61).
2473
Taglialatela M
et al.
Regulation of the human ether-a-gogo related gene (HERG) K+ channels by reactive oxygen species.
Proc. Natl. Acad. Sci. U.S.A.,
1997
Oct
14
, 94 (11698-703).
2474
Schulze-Bahr E
et al.
Autosomal recessive long-QT syndrome (Jervell Lange-Nielsen syndrome) is genetically heterogeneous.
Hum. Genet.,
1997
Oct
, 100 (573-6).
2475
Wang S
et al.
Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation.
FEBS Lett.,
1997
Nov
3
, 417 (43-7).
2476
Rampe D
et al.
A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
FEBS Lett.,
1997
Nov
3
, 417 (28-32).
2477
Mohammad S
et al.
Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
Am. J. Physiol.,
1997
Nov
, 273 (H2534-8).
2478
Lees-Miller JP
et al.
Electrophysiological characterization of an alternatively processed ERG K+ channel in mouse and human hearts.
Circ. Res.,
1997
Nov
, 81 (719-26).
2479
London B
et al.
Two isoforms of the mouse ether-a-go-go-related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current.
Circ. Res.,
1997
Nov
, 81 (870-8).
2480
Wang Q
et al.
Molecular genetics of long QT syndrome from genes to patients.
Curr. Opin. Cardiol.,
1997
May
, 12 (310-20).
2481
Zou A
et al.
Single HERG delayed rectifier K+ channels expressed in Xenopus oocytes.
Am. J. Physiol.,
1997
Mar
, 272 (H1309-14).
2482
Suessbrich H
et al.
The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes.
Br. J. Pharmacol.,
1997
Mar
, 120 (968-74).
2483
Chiesa N
et al.
A novel role for HERG K+ channels: spike-frequency adaptation.
J. Physiol. (Lond.),
1997
Jun
1
, 501 ( Pt 2) (313-8).
2484
Le Marec H
et al.
[Congenital long QT syndromes]
Arch Mal Coeur Vaiss,
1997
Jun
, 90 Spec No 3 (25-35).
2485
McDonald TV
et al.
A minK-HERG complex regulates the cardiac potassium current I(Kr).
Nature,
1997
Jul
17
, 388 (289-92).
2486
Wang S
et al.
A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes.
J. Physiol. (Lond.),
1997
Jul
1
, 502 ( Pt 1) (45-60).
2487
Ducic I
et al.
Comparative effects of loratadine and terfenadine on cardiac K+ channels.
J. Cardiovasc. Pharmacol.,
1997
Jul
, 30 (42-54).
2488
Li X
et al.
The human delta1261 mutation of the HERG potassium channel results in a truncated protein that contains a subunit interaction domain and decreases the channel expression.
J. Biol. Chem.,
1997
Jan
10
, 272 (705-8).
2489
Tanaka T
et al.
Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome.
Circulation,
1997
Feb
4
, 95 (565-7).
2490
Titus SA
et al.
The Drosophila erg K+ channel polypeptide is encoded by the seizure locus.
J. Neurosci.,
1997
Feb
1
, 17 (875-81).
2491
Wang XJ
et al.
The seizure locus encodes the Drosophila homolog of the HERG potassium channel.
J. Neurosci.,
1997
Feb
1
, 17 (882-90).
2492
Wymore RS
et al.
Tissue and species distribution of mRNA for the IKr-like K+ channel, erg.
Circ. Res.,
1997
Feb
, 80 (261-8).
2493
Shi W
et al.
Identification of two nervous system-specific members of the erg potassium channel gene family.
J. Neurosci.,
1997
Dec
15
, 17 (9423-32).
2494
Barros F
et al.
Demonstration of an inwardly rectifying K+ current component modulated by thyrotropin-releasing hormone and caffeine in GH3 rat anterior pituitary cells.
Pflugers Arch.,
1997
Dec
, 435 (119-29).
2495
Arcangeli A
et al.
HERG- and IRK-like inward rectifier currents are sequentially expressed during neuronal development of neural crest cells and their derivatives.
Eur. J. Neurosci.,
1997
Dec
, 9 (2596-604).
2496
Terlau H
et al.
Amino terminal-dependent gating of the potassium channel rat eag is compensated by a mutation in the S4 segment.
J. Physiol. (Lond.),
1997
Aug
1
, 502 ( Pt 3) (537-43).
2497
Priori SG
et al.
Molecular biology of the long QT syndrome: impact on management.
,
1997
Aug
, 20 (2052-7).
2498
Kimura T
et al.
[A family with facioscapulohumeral muscular dystrophy and hereditary long QT syndrome]
Rinsho Shinkeigaku,
1997
Aug
, 37 (690-2).
2499
Lacerda AE
et al.
Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart.
Mol. Pharmacol.,
1997
Aug
, 52 (314-22).
2500
Ko CM
et al.
Suppression of mammalian K+ channel family by ebastine.
J. Pharmacol. Exp. Ther.,
1997
Apr
, 281 (233-44).
2501
Sanguinetti MC
et al.
Molecular physiology of cardiac delayed rectifier K+ channels.
,
1997
, Suppl 12 (170-2).
2502
Drici MD
et al.
Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart.
Circulation,
1996
Sep
15
, 94 (1471-4).
2503
Priori SG
et al.
A molecular basis for the therapy of the long QT syndrome.
Arch Mal Coeur Vaiss,
1996
Sep
, 89 (1185-7).
2504
Satler CA
et al.
Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome.
Am. J. Med. Genet.,
1996
Oct
2
, 65 (27-35).
2505
Roden DM
et al.
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.
Circulation,
1996
Oct
15
, 94 (1996-2012).
2506
Priori SG
et al.
The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
,
1996
Oct
12
, 126 (1727-31).
2507
Faravelli L
et al.
A HERG-like K+ channel in rat F-11 DRG cell line: pharmacological identification and biophysical characterization.
J. Physiol. (Lond.),
1996
Oct
1
, 496 ( Pt 1) (13-23).
2508
Busch AE
et al.
Inhibition of IKs in guinea pig cardiac myocytes and guinea pig IsK channels by the chromanol 293B.
Pflugers Arch.,
1996
Oct
, 432 (1094-6).
2509
Barhanin J
et al.
K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current.
Nature,
1996
Nov
7
, 384 (78-80).
2510
Guatteo E
et al.
A novel K+ channel blocker isolated from 'hiccup nut' toxin.
Neuroreport,
1996
Nov
4
, 7 (2575-9).
2511
Kiehn J
et al.
Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.
Circulation,
1996
Nov
15
, 94 (2572-9).
2512
Arcangeli A
et al.
Soluble or bound laminin elicit in human neuroblastoma cells short- or long-term potentiation of a K+ inwardly rectifying current: relevance to neuritogenesis.
Cell Adhes. Commun.,
1996
Nov
, 4 (369-85).
2514
Benson DW
et al.
Missense mutation in the pore region of HERG causes familial long QT syndrome.
Circulation,
1996
May
15
, 93 (1791-5).
2515
Spector PS
et al.
Fast inactivation causes rectification of the IKr channel.
J. Gen. Physiol.,
1996
May
, 107 (611-9).
2516
Sanguinetti MC
et al.
Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia.
Proc. Natl. Acad. Sci. U.S.A.,
1996
Mar
5
, 93 (2208-12).
2518
Spector PS
et al.
Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
Circ. Res.,
1996
Mar
, 78 (499-503).
2519
Schönherr R
et al.
Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel.
J. Physiol. (Lond.),
1996
Jun
15
, 493 ( Pt 3) (635-42).
2520
Snyders DJ
et al.
High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Mol. Pharmacol.,
1996
Jun
, 49 (949-55).
2521
Priori SG
et al.
Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Circ. Res.,
1996
Jun
, 78 (1009-15).
2522
Russell MW
et al.
The molecular genetics of the congenital long QT syndromes.
Curr. Opin. Cardiol.,
1996
Jan
, 11 (45-51).
2523
Smith PL
et al.
The inward rectification mechanism of the HERG cardiac potassium channel.
Nature,
1996
Feb
29
, 379 (833-6).
2524
Lazzara R
Mechanisms and management of congenital and acquired long QT syndromes.
Arch Mal Coeur Vaiss,
1996
Feb
, 89 Spec No 1 (51-5).
2525
Jurkiewicz NK
et al.
Mechanism of action potential prolongation by RP 58866 and its active enantiomer, terikalant. Block of the rapidly activating delayed rectifier K+ current, IKr.
Circulation,
1996
Dec
1
, 94 (2938-46).
2526
Roy M
et al.
HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.
Circulation,
1996
Aug
15
, 94 (817-23).
2527
Suessbrich H
et al.
Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole.
FEBS Lett.,
1996
Apr
29
, 385 (77-80).
2528
Robertson GA
et al.
Potassium currents expressed from Drosophila and mouse eag cDNAs in Xenopus oocytes.
Neuropharmacology,
1996
, 35 (841-50).
2529
Roden DM
et al.
Recent advances in understanding the molecular mechanisms of the long QT syndrome.
J. Cardiovasc. Electrophysiol.,
1995
Nov
, 6 (1023-31).
2530
Wang Q
et al.
SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome.
Cell,
1995
Mar
10
, 80 (805-11).
2531
Curran ME
et al.
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
Cell,
1995
Mar
10
, 80 (795-803).
2532
Trudeau MC
et al.
HERG, a human inward rectifier in the voltage-gated potassium channel family.
Science,
1995
Jul
7
, 269 (92-5).
2533
Keating MT
Genetic approaches to cardiovascular disease. Supravalvular aortic stenosis, Williams syndrome, and long-QT syndrome.
Circulation,
1995
Jul
1
, 92 (142-7).
2534
Schwartz PJ
et al.
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Circulation,
1995
Dec
15
, 92 (3381-6).
2535
Kiehn J
et al.
Cloned human inward rectifier K+ channel as a target for class III methanesulfonanilides.
Circ. Res.,
1995
Dec
, 77 (1151-5).
2536
Sanguinetti MC
et al.
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
Cell,
1995
Apr
21
, 81 (299-307).
2537
Nabeshima T
et al.
Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABAA and muscarinic receptors induced by cycloheximide.
J. Pharmacol. Exp. Ther.,
1991
Apr
, 257 (271-5).
2538
Zarrindast MR
et al.
Involvement of GABAA receptor sites in diazepam hypothermia.
Gen. Pharmacol.,
1989
, 20 (855-9).